



Bibliografía

1. Foley RN, Parfrey PS, Sarnak MJ. Cardiovascular disease in chronic renal disease: Clinical epidemiology of cardiovascular disease in chronic renal disease. *Am J Kidney Dis*:32 (Suppl 3):S112-S119, 1998.
2. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. *N Engl J Med*:339:799-805, 1998.
3. Levey AS. Controlling the epidemic of cardiovascular disease in chronic renal disease: where do we start? *Am J Kidney Dis* : 32 (Suppl 3): S5-S13, 1998.
4. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. *Am J Kidney Dis*: 35 (Suppl 1): S117-S131, 2000.
5. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. *Am J Kidney Dis* 27: 347-54, 1996.
6. Mann JFE, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril : the HOPE randomized trial. *Ann Intern Med* 134: 629-636; 2001.
7. Ruilope KM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H y cols. Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) study. *J Am Soc Nephrol* 12: 218-225; 2001.
8. Weiner DE, Tighiouart H, Stark PC, Amin MG, MacLeod B, Griffith JL y cols. Kidney disease as a risk factor to recurrent cardiovascular disease and mortality. *Am J Kidney Dis* 44: 198-206; 2004.
9. Weiner DE, Tighiouart H, Stark PC, Amin MG, MacLeod B, Griffith JL y cols. Kidney disease as a risk factor to recurrent cardiovascular disease and all-cause mortality: a pooled analysis of community-based study. *J Am Soc Nephrol* 15: 1307-15, 2004.
10. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. *N Engl J Med* 351: 1296-1305, 2004.
11. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau J-L et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. *N Engl J Med* 351: 1285-1295, 2004.
12. Hostetter TH. Chronic kidney disease predicts cardiovascular disease. *N Engl J Med* 351: 1344-1346, 2004.
13. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA Izzo Jr y cols. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA*: 289: 2560-2572, 2003.
14. European Society of Hypertension - European Society of Cardiology guidelines for management of arterial hypertension. *J Hypertens*: 21: 1011-1053, 2003.
15. Annual Report: ESRD clinical performance measures project. *Am J Kidney Dis*: 39 (Suppl 2) S4-S61, 2002.
16. Amenábar JJ, García-López F, Robles NR, Saracho R por el Comité de Registros de la SEN. Informe de diálisis y trasplante de la Sociedad Española de Nefrología y Registros Autonómicos correspondientes al año 1999. *Nefrología* 21: 246-252, 2001.
17. Palmer BF. Renal dysfunction complicating the treatment of hypertension. *N Engl J Med*: 347: 1256-1261, 2002.
18. Burden R, Dasgupta I. How good are nephrologists at controlling blood pressure in renal patients. *Nephrol Dial Transplant*: 15: 440-441, 2000
19. Tonelli M, Gill J, Pandeya S, Bohm C, Levin A, Kiberd BA. Slowing the progression of chronic renal insufficiency. *CAMJ*: 166: 906-907, 2002.
20. Nissenson AR, Collins AJ, Hurley J, Petersen H, Pereira BJG, Steinberg EP. Opportunities for improving the care of patients with chronic renal insufficiency: current practice patterns. *J Am Soc Nephrol*: 12: 1713-1720, 2001.
21. Hsu CY, Bates DW, Kuperman GJ, Curhan GC. Blood pressure and angiotensin converting enzyme inhibitor use in hypertensive patients with chronic renal insufficiency. *Am J Hypertens*:14:1219-25, 2001.
22. Best PJ, Reddan DN, Berger PB, Szczech LA, McCullough, Califf RM. Cardiovascular disease and chronic kidney disease: insights and an update. *Am Heart J* 148; 230-242, 2004.
23. Nickolas TL, Frisch GD, Opatowsky AR, Arons R, Radhakrishnan J. Awareness of kidney disease in the US population: findings from the National Health and Nutrition Examination Survey (NHANES) 1999 to 2000. *Am J Kidney Dis* 44: 185-197, 2004.
24. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Cullerton B, Hamm LL y cols. Kidney Disease as a Risk Factor for Development of Cardiovascular Disease. A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. *Circulation*:108:2154-2169, 2003.
25. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, y cols. National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. *Ann Intern Med*: 139: 137-147, 2003.
26. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. *Am J Kidney Dis*: 39 (Suppl 1): S1-S266, 2002.
27. K/DOQI Clinical Practice Guidelines for managing dyslipidemias in chronic kidney disease. *Am J Kidney Dis*: 41 (Suppl 3): S1-S89, 2003.
28. Levey AS, Coresh J. Should the K/DOQI definition of chronic kidney disease be changed? *Am J Kidney Dis*: 42:626-630, 2003.
29. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. *Am J Kidney Dis* 43 (suppl 1): S1-S290, 2004.
30. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA Izzo Jr y cols. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and

BIBLIOGRAFÍA

- Treatment of High Blood Pressure. JNC 7-complete version. Hypertension: 42: 1206-52, 2003.
31. European best practice guidelines for hemodialysis (Part 1). *Nephrol Dial Transplant*: 17 (Suppl 7): S1 – S109, 2002.
 32. European best practice guidelines for renal transplantation (Part 2). *Nephrol Dial Transplant*: 17 (Suppl 4): S1 – S67, 2002.
 33. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization/International Society of Hypertension statement on management of hypertension *J Hypertens* 2003; 21: 1983-1992.
 34. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF y cols. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV):summary. *BMJ* 328: 634-40, 2004.
 35. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J y cols. European guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J*: 24: 1601-1610, 2003.
 36. Guía sobre el diagnóstico y el tratamiento de la hipertensión arterial en España 2002. *Hipertensión*: 19 (Supl 3): S1-S74. Actualizada a 1-03-2003 en <http://www.seh-lelha.org/>, 2002
 37. Brotons C, Royo-Bordonada MA, Álvarez-Sala L, Armario P, Artigao R, Conté P y cols. Adaptación española de la guía europea de prevención cardiovascular. *Nefrología* 24: 312-28,2004.
 38. López Bescós L, Arós Borau F, Lidón Corbi RM Cequier Fillat A, Bueno H, Alonso JJ, y cols. Actualización (2002) de las Guías de Práctica Clínica de la Sociedad Española de Cardiología en angina inestable /infarto sin elevación del segmento ST. *Rev Esp Cardiol*: 55: 631 – 642. 2002.
 39. Guía de práctica clínica sobre hipertensión arterial. Servicio Vasco de Salud. Vitoria, pp1-106, 2002.
 40. Peters NS, Schilling RJ, Kanagaratnam P, Markides V. Atrial fibrillation: strategies to control, combat, and cure. *Lancet*: 359: 593-630, 2002.
 41. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ*: 324: 71-86, 2002.
 42. Executive summary on the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA*: 285: 2486-2497, 2001.
 43. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS y cols. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary. *Circulation*: 104: 2996-3007, 2001.
 44. Cain AE, Khalil RA: Pathophysiology of essential hypertension: role of the pump, the vessel, and the kidney. *Semin Nephrol* 22: 3-16, 2002.
 45. Oparil S, Zaman MA, Calhoun DA: Pathogenesis of hypertension. *Ann Intern Med* 139: 761-776, 2003.
 46. Ritz E, Adamczak M, Zeier M: Kidney and hypertension-causes. Update 2003. *Herz* 28: 663-667, 2003.
 47. Cusi D, Barlassina C, Taglietti MV: Genetics of human hypertension. *J Nephrol* 16: 609-615, 2003.
 48. Rodriguez-Iturbe B, Vaziri ND, Herrera-Acosta J, Johnson RJ: Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all. *Am J Physiol Renal Physiol* 286: F606-F616, 2004.
 49. Weinberger MH: Salt sensitivity of blood pressure in humans. *Hypertension* 27: 481-490, 1996.
 50. Hall JE: The kidney, hypertension, and obesity. *Hypertension* 41 (3 Pt 2): 625-633, 2003.
 51. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease: Executive summary. *Am J Kidney Dis* 43 (Suppl 1): S16-S41, 2004.
 52. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. *Am J Kidney Dis* 32 (Suppl 3): S112-S119, 1998.
 53. Henry RM, Kostense PJ, Bos G, Dekker JM, Nijpels G, Heine RJ, y cols: Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn study. *Kidney Int* 62: 1402-1407, 2002.
 54. Locatelli F, Bommer J, London GM, Martín-Malo A, Wanner C, Yaqoob M, y cols: Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment. *Nephrol Dial Transplant* 16: 459-468, 2001.
 55. Prichard S: Risk factors for coronary artery disease in patients with renal failure. *Am J Med Sci* 325: 209-213, 2003.
 56. Zoccali C, Mallamaci F, Tripepi G: Traditional and emerging cardiovascular risk factors in end-stage renal disease. *Kidney Int Suppl*: 63 (Suppl 85):S105-S110; 2003.
 57. Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J: The prevalence of non-traditional risk factors for coronary heart disease in patients with chronic kidney disease. *Ann Intern Med* 140: 9-17; 2004.
 58. Kasiske BL: Cardiovascular disease after renal transplantation. *Semin Nephrol* 20: 176-187; 2000.
 59. Tyralla K, Amann K: Morphology of the heart and arteries in renal failure. *Kidney Int Suppl*: 63 (Suppl 84):S80-S83, 2003.
 60. Amann K, Tyralla K, Gross ML, Eifert T, Adamczak M, Ritz E: Special characteristics of atherosclerosis in chronic renal failure. *Clin Nephrol* 60 (suppl 1): S13-21, 2003.
 61. Safar ME, London GM, Plante GE: Arterial stiffness and kidney function. *Hypertension* 43: 163-168, 2004.
 62. London GM: Left ventricular alterations and end-stage renal disease. *Nephrol Dial Transplant* 17 (Suppl 1): 29-36, 2002.
 63. Campistol JM: Uremic myopathy. *Kidney Int* 62: 1901-1913, 2002.
 64. London GM: Cardiovascular disease in chronic renal failure: pathophysiological aspects. *Semin Dial* 16: 85-94, 2003.
 65. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PWF, Levy D: Predictors of new-onset kidney disease in a community-based population. *JAMA* 291: 844-850, 2004.
 66. Chen J, Muntner P, Hamm LH, Jones DW, Batuman V, Fonseca V, y cols. The metabolic syndrome and chronic kidney disease in U.S. adults. *Ann Intern Med* 140: 167-174, 2004.
 67. Fogo A, Breyer JA, Smith MC, Cleveland WH, Agodoa L, Kirk KA, y cols. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Diseases (AASK). *Kidney Int* 51: 244-252, 1997.

68. Harvey JM, Howie AJ, Lee SJ, Newbold KM, Adu D, Michael J, y cols. Renal biopsy findings in hypertensive patient with proteinuria. *Lancet* 340:1435-1436, 1992.
69. Luke RG: Hypertensive nephrosclerosis: pathogenesis and prevalence. *Nephrol Dial Transplant* 14:2271-2278, 1999.
70. Egido J: Vasoactive hormones and renal sclerosis. *Kidney Int* 49: 578-597, 1996.
71. Wardle EN: Renal collagen synthesis and its control. *Nephron* 83: 106-110, 1999.
72. Isaka Y, Akagi Y, Ando Y, Tsujie M, Imai E: Cytokines and glomerulosclerosis. *Nephrol Dial Transplant* 14: 30-32 1999.
73. Luft FC: Hypertensive nephrosclerosis-a cause of end stage renal disease ? *Nephrol Dial Transplant* 15: 1515-1517, 2000.
74. Brown DM, Provoost AP, Daly MJ, Lander ES, Jacob HJ: Renal disease susceptibility and hypertension are under independent genetic control in the fawn-hooded rat. *Nature Genet* 12: 44-51, 1996.
75. Bergman S, Key BO, Kirk KA, Warnock DG, Rostand SG: Kidney disease in the first-degree relatives of African-Americans with hypertensive end-stage renal disease. *Am J Kidney Dis* 27: 341-346, 1996.
76. O'Dea DF, Murphy SW, Hefferton D, Parkfrey PS: Higher risk for renal failure in first-degree relatives of white patients with end-stage renal disease: A population based study. *Am J Kidney Dis* 32: 794-801, 1998.
77. Marcantoni C, Ma L-J, Federspiel C, Fogo AB: Hypertensive nephrosclerosis in African Americans versus Caucasians. *Kidney Int* 62: 172-180, 2002.
78. Hollenberg NK: Renal function in the patient with hypertension. *Med Clin North Am* 88: 131-140, 2004.
79. Kincaid-Smith P: Hypothesis: Obesity and the insulin resistance syndrome play a major role in end-stage renal failure attributed to hypertension and labelled 'hypertensive nephrosclerosis'. *J Hypertens* 22: 1051-1055, 2004.
80. Andronico G, Ferraro-Monterello R, Mangano MT, Rome M, Rasputi F, Pinto A, y cols. Insulin resistance and glomerular haemodynamics and essential hipertensión. *Kidney Int* 62: 1005-1009, 2002.
81. Chen J, Muntner P, Hamm LL, Fonseca V, Batuman V, Whelton PK, y cols. Insulin resistance and risk of chronic kidney disease in non-diabetic US adults. *J Am Soc Nephrol* 14: 469-477, 2003.
82. Bloch MJ, Basile J: The diagnosis and management of renovascular disease: a primary care perspective. Part I. Making the diagnosis. *J Clin Hypertens* 5: 210-218, 2003.
83. Zoccali C, Mallamaci F, Finocchiaro P: Atherosclerotic renal artery stenosis: epidemiology, cardiovascular outcomes, and clinical prediction rules. *J Am Soc Nephrol* 13 (Suppl 3): S179-S183, 2002.
84. Nally JV, Barton DP: Contemporary approach to diagnosis and evaluation of renovascular hypertension. *Urol Clin North Am* 28: 781-791, 2001.
85. Lerman L, Textor SC: Pathophysiology of ischemic nephropathy. *Urol Clin North Am* 28: 793-803, 2001.
86. Mailloux LU, Napolitano B, Bellucci AG, Vernace M, Wilkes BM, Mossey RT: Renal vascular disease causing end-stage renal disease, incidence, clinical correlates, and outcomes: A 20-year clinical experience. *Am J Kidney Dis* 24: 622-629, 1994.
87. Murphy TP, Rundback JH, Cooper C, Kiernan MS: Chronic renal ischemia: implications for cardiovascular disease risk. *J Vasc Interv Radiol* 13: 1187-1198, 2002.
88. Modi K, Rao VK: Atheroembolic renal disease. *J Am Soc Nephrol* 12: 1781-1787, 2001.
89. Scoble JE: Atherosclerotic nephropathy. *Kidney Int Suppl*: 56 (Suppl 71): S106-S109; 1999.
90. Coresh J, Astor B, Sarnak MJ: Evidence for increased cardiovascular disease risk in patients with chronic kidney disease. *Curr Opin Nephrol Hypertens* 13: 73-81, 2004
91. Keane WF, Eknoyan G: Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. *Am J Kidney Dis* 33: 1004-1010, 1999.
92. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. *Am J Kidney Dis* 41: 1-12, 2003.
93. McClellan WM, Knight DF, Karp H, Brown WW: Early detection and treatment of renal disease in hospitalized diabetic and hypertensive patients: important differences between practice and published guidelines. *Am J Kidney Dis* 29: 368-375, 1997.
94. Locatelli F, Del Vecchio L, Pozzoni P: The importance of early detection of chronic kidney disease. *Nephrol Dial Transplant* 17: S2-S7, 2002.
95. Remuzzi G, Ruggenti P, Perico N: Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. *Ann Intern Med* 136: 604-615, 2002.
96. Rossert J, Fouqueray B, Jacques Boffa J: Anemia management and delay of chronic renal failure progression. *J Am Soc Nephrol* 14: S173-S177, 2003.
97. Górriz JL, Sancho A, Pallardó LM, Amoedo ML, Martín M, Sanz P, y cols. Significado pronóstico de la diálisis programada en pacientes que inician tratamiento sustitutivo renal. Un estudio multicéntrico español. *Nefrología* 22: 49-59, 2002.
98. De Francisco ALM, Fernández-Fresnedo G: Llegada tardía a diálisis como consecuencia de insuficiencia renal no identificada. *Nefrología* 22: 95-97, 2002.
99. Levinsky NG: Specialist evaluation in chronic kidney disease: too little, too late. *Ann Intern Med* 137: 542-543, 2002.
100. Obrador GT, Arora P, Kausz AT, Ruthazer R, Pereira BJ, Levey AS: Level of renal function at the initiation of dialysis in the U.S. end-stage renal disease population. *Kidney Int* 56: 2227-2235, 1999.
101. United States Renal Data System: Excerpts from the 2000 U.S. Renal Data System Annual Data Report: Atlas of End Stage Renal Disease in the United States. *Am J Kidney Dis* 36: S1-S279, 2000.
102. Stengel B, Billon S, van Dijk PCW, Jager KJ, Dekker FW, Simpson K, y cols. on behalf of the ERA-EDTA Registry Committee: Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. *Nephrol Dial Transplant* 18: 1824-1833, 2003.
103. Amenábar JJ, García F, Robles NR, Saracho R, Pinilla J, Gentil MA, y cols. Informe de diálisis y trasplante de la Sociedad Española de Nefrología y Registros Autonómicos, año 2000. *Nefrología* 22: 310-317, 2002.

BIBLIOGRAFÍA

104. De Francisco ALM, Otero A: Epidemiología de la enfermedad renal crónica en España. *Nefrología* 23; 475-477, 2003.
105. Otero A, Abelleira A, Camba MJ, Pérez C, Armada E, Esteban J, y cols. Prevalencia de insuficiencia renal oculta en la provincia de Ourense. *Nefrología* 23 (suppl 6): 26, 2003.
106. Simal F, Martín JC, Bellido J, Arzúa D, Mena FJ, González I, y cols. Prevalencia de la enfermedad renal crónica leve y moderada en población general. *Nefrología* 24: 329-337, 2004.
107. Gorostidi M, Alonso JL, González de Cangas B, Jiménez F, Vaquero F, Moína MJ, y cols. Prevalencia de insuficiencia renal en población de edad avanzada y factores asociados. Resultados preliminares. XXXIV Congreso Nacional de la SEN. Resumen en *Nefrología* 24, 2004 (en prensa).
108. Levey AS, Betó JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, y cols. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? what do we need to learn? where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. *Am J Kidney Dis* 32: 853-906, 1998.
109. Mann JFE, Gerstein HC, Yi QL, Lonn EM, Hoogwerf BJ, Rashkow A, y cols. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomised study. *J Am Soc Nephrol* 14: 641-647, 2003.
110. Smith HW: Measurement of the filtration rate, in *The Kidney: Structure and Function in Health and Disease* (chap 3), New York, Oxford University Press, 1951: 39-62, 143-202.
111. Levey AS: Measurement of renal function in chronic renal disease. *Kidney Int* 38: 167-184, 1990.
112. Perrone RD, Madias NE, Levey AS: Serum creatinine as an index of renal function: new insights into old concepts. *Clin Chem* 38: 1933-1953, 1992.
113. Perrone RD, Steinman TI, Beck CJ, Skibinski CI, Royal HD, Lawlor M y cols. Utility of radioisotopic filtration markers in chronic renal insufficiency: simultaneous comparison of ¹²⁵I-iothalamate, ¹⁶⁹Yb-DTPA, ⁹⁹Tc-DTPA, and inulin. *Am J Kidney Dis* 16: 224-235, 1990.
114. Dalmeida W, Suki WN: Measurement of GFR with non-radioisotopic radio contrast agents. *Kidney Int* 43: 725-728, 1988.
115. Krutzén E, Bäck SE, Nilsson-Ehle I, Nilsson-Ehle P: Plasma clearance of a new contrast agent, iohexol: a method for the determination of glomerular filtration rate. *J Lab Clin Med* 104, 955-61, 1984.
116. Brandstrom E, Grzegorzczak A, Jacobsson L: GFR measurements with iohexol and ⁵¹Cr-EDTA. A comparison of the two favoured GFR markers in Europe. *Nephrol Dial Transplant* 38: 1176, 1998.
117. Nilsson-Ehle P, Grubb A: New markers for the determination of GFR: iohexol clearance and cystatin C concentration. *Kidney Int* 46 (suppl 47), S17-S19, 1994.
118. Walser M: Assessing renal function from creatinine measurements in adults with chronic renal failure. *Am J Kidney Dis* 32: 23-31, 1998.
119. Rodrigo E, Martín de Francisco AL, Escallada R, Ruiz JC, Fresnedo GF, Piñera C, Arias M. Measurement of renal function in pre-ESRD patients. *Kidney Int* 61 (suppl 80): S11-S17, 2002.
120. Molitch ME, Rodman E, Hirsch CA, Dubinsky E: Spurious serum creatinine elevations in ketoacidosis. *Ann Intern Med* 93: 280, 1980.
121. Doolan PD, Alpen EL, Theil GB: A clinical appraisal of the plasma concentration and endogenous clearance of creatinine. *Am J Med* 32: 65-79, 1962.
122. Mitch WE, Walser M: A proposed mechanism of reduced creatinine excretion in severe chronic renal failure. *Nephron* 21: 248-254, 1978.
123. Mitch WE, Collier VU, Walser M: Creatinine metabolism in chronic renal failure. *Clin Sci* 58: 327-335, 1980.
124. Jones JD, Burnett PC: Implication of creatinine and gut flora in the uremic syndrome: induction of creatininase in colon contents of the rat by dietary creatinine. *Clin Chem* 18: 280-284, 1972.
125. Kopple JD, Chumlea WC, Gassman JJ, Hotlinger DL, Maroni BJ, Merrill D, y cols. Relationship between GFR and nutritional status-Results from the MDRD study. *J Am Soc Nephrol* 6: 335, 1994 (abstr).
126. Pollock CA: Protein intake in renal disease. *J Am Soc Nephrol* 8: 777-783, 1997.
127. Ikitzler TA, Greene JH, Wingard RL, Parker RA, Hakim RM: Spontaneous dietary protein intake during progression of chronic renal failure. *J Am Soc Nephrol* 6: 1386-1391, 1995.
128. Rowe JW, Andres R, Tobin JD, Nomis AN, Shock NW: The effect of age on creatinine clearance in men: a cross sectional and longitudinal study. *J Gerontol* 31:155-163, 1976.
129. Sinton TC, De Leacy EA, Cowley DM: Comparison of ⁵¹Cr EDTA clearance with formulae in the measurement of glomerular filtration rate. *Pathology* 18: 445-447, 1986.
130. Shemesh O, Golbetz H, Kriss JP, Myers BD: Limitations of creatinine as a filtration marker in glomerulopathic patients. *Kidney Int* 28: 830-838, 1985.
131. Bauer JH, Brooks CS, Burch RN: Renal function studies in man with advanced renal insufficiency. *Am J Kidney Dis* 11: 30-35, 1982.
132. Walser M, Drew HH, LaFrance ND: Creatinine measurements often yield false estimates of progression in chronic renal failure. *Kidney Int* 34: 412-418, 1988.
133. Levey AS, Bosch JP, Breyer-Lewis J, Greene T, Rogers N, Roth A: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. *Ann Intern Med* 130: 461-470, 1999.
134. Lewis J, Agodoa L, Cheek D, Greene T, Middleton J, O'Connor D, y cols. Comparison of cross-sectional renal function measurements in African Americans with hypertensive nephrosclerosis and of primary formulas to estimate glomerular filtration rate. *Am J Kidney Dis* 38: 744-753, 2001.
135. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. *Nephron* 16: 31-41, 1976.
136. Rolin HA, May PM, Wei R: Inaccuracy of estimated creatinine clearance for prediction of iohalamate glomerular filtration rate. *Am J Kidney Dis* 4: 48-54, 1984.
137. Toto RD, Kirk KA, Coresh J, Jones C, Appel L, Wright J, y cols. Evaluation of serum creatinine for estimating glomerular filtration rate in African Americans with hypertensive nephrosclerosis: Results from the African-American Study of Kidney Disease and Hypertension (AASK). *J Am Soc Nephrol* 8: 279-287, 1997.
138. Walser M, Drew HH, Guldán JL: Prediction of glomerular filtration rate from serum creatinine concentration in advanced chronic renal failure. *Kidney Int* 44: 1145-1148, 1993.
139. Coresh J, Toto RD, Kirk KA, Whelton PK, Massry S, Jones C, y cols. Creatinine clearance as a measure of GFR in screenees

- for the African-american study of kidney disease and hypertension pilot study. *Am J Kidney Dis* 32: 32-42, 1998.
140. Levey AS, Greene T, Jusek J, Beck GJ, Group MS: A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]. *J Am Soc Nephrol* 11: A1828, 2000.
 141. Vervoort G, Willems HL, Wetzels JFM: Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation. *Nephrol Dial Transplant* 17: 1909-1913, 2002.
 142. Bostom AG, Kronenberg F, Ritz E: Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. *J Am Soc Nephrol* 13: 2140-2144, 2002.
 143. Rule AD, Gussak HM, Pond GR, Bergstralh EJ, Stegall MD, Cosio FG, y cols. Measured and estimated GFR in healthy potential kidney donors. *Am J Kidney Dis* 43: 112-119, 2004.
 144. Lin J, Knight EL, Hogan ML, Singh AK: A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. *J Am Soc Nephrol* 14: 2573-2580, 2003.
 145. Nankivell BJ, Gruenewald SM, Allen RDM, Chapman JR: Predicting glomerular filtration rate after kidney transplantation. *Transplantation* 59: 1683-1689, 1995.
 146. Mourad A, Carney S, Gillies A, Hibberd A, Trevillian P, Nanra R: Measurement of glomerular filtration rate in renal transplant recipients: a comparison of methods. *Nephrology* 7: 77-82, 2002.
 147. Stoves J, Lindley EJ, Barnfield MC, Burniston MT, Newstead CG: MDRD equation estimates of glomerular filtration rate in potential living kidney donors and renal transplant recipients with impaired graft function. *Nephrol Dial Transplant* 17: 2036-2037, 2002.
 148. Mariat C, Alamartine E, Barthelemy JC, de Filippis JP, Thibaudin D, Berthoux P, y cols. Assessing renal graft function in clinical trials: can test predicting glomerular filtration rate substitute for a reference method? *Kidney Int* 65: 289-297, 2004.
 149. Goldberg TH, Finkelstein MS: Difficulties in estimating glomerular filtration rate in the elderly. *Arch Intern Med* 147: 1430-1433, 1987.
 150. Brion LP, Boeck MA, Gauthier B: Estimation of glomerular filtration rate in anorectic adolescents. *Pediatr Nephrol* 3: 16-21, 1989.
 151. Skluzacek PA, Szewc RG, Nolan CR, Riley D, Lee S, Pergola PE: Prediction of GFR in liver transplant candidates. *Am J Kidney Dis* 42: 1169-1176, 2003.
 152. Knight EL, Verhave JC, Spiegelman D, Hillege HL, De Zeeuw D, Curhan GC, y cols. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. *Kidney Int* 65: 1416-1420, 2004.
 153. Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR: Screening for proteinuria in US adults. A cost effectiveness analysis. *JAMA* 290: 3101-3114, 2003.
 154. Fernández-Fresnedo G, Escallada R, Rodrigo E, De Francisco ALM, Cotorruelo JG, Sanz De Castro S, y cols. The risk of cardiovascular disease associated with proteinuria in renal transplant patients. *Transplantation* 73:1345-8, 2002.
 155. American Diabetes Association: Nephropathy in diabetes. Position statement. *Diabetes Care* 27: S79-S82, 2004.
 156. Ginsberg JM, Chang BS, Matarese RA, Garella S: Use of single voided urine samples to estimate quantitative proteinuria. *N Eng J Med* 309: 1543-1546, 1983.
 157. Schwab SJ, Christensen RL, Dougherty K, Klahr S: Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples. *Arch Intern Med* 147: 943-944, 1987.
 158. Steinhäuslin F, Wauters JP: Quantitation of proteinuria in kidney transplant patients: accuracy of the urinary protein/creatinine ratio. *Clin Nephrol* 43: 110-115, 1995.
 159. Torng S, Rigatto C, Rush DN, Nickerson P, Jeffery JR: The urine protein to creatinine ratio (P/C) as a predictor of 24-hour urine protein excretion in renal transplant patients. *Transplantation* 72: 1453-1456, 2001.
 160. Rodrigo E, Piñera C, Ruiz JC, Fernández-Fresnedo G, Escallada R, Herráez I, y cols. Quantitation of 24-hour urine protein excretion in kidney transplant patients by the use of protein to creatinine ratio. *Transplant Proc* 35: 702, 2003.
 161. Zelmanovitz T, Gross JL : Proteinuria is still useful for the screening and diagnosis of overt diabetic nephropathy. *Diabetes Care* 21: 1076-1079, 1998.
 162. Rodby RA, Rohde RD, Sharon Z, Pohl MA, Bain RP, Lewis EJ: The urine protein to creatinine ratio as a predictor of 24-hour urine protein excretion in type 1 diabetic patients with nephropathy. *Am J Kidney Dis* 26: 904-909, 1995.
 163. Chitalia VC, Kothari J, Wells EJ, Livesey JH, Robson RA, Searle M: Cost-benefit analysis and prediction of 24-hour proteinuria from spot urine protein-creatinine ratio. *Clin Nephrol* 55: 436-447, 2001.
 164. Risberg A, Larsson A, Olsson K, Lyrenas S, Sjoquist M: Relationship between urinary albumin and albumin/creatinine during normal pregnancy and pre-eclampsia. *Scand J Clin Lab Invest* 64: 17-23, 2004.
 165. Nathan DM, Rosenbaum C, Protasowicki VD: Single-void urine samples can be used to estimate quantitative microalbuminuria. *Diabetes Care* 10: 414-418, 1987.
 166. Zelmanovitz T, Gross JL, Oliveira JR, Paggi A, Tatsch M, Azevedo M: The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. *Diabetes Care* 20: 516-519, 1997.
 167. Ahn CW, Song YD, Kim JH, Lim SK, Choi KH, Kim KR, y cols. The validity of random urine specimen albumin measurement as a screening test for diabetic nephropathy. *Yonsei Med J* 40: 40-45, 1999.
 168. Ng WY, Lui KF, Thai AC: Evaluation of a rapid screening test for microalbuminuria with spot measurement of urine albumin-creatinine ratio. *Ann Acad Med Singapore* 29: 62-65, 2000.
 169. James MA, Fotherby MD, Potter JF: Screening tests for microalbuminuria in non-diabetic elderly and their relation to blood pressure. *Clin Sci* 88: 185-190, 1995.
 170. Mosca A, Paleari R, Ceriotti F, Lapolla A, Fedele D: Biological variability of albumin excretion rate and albumin-to-creatinine ratio in hypertensive type 2 diabetic patients. *Clin Chem Lab Med* 41: 1229-1233, 2003.
 171. Jacobs DR, Murtaugh MA, Steffes M, Yu X, Roseman J, Gotes FO: Gender- and race-specific determination of albumin excretion using albumin-to-creatinine ratio in single, untimed urine specimen. The Coronary Artery Risk Development in Young adults Study. *Am J Epidemiol* 155: 1114-1119, 2002.

BIBLIOGRAFÍA

172. Matixx HJ, Hsu C-Y, Shaykevich S, Curhan G: Use of the albumin/creatinine ratio to detect microalbuminuria: implications of sex and race. *J Am Soc Nephrol* 13: 1034-1039, 2002.
173. Tamura S, Shimizu T, Kawakatsu H, Tateishi S: Correlation between 24-hour urinary protein excretion and protein/creatinine ratio in the first voided morning urine sample. *Nippon Jinzo Gakkai Shi* 46: 26-34, 2004.
174. Wachtell K, Visen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, y cols. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. *Ann Intern Med* 139: 901-906, 2003.
175. Meinhardt U, Ammann RA, Fluck C, Diem P, Mullis PE: Microalbuminuria in diabetes mellitus: efficacy of a new screening method in comparison with timed overnight urine collection. *J Diabetes Complications* 17: 254-257, 2003.
176. Gerber LM, Johnston K, Alderman MH: Assessment of a new dipstick test in screening for microalbuminuria in patients with hypertension. *Am J Hypertens* 11: 1321-1327, 1998.
177. Agarwal R, Panesar A, Lewis RR: Dipstick proteinuria: can it guide hypertension management? *Am J Kidney Dis* 39: 1190-1195, 2002.
178. Baskar V, Kamalakannan D, Holland MR, Catchpole CR, Singh BM. Uncertain clinical utility of contemporary strategies for microalbuminuria testing. *Diabetes Obes Metab* 5: 262-266, 2003.
179. Jones CA, Francis ME, Eberhardt MS, Chavers B, Coresh J, Kusek JW, y cols. Microalbuminuria in the US population: third National Health Nutrition Examination Survey. *Am J Kidney Dis* 39: 445-459, 2002.
180. Brown WW, Peters RM, Ohmit SE, Keane WF, Collins A, Chen SC, y cols. Early detection of kidney disease in community settings: the Kidney Early Evaluation Program (KEEP). *Am J Kidney Dis* 42: 22-35, 2003.
181. Jensen JS, Clausen P, Borch-Johnsen K, Jensen G: Detecting microalbuminuria by urinary albumin/creatinine concentration ratio. *Nephrol Dial Transplant* 12 (suppl 2): 6-9, 1997.
182. Gai M, Motta D, Cantaluppi V, Fop F, Jeantet A, Segoloni GP, y cols. Proteinuria dipstick test: is it time to change? *Kidney Int* 63: 2326-2327, 2003.
183. Chadban SJ, Briganti EM, Kerr PG, Dunstan DW, Welborn TA, Zimmet PZ, y cols. Prevalence of kidney damage in Australian adults: the AusDiab Kidney Study. *J Am Soc Nephrol* 14: S131-S138, 2003.
184. Iseki K, Ikemiya Y, Iseki C, Takishita S: Proteinuria and the risk of developing end-stage renal disease. *Kidney Int* 63: 1468-1474, 2003.
185. Kannel WB, Stampfer MJ, Castelli WP, Verter J: The prognostic significance of proteinuria: the Framingham study. *Am Heart J* 108: 1347-1352, 1984.
186. Romundstad S, Holmen J, Kvenild K, Aakervik O, Hallan H: Clinical relevance of microalbuminuria screening in self-reported diabetic/non-hypertensive persons identified in a large health screening-the Nord-Trøndelag Health Study (HUNT), Norway. *Clin Nephrol* 59: 241-251, 2003.
187. Topham PS, Jethwa A, Watkins M, Rees Y, Feehally J: The value of urine screening in a young adult population. *Fam Pract* 21: 18-21, 2004.
188. Iseki K, Iseki C, Ikemiya Y, Fukiyama K: Risk of developing end-stage renal disease in a cohort of mass screening. *Kidney Int* 49: 800-805, 1996.
189. Allwall N, Lohi A. A population study on renal and urinary tract diseases. *Acta Med Scand* 194: 525-528, 1973.
190. Ruiz JC, López G. Técnicas de imagen en nefrología. En: *Nefrología clínica*. Hernando L, ed. Editorial Panamericana, 2ª edición. Madrid 2003, 135-144.
191. Marín R, Gorostidi M, Pobes A: Hipertensión arterial y enfermedad vascular renal: nefroangioesclerosis. *Nefrología* 22 (suppl 1): 36-45, 2002.
192. Marín R, Gorostidi M: Nefroesclerosis. En: Hernando L, Aljama P, Arias M, Caramelo C, Ejido J, Lamas S, eds. *Nefrología clínica*. Madrid: Editorial Médica Panamericana: 221-232, 2003.
193. Ruilope LM: The kidney and cardiovascular risk. *Nephrol Dial Transplant* 12: 243-245, 1997.
194. Ruilope LM: The kidney as part of the cardiovascular system. *J Cardiovasc Pharmacol* 33 (suppl 1): S7-S10, 1999.
195. Ruilope LM, van Veldhuisen DJ, Ritz E, Luscher TF: Renal function: the Cinderella of cardiovascular risk profile. *J Am Coll Cardiol* 38: 1782-1787, 2001.
196. Ruilope LM: The kidney as a sensor of cardiovascular risk in essential hypertension. *J Am Soc Nephrol* 13: S165-S168, 2002.
197. Kasiske BL: The kidney in cardiovascular disease. *Ann Intern Med* 134: 707-709, 2001.
198. Campo C, Segura J, Ruilope LM: Riesgo cardiovascular asociado a la insuficiencia renal. *Hipertensión* 18: 285-290, 2001.
199. Pérez I, Luño J: La insuficiencia renal es un importante factor de riesgo cardiovascular. *Nefrología* 22: 306-309, 2002.
200. Ritz E: Minor renal dysfunction: an emerging independent cardiovascular risk factor. *Heart* 89: 963-964, 2003.
201. Ritz E, McClellan WM: Overview: increased cardiovascular risk in patients with minor renal dysfunction: an emerging issue with far-reaching consequences. *J Am Soc Nephrol* 15: 513-16, 2004.
202. Best PJ, Holmes DR: Chronic kidney disease as a cardiovascular risk factor. *Am Heart J* 145: 383-386, 2003.
203. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. *Arch Intern Med* 164: 659-663, 2004.
204. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, y cols. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report. *JAMA* 289: 2560-2572, 2003.
205. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, y cols. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. JNC 7 – Complete version. *Hypertension* 42: 1206-1252, 2003.
206. Guidelines Committee: 2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. *J Hypertens* 21: 1011-1053, 2003.
207. Culleton BF, Larson MG, Evans JC, Wilson PWF, Barrett BJ, Parfrey PS, y cols. Prevalence and correlates of serum creatinine levels. The Framingham Heart Study. *Arch Intern Med* 159: 1785-1790, 1999.

208. Culleton BF, Larson MG, Wilson PWF, Evans JC, Parfrey PS, Parfrey PS, y cols. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. *Kidney Int* 56: 2214-2219, 1999.
209. Garg AX, Clark WF, Haynes RB, House AA: Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. *Kidney Int* 61: 1486-1494, 2002.
210. Muntner P, He J, Hamm L, Loria C, Whelton PK: Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. *J Am Soc Nephrol* 13: 745-753, 2002.
211. Henry RMA, Kostense PJ, Bos G, Dekker JM, Nijpels G, Heine RJ, y cols. Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn study. *Kidney Int* 62: 1402-1407, 2002.
212. Abramson JL, Jurkovic CT, Vaccarino V, Weintraub WS, McClellan W: Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study. *Kidney Int* 64: 610-615, 2003.
213. Fried LP, Kronmal RA, Newman AB, Bild DE, Mittelmark MB, Polak JF, y cols. for the Cardiovascular Health Study Collaborative Research Group: Risk factors for 5-year mortality in older adults. The Cardiovascular Health Study. *JAMA* 279: 585-592, 1998.
214. Manjunath G, Tighiouart H, Coresh J, MacLeod B, Salem DN, Griffith JL, y cols. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. *Kidney Int* 63: 1121-1129, 2003.
215. Fried LP, Shlipak MG, Crump C, Bleyer AJ, Gottdiener JS, Kronmal RA, y cols. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. *J Am Coll Cardiol* 41: 1364-1372, 2003.
216. Shlipak MG, Fried LP, Stehman-Breen C, Siscovick D, Newman AB: Chronic renal insufficiency and cardiovascular events in the elderly: findings from the Cardiovascular Health Study. *Am J Geriatr Cardiol* 13: 81-90, 2004.
217. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, y cols. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: results from the Hypertension Detection and Follow-up Program. *Hypertension* 13 (5 suppl): 180-93, 1989.
218. Flack J, Neaton J, Daniels B, Esunge P: Ethnicity and renal disease: lessons from the Multiple Risk Factor Intervention Trial and the Treatment of Mild Hypertension Study. *Am J Kidney Dis* 21 (4 Suppl 1): 31-40, 1993.
219. Schillaci G, Reboldi G, Verdecchia P: High-normal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension. *Arch Intern Med* 161: 886-891, 2001.
220. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, y cols. for the HOT study group: Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. *Lancet* 351: 1755-1762, 1998.
221. Zanchetti A, Hansson L, Dahlöf B, Elmfeldt D, Kjeldsen S, Kolloch R, y cols. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment (HOT) study. *J Hypertens* 19: 1149-1160, 2001.
222. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). *JAMA* 265: 3255-3264, 1991.
223. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, y cols. for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. *Lancet* 350: 757-764, 1997.
224. Wang JG, Staessen JA, Gong L, Liu L, for the Systolic Hypertension in China (Syst-China) Collaborative Group: Chinese trial on isolated systolic hypertension in the elderly. *Arch Intern Med* 160: 211-220, 2000.
225. Pahor M, Shorr RI, Somes GW, Cushman WC, Ferrucci L, Bailey JE, y cols. Diuretic-based treatment and cardiovascular events in patients with mild renal dysfunction enrolled in the Systolic Hypertension in the Elderly Program. *Arch Intern Med* 158: 1340-1345, 1998.
226. Wang JG, Staessen JA, Fagard RH, Birkenhäger WH, Gong L, Liu L, for the Systolic Hypertension in China (Syst-China) Trial Collaborative Group: Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. *Hypertension* 37: 1069-1074, 2001.
227. de Leeuw PW, Thijs L, Birkenhäger WH, Voyaki SM, Efstratopoulos AD, Fagard RH, y cols. for the Systolic Hypertension in Europe (Sist.-Eur) Trial Investigators: Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial. *J Am Soc Nephrol* 13: 2213-2222, 2002.
228. Segura J, Campo C, Gil P, Roldán C, Vigil L, Rodicio JL, y cols. Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. *J Am Soc Nephrol* 15: 1616-1622, 2004.
229. Matts JP, Karnegis JN, Campos CT, Fitch LL, Johnson JW, Buchwald H: Serum creatinine as an independent predictor of coronary heart disease mortality in normotensive survivors of myocardial infarction. POSCH Group. *J Fam Pract* 36: 497-503, 1993.
230. Anderson RJ, O'Brien M, MaWhinney S, VillaNueva CB, Moritz TE, Sethi GK, y cols. Renal failure predisposes patients to adverse outcome after coronary artery bypass surgery. VA Cooperative Study #5. *Kidney Int* 55: 1057-1062, 1999.
231. Anderson RJ, O'Brien M, MaWhinney S, VillaNueva CB, Moritz TE, Sethi GK, y cols. Mild renal failure is associated with adverse outcome after cardiac valve surgery. *Am J Kidney Dis* 35: 1127-1134, 2000.
232. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW: The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. *J Am Coll Cardiol* 35: 681-689, 2000.
233. Hillege HL, Girbes AR, de Kam PJ, Boomsma D, de Zeeuw D, Charlesworth A, y cols. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. *Circulation* 102: 203-210, 2000.
234. McCullough PA, Soman SS, Shah SS, Smith ST, Marks KR, Yee J, y cols. Risks associated with renal dysfunction in patients in the coronary care unit. *J Am Coll Cardiol* 36: 679-684, 2000.
235. Rubenstein MH, Harrell LC, Sheynberg BV, Schunkert H, Bazari H, Palacios IF: Are patients with renal failure good

BIBLIOGRAFÍA

- candidates for percutaneous coronary revascularization in the new device era? *Circulation* 102: 2966-2972, 2000.
236. Beattie JN, Soman SS, Sandberg KR, Yee J, Borzak S, Garg M, y cols. Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction. *Am J Kidney Dis* 37: 1191-1200, 2001.
 237. Szczech LA, Reddan DN, Owen WF, Califf R, Racz M, Jones RH, y cols. Differential survival after coronary revascularization procedures among patients with renal insufficiency. *Kidney Int* 60: 292-299, 2001.
 238. Hemmelgarn BR, Ghali WA, Ouan H, Brant R, Norris CM, Taub KJ, y cols. Poor long-term survival after coronary angiography in patients with renal insufficiency. *Am J Kidney Dis* 37: 64-72, 2001.
 239. The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. *N Engl J Med* 342: 145-153, 2000.
 240. Shlipak MG, Simon JA, Grady D, Lin F, Wenger NK, Furberg CD, for the Heart and Estrogen/progestin Replacement Study (HERS) Investigators: Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. *J Am Coll Cardiol* 38: 705-711, 2001.
 241. Kearney MT, Fox KA, Lee AJ, Prescott RJ, Shah AM, Batin PD, y cols. Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. *J Am Coll Cardiol* 40: 1801-1808, 2002.
 242. McClellan WM, Flanders WD, Langston RD, Jurkowitz C, Presley R: Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. *J Am Soc Nephrol* 13: 1928-1936, 2002.
 243. Mahon NG, Blackstone EH, Francis GS, Starling RC, Young JB, Lauer MS: The prognostic value of estimated creatinine clearance alongside functional capacity in ambulatory patients with chronic congestive heart failure. *J Am Coll Cardiol* 40: 1106-1113, 2002.
 244. Soman SS, Sandberg KR, Borzak S, Hudson MP, Yee J, McCullough PA: The independent association of renal dysfunction and arrhythmias in critically ill patients. *Chest* 122: 669-677, 2002.
 245. Walsh CR, O'Donnell CJ, Camargo CA Jr, Giugliano RP, Lloyd-Jones DM: Elevated serum creatinine is associated with 1-year mortality after acute myocardial infarction. *Am Heart J* 144: 1003-1011, 2002.
 246. Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McClellan MB: Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. *Ann Intern Med* 137: 555-562, 2002.
 247. Wright RS, Reeder GS, Herzog CA, Albright RC, Williams BA, Dvorak DL, y cols. Acute myocardial infarction and renal dysfunction: a high-risk combination. *Ann Intern Med* 137: 563-570, 2002.
 248. McCullough PA, Nowak RM, Foreback C, Tokarski G, Tomlanovich MC, Khoury N, y cols. Emergency evaluation of chest pain in patients with advanced kidney disease. *Arch Intern Med* 162: 2464-2468, 2002.
 249. Al Suwaidi J, Reddan DN, Williams K, Pieper KS, Harrington RA, Califf RM, y cols. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. *Circulation* 106: 974-980, 2002.
 250. Januzzi JL, Cannon CP, DiBattiste PM, Murphy S, Weintraub W, Braunwald E; TACTICS-TIMI 18 Investigators: Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial). *Am J Cardiol* 90: 1246-1249, 2002.
 251. Best PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR, y cols. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. *J Am Coll Cardiol* 39: 1113-1119, 2002.
 252. Shaw RE, Anderson HV, Brindis RG, Krone RJ, Klein LW, McKay CR, y cols. Development of a risk adjustment mortality model using the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR) experience: 1998-2000. *J Am Coll Cardiol* 39: 1104-1112, 2002.
 253. Szczech LA, Best PJ, Crowley E, Brooks MM, Berger PB, Bittner V, y cols. Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Outcomes of patients with chronic renal insufficiency in the bypass angioplasty revascularization investigation. *Circulation* 105: 2253-2258, 2002.
 254. Gruberg L, Weissman NJ, Waksman R, Laird JR Jr, Pinnow EE, Wu H, y cols. Comparison of outcomes after percutaneous coronary revascularization with stents in patients with and without mild chronic renal insufficiency. *Am J Cardiol* 89: 54-57, 2002.
 255. Freeman RV, Mehta RH, Al Badr W, Cooper JV, Kline-Rogers E, Eagle KA: Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. *J Am Coll Cardiol* 41: 718-724, 2003.
 256. Wison S, Foo K, Cunningham J, Cooper J, Deane A, Knight C, y cols. Renal function and risk stratification in acute coronary syndromes. *Am J Cardiol* 91: 1051-1054, 2003.
 257. Reinecke H, Trey T, Matzkies F, Fobker M, Breithardt G, Schaefer RM: Grade of chronic renal failure, and acute and long-term outcome after percutaneous coronary interventions. *Kidney Int* 63: 696-701, 2001.
 258. Gruberg L, Weissman NJ, Pichard AD, Waksman R, Kent KM, Satler LF, y cols. Impact of renal function on morbidity and mortality after percutaneous aortocoronary saphenous vein graft intervention. *Am Heart J* 145: 529-534, 2003.
 259. Chae CU, Albert CH, Glynn RJ, Guralnik JM, Curhan GC: Mild renal insufficiency and risk of congestive heart failure in men and women ≥ 70 years of age. *Am J Cardiol* 92: 682-686, 2003.
 260. Santopinto JJ, Fox KAA, Goldberg RJ, Budaj A, Piñero G, Avezum A, y cols. on behalf of the GRACE Investigators: Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE). *Heart* 89: 1003-1008, 2003.
 261. Mogensen CE, Christensen CK: Predicting diabetic nephropathy in insulin-dependent patients. *N Engl J Med* 311: 89-93, 1984.
 262. Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. *N Engl J Med* 310: 356-360, 1984.
 263. Casado S, Vázquez A, Sierra M, Caramelo C: Microalbuminuria: mecanismos y significado. *Nefrología* 17: 271-274, 1997.
 264. Stephenson JM, Kenny S, Stevens LK, Fuller JH, Lee E: Proteinuria and mortality in diabetes: the WHO

- Multinational Study of Vascular Disease in Diabetes. *Diabet Med* 12: 149-155, 1995.
265. Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH: Albuminuria and poor glycemic control predict mortality in NIDDM. *Diabetes* 44:1303-1309, 1995.
 266. Miettinen H, Haffner SM, Lehto S, Ronnema T, Pyorala K, Laakso M: Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. *Stroke* 27: 2033-2039, 1996.
 267. Dinneen SF, Gerstein HC: The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. *Arch Intern Med* 157: 1413-1418, 1997.
 268. Valmadrid CT, Klein R, Moss SE, Klein BE: The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. *Arch Intern Med* 160: 1093-1100, 2000.
 269. Yudkin JS, Forrest RD, Jackson CA: Microalbuminuria as predictor of vascular disease in non-diabetic subjects. *Islington Diabetes Survey. Lancet* 2: 530-533, 1998.
 270. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE: Microalbuminuria as predictor of increased mortality in elderly people. *BMJ* 300: 297-300, 1990.
 271. Wagner DK, Harris T, Madans JH: Proteinuria as a biomarker: risk of subsequent morbidity and mortality. *Environ Res* 66: 160-172, 1994.
 272. Kuusisto J, Mykkanen L, Pyorala K, Laakso M: Hyperinsulinemic microalbuminuria. A new risk indicator for coronary heart disease. *Circulation* 91: 831-837, 1995.
 273. Ljungman S, Wikstrand J, Hartford M, Berglund G: Urinary albumin excretion – a predictor of risk of cardiovascular disease. A prospective 10-year follow-up of middle-aged nondiabetic normal and hypertensive men. *Am J Hypertens* 9: 770-778, 1996.
 274. Agewall S, Wikstrand J, Ljungman S, Fagerberg B: Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes. *Risk Factor Intervention Study Group. Am J Cardiol* 80: 164-169, 1997.
 275. Grimm RJ, Svendsen K, Kasiske B, y cols. Proteinuria as a risk factor for mortality over 10 years of follow-up. *MRFIT Research Group: Multiple Risk Factor Intervention Trial. Kidney Int* 63: S10-S14, 1997.
 276. Bigazzi R, Bianchi S, Baldari D, Campese VM: Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. *J Hypertens* 16: 1325-1333, 1998.
 277. Jager A, Kostense PJ, Ruhe HG, Heine RJ, Nijpels G, Dekker JM, y cols. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. *Arterioscler Thromb Vasc Biol* 19: 617-624, 1999.
 278. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS: Urinary albumin excretion. An independent predictor of ischemic heart disease. *Arterioscler Thromb Vasc Biol* 19: 1992-1997, 1999.
 279. Culleton BF, Larson MG, Parfrey PS, Kannel WB, Levy D: Proteinuria as a risk factor for cardiovascular disease and mortality in older people: a prospective study. *Am J Med* 109: 1-8, 2000.
 280. Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K: Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. *Hypertension* 35: 898-903, 2000.
 281. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, y cols. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). *Lancet* 356: 366-372, 2000.
 282. Roest M, Banga JD, Janssen WMT, Grobbee DE, Sixma JJ, de Jong PE, y cols. : Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women. *Circulation* 103: 3057-3061, 2001.
 283. Diercks GF, Hillege HL, van Boven AJ, Kors JA, Crijns HJ, Grobbee DE, y cols. Microalbuminuria modifies the mortality risk associated with electrocardiographic ST-T segment changes. *J Am Coll Cardiol* 40: 1401-1407, 2002.
 284. Gerstein HC, Mann JFF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, y cols. for the HOPE Study Investigators: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. *JAMA* 286: 421-426, 2001.
 285. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, y cols. for the Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group: Urinary albumin excretion predicts cardiovascular and non-cardiovascular mortality in general population. *Circulation* 106: 1777-1782, 2002.
 286. Romundstad S, Holmen J, Kvenild K, Hallan H, Ellekjaer H: Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study. The Nord-Trøndelag Health Study (HUNT), Norway. *Am J Kidney Dis* 42: 466-473, 2003.
 287. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, y cols. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. *Ann Intern Med* 139: 901-906, 2003.
 288. Segura J, Campo C, Ruilope LM: Proteinuria: an underappreciated risk factor in cardiovascular disease. *Curr Cardiol Rep* 4: 458-462, 2002.
 289. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, y cols. for the LIFE study group: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet* 359: 995-1003, 2002.
 290. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, y cols. for the LIFE study group: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet* 359: 1004-1010, 2002.
 291. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL y cols. Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. *Hypertension* 42:1050-65, 2003.
 292. Rigatto C. Clinical epidemiology of cardiac disease in renal transplant recipients. *Semin Dial* 16: 106-110, 2003.

BIBLIOGRAFÍA

293. Kasiske BL, Guijarro C, Massy Z, Wiederkehr MR, Ma JZ. Cardiovascular disease after renal transplantation. *J Am Soc Nephrol* 7: 158-65, 1996.
294. United States Renal Data System. USRDS 2002; Annual Data Report. Bethesda MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Available at: <http://www.usrds.org/reference.htm>, 2002
295. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, Klag MJ. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. *J Am Soc Nephrol* 13:1918-27, 2002.
296. Cheung AK, Sarnak MJ, Yang G, Dwyer JT, Heyka RJ, Rocco MV y cols. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. *Kidney Int* 58: 353-62, 2000.
297. Locatelli F, Pozzoni P, Tentori F, del Vecchio L. Epidemiology of cardiovascular risk in patients with chronic kidney disease. *Nephrol Dial Transplant*. 18 (Suppl 7):S2-S9, 2003.
298. Zoccali C, Mallamaci F, Tripepi G. Novel Cardiovascular Risk Factors in End-Stage Renal Disease. *J Am Soc Nephrol* 15 (supl 1): S77-S80, 2004.
299. Kasiske BL, Chakkerla HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. *J Am Soc Nephrol* 11:1735-43, 2000.
300. Jindal RM, Hjelmæsæth J. Impact and management of post-transplant diabetes mellitus. *Transplantation* 70 (11 Suppl): S558-S563, 2000.
301. Torregrosa JV. Cardiovascular risk and diabetogenicity associated with CNI use: a comparison between cyclosporine and tacrolimus. *Transplant Int* 2004 (en prensa)
302. Culleton BF, Wilson PW. Cardiovascular disease: risk factors, secular trends, and therapeutic guidelines. *J Am Soc Nephrol* 9: S5-15, 1998.
303. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, y cols. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. *Am J Kidney Dis* 27: 347-54, 1996.
304. McMahon LP, Roger SD, Levin A, for the Slimheart Investigators group. Development, prevention, and potential reversal of left ventricular hypertrophy in chronic kidney disease. *J Am Soc Nephrol* 15: 1640-47, 2004.
305. Wheeler DC, Townend JN, Landray MJ. Cardiovascular risk factors in predialysis patients: baseline data from the Chronic Renal Impairment in Birmingham (CRIB) study. *Kidney Int (Supl. 84): S201-3*, 2003.
306. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE. Outcome and risk factors for left ventricular disorders in chronic uremia. *Nephrol Dial Transplant* 11: 1277-1285, 1996.
307. Silberberg JS, Barre P, Prichard SS, Sniederma AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. *Kidney Int* 36: 286-290, 1989.
308. London GM, Pannier B, Guerin P, Blacher J, Marchais SJ, Darne B. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: Follow-up of an interventional study. *J Am Soc Nephrol* 12: 2759-67, 2001.
309. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE. Long-term evolution of cardiomyopathy in dialysis patients. *Kidney Int.* 54:1720-5, 1998.
310. Huting J, Kramer W, Schütterle G, Wizemann V. Analysis of left ventricular changes associated with chronic hemodialysis. *Nephron* 49: 284-90, 1998.
311. Parfrey PS, Harnett JD, Foley RN, Kent GM, Murray DC, Barre PE, Guttmann RD. Impact of renal transplantation on uremic cardiomyopathy. *Transplantation*:60: 908-14, 1995.
312. Rigatto C, Foley RN, Kent GM, Guttmann R, Parfrey PS. Long-term changes in left ventricular hypertrophy after renal transplantation. *Transplantation* 70:570-5, 2000.
313. Brahimi M, Dahan M, Dabire H, Levy BI. Impact of pulse pressure on degree of cardiac hypertrophy in patients with chronic uremia. *J Hypertens* 18: 1645-50, 2000.
314. Ventura JE, Tavella N, Romero C, Petraglia A, Baez A, Munoz L. Aortic valve calcification is an independent factor of left ventricular hypertrophy in patients on maintenance hemodialysis. *Nephrol Dial Transplant* 17: 1795-801, 2002.
315. London GM, Guerin AP, Marchais SJ, Pannier B, Safar M, Day M, y cols. Cardiac and arterial interactions in end-stage renal disease. *Kidney Int* 50: 600-608, 1996.
316. Nitta K, Akiba T, Uchida K, Otsu S, Otsu Y, Takei T y cols. Left ventricular hypertrophy is associated with arterial stiffness and vascular calcification. *Hypertens Res* 27: 47-52, 2004.
317. Fagugli RM, Pasini P, Quintaliani G, Pasticci F, Cio G, Cicconi B, y cols. Association between extracellular water, left ventricular mass and hypertension in haemodialysis patients. *Nephrol Dial Transplant.* 18:2332-8, 2003.
318. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Candela V, Labate C, Tassone F. Left ventricular hypertrophy and nocturnal hypoxemia in hemodialysis patients. *J Hypertens* 19:287-93, 2001.
319. Hernandez D, Lacalzada J, Barragan A, Laynez I, Salido E, Barrios Y, y cols. Hipertrofia ventricular izquierda después del trasplante renal: prevención y tratamiento. *Nefrología* 24(supl IV): S43-S48, 2004.
320. Ritz E, Rambašek M, Mall G, Rufmann K, Mandelbaum A. Cardiac changes in uraemia and their possible relationship to cardiovascular instability on dialysis. *Nephrol Dial Transplant* 5(supl 1): 93-97, 1990.
321. Roig E, Betriu A, Castaner A, Magrina J, Sanz G, Navarro-Lopez F. Disabling angina pectoris with normal coronary arteries in patients undergoing long-term hemodialysis. *Am J Med.* 71:431-4, 1981.
322. Mall G, Huther W, Schneider J, Lundin P, Ritz E. Diffuse intermyocardiocytic fibrosis in uremic patients. *Nephrol Dial Transplant* 5: 39-44, 1990.
323. Zoccali C, Benedetto FA, Mallamaci T, y cols. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. *J Am Soc Nephrol* 12: 2768-2774, 2001.
324. Stack AG, Saran R. Clinical correlates and mortality impact of left ventricular hypertrophy among new ESRD patients in the United States. *Am J Kidney Dis.* 40:1202-10, 2002.
325. Fathi R, Isbel N, Haluska B, Case C, Johnson DW, Marwick TH.: Correlates of subclinical left ventricular dysfunction in ESRD. *Am J Kidney Dis* 41: 1016-1025, 2003.
326. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. *Am J Kidney Dis* 28: 53-61, 1996.

327. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giaccone G, Stancanelli B, y cols. Left ventricular mass monitoring in the follow-up of dialysis patients. Prognostic value of left ventricular progression. *Kidney Int* 65: 1492-98, 2004.
328. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE. Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. *J Am Soc Nephrol* 11: 912-16, 2000.
329. Paoletti E, Specchia C, Di Maio G, Bellino D, Damasio B, Cassottana P, y cols. The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: a 10 year survey. *Nephrol Dial Transplant*. 2004 (en prensa)
330. Ohashi H, Oda H, Ohno M, Sakata S. Predictors of survival in continuous ambulatory peritoneal dialysis patients: the importance of left ventricular hypertrophy and diabetic nephropathy. *Adv Perit Dial* 15:87-90, 1999.
331. Rigatto C, Foley R, Jeffery J, Negrijn C, Tribula C, Parfrey P. Electrocardiographic left ventricular hypertrophy in renal transplant recipients: prognostic value and impact of blood pressure and anemia. *J Am Soc Nephrol*. 14:462-8, 2003.
332. Ozkahya M, Ok E, Cirit M, Aydn S, Akcicek F, Basci A, Mees EJD. Regression of left ventricular hypertrophy in hemodialysis patients by volume control without antihypertensive agents. *Nephrol Dial Transplant* 13: 1489-93, 1998.
333. Fagugli RM, Reboli G, Quintaliani G, Pasini P, Ciao G, Cicconi B, y cols. Short daily hemodialysis: blood pressure control and left ventricular mass reduction in hypertensive hemodialysis patients. *Am J Kidney Dis* 38:371-6, 2001.
334. Chan CT, Floras JS, Miller JA, Richardson RM, Pierratos A. Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. *Kidney Int* 61: 2235-9, 2002.
335. Wang MC, Tseng CC, Tsai WC, Huang JJ. Blood pressure and left ventricular hypertrophy in patients on different peritoneal dialysis regimens. *Perit Dial Int* 21:36-42, 2001.
336. Unger P, Wissing KM, De Pauw L, Neubauer J, van de Borne P. Reduction of left ventricular diameter after surgical arteriovenous fistula closure in renal transplant recipients. *Transplantation* 74: 73-9, 2002.
337. Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Ubago JLM. Losartan-dependent regression of myocardial fibrosis associated with reduction of left ventricular chamber stiffness in hypertensive patients. *Circulation* 105: 2512-17, 2002.
338. Resnick LM, Lester MH. Differential effects of antihypertensive drug therapy on arterial compliance. *Am J Hypertens*. 15:1096-100, 2002.
339. Cannella G, Paoletti E, Delfino R, Peloso G, Molinari S, Traverso GB. Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy. *Kidney Int* 44:881-6, 1993.
340. Cannella G, Paoletti E, Delfino R, Peloso G, Rolla D, Molinari S. Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. *Am J Kidney Dis* 30:659-64, 1997.
341. London GM, Pannier B, Guerin AP, Marchais SJ, Safar ME, Cuche JL. Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. *Circulation* 90:2786-96, 1994.
342. Paoletti E, Cassottana P, Bellino D, Specchia C, Messa P, Cannella G. Left ventricular geometry and adverse cardiovascular events in chronic hemodialysis patients on prolonged therapy with ACE inhibitors. *Am J Kidney Dis* 40:728-36, 2002.
343. Suzuki H, Nakamoto H, Okada H, Sugahara S, Kanno Y. A selective angiotensin receptor, valsartan, produces regression of left ventricular hypertrophy associated with a reduction of arterial stiffness. *Adv Perit Dial* 19: 59-66, 2003.
344. Dyadyk AI, Bagriy AE, Lebeb IA, y cols. ACE inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure. *Nephrol Dial Transplant* 12: 947-51, 1997.
345. Suwelack B, Gerhardt U, Hausberg M, y cols. Comparison of quinapril versus atenolol: effects on blood pressure and cardiac mass after renal transplantation. *Am J Cardiol* 86: 583-5, 2000.
346. Klingbeil AU, Muller HJ, Delles C, Fleischmann E, Schmieler RE. Regression of left ventricular hypertrophy by AT1 receptor blockade in renal transplant recipients. *Am J Hypertens* 13: 1295-300, 2000.
347. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM. Impact of Aortic Stiffness Attenuation on Survival of Patients in End-Stage Renal Failure. *Circulation* 103:987-992, 2001.
348. Efrati S, Zaidenstein R, Dishy V, Beberashvili I, Sharist M, Averbukh Z, y cols. ACE inhibitors and survival of hemodialysis patients. *Am J Kidney Dis* 40: 1023-1029, 2002.
349. Pascual J, Teruel JL, Marcen R, Liano F, Moya JL, Jimenez M, y cols. Hemodynamic and cardiac effects of erythropoietin in patients on regular dialysis. *Int J Artif Organs* 15:349-53, 1992.
350. Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, Cartier P, y cols. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. *Kidney Int* 58:1325-35,2000.
351. Hayashi T, Suzuki A, Shoji T. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. *Am J Kidney Dis* 35; 250-6, 2000.
352. London GM, Marchais SJ, Guerin AP, Metivier F, Adda H, Pannier B. Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients. *Kidney Int Suppl.* (supl 84):S88-93, 2003.
353. London GM. Cardiovascular calcifications in uremic patients. Clinical impact on cardiovascular function. *J Am Soc Nephrol* 14(supl 9): S305-S309, 2003.
354. Zebe H. Atrial fibrillation in dialysis patients. *Nephrol Dial Transplant* 15: 765-8, 2000.
355. Vazquez E, Sanchez-Perales C, Lozano C, Garcia-Cortes MJ, Borrego F, Guzman M, y cols. Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis *Am J Cardiol*.:92:868-71, 2003.
356. Wiesholzer M, Harm F, Tomasek G, Barbieri G, Putz D, Balcke P. Incidence of stroke among chronic hemodialysis patients with nonrheumatic atrial fibrillation. *Am J Nephrol* 21: 35-9, 2001.
357. Abe S, Yoshizawa M, Nakanishi N, Yazawa T, Yokota K, Honda M, y cols. Electrocardiographic abnormalities in patients receiving hemodialysis. *Am Heart J* 131: 1137-44, 1996.

BIBLIOGRAFÍA

358. Abbot KC, Trespalacios FC, Taylor AJ, Agodoa LY. Atrial fibrillation in chronic dialysis patients in the United States: risk factor for hospitalization and mortality. *BMC Nephrol*. 4:1, 2003.
359. Abbott KC, Reynolds JC, Taylor AJ, Agodoa LY. Hospitalized atrial fibrillation after renal transplantation in the United States. *Am J Transplant* 3:471-6, 2003.
360. Kocheril AG. Arrhythmia issues in patients with renal disease. *Semin Nephrol* 21: 57-65, 2001.
361. Vazquez E, Sanchez-Perales C, Garcia-Cortes MJ, Borrego F, Lozano C, Guzman M, y cols. Ought dialysis patients with atrial fibrillation be treated with oral anticoagulants? *Int J Cardiol* 87: 135-9, 2003.
362. Madrid H, Bueno MG, Rebollo JM, Marin I, Pena G, Bernal E. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. *Circulation* 106: 331-336, 2002.
363. Zaman AG, Kearney MT, Schechter C, Worthley SG, Nolan J. Angiotensin-converting enzyme inhibitors as adjunctive therapy in patients with persistent atrial fibrillation. *Am Heart J*. 147:823-7, 2004.
364. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijs HJ, Frye RL, y cols. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. *Circulation* 23;104:2118-50, 2001.
365. Gage BF, Boechler M, Doggette AL, Fortune G, Flaker GC, Rich MW, y cols. MJ. Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. *Stroke*.31:822-7, 2000.
366. Boos CJ, More RS. Anticoagulation for non-valvular atrial fibrillation. Towards a new beginning with ximelagatran. *Curr Control Trials Cardiovasc Med*. 2004 (en prensa).
367. Sánchez Perales MC, Vazquez E, Garcia Cortes MJ, Borrego FJ, Borrego J, Perez del Barrio P, y cols. Antiagregación plaquetaria y riesgo hemorrágico en hemodiálisis. *Nefrología* 22; 456-62, 2002.
368. Orth SR. Smoking and the kidney. *J Am Soc Nephrol* 2002; 132: 1663-72.
369. Rostand SG, Kirk KA, Rutsky EA. Relationship of coronary risk factors to hemodialysis-associated ischemic heart disease. *Kidney Int* 22: 304-8, 1982.
370. Chow FY, Polkinghorne KR, Chadban SJ, Atkins RC, Kerr PG. Cardiovascular risk in dialysis patients: a comparison of risk factors and cardioprotective therapy between 1996 and 2001. *Nephrology* 8:177-83, 2003.
371. Foley RN, Herzog CA, Collins AJ. Smoking and cardiovascular outcomes in dialysis patients: the United States Renal Data System Wave 2 study. *Kidney Int*. 63:1462-7, 2003.
372. Parfrey PS, Harnett JD, Griffiths SM, Gault MH, Barre PE. Congestive heart failure in dialysis patients. *Arch Intern Med* 148: 1519-1525, 1988.
373. Comorbid conditions and correlations with mortality risk among 3.399 incident hemodialysis patients. *Am J Kidney Dis* 20 (supl 2): 32-38, 1992.
374. Biesenbach G, Zazgornik J. Influence of smoking on the survival rate of diabetic patients requiring hemodialysis. *Diabetes Care* 19: 625-8, 1996.
375. Stack AG, Bloembergen WE: Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: A cross-sectional study. *J Am Soc Nephrol* 12: 1516-1523, 2001.
376. O'Hare AM, Hsu Cy CY, Bacchetti P, Johansen KL: Peripheral vascular disease risk factors among patients undergoing hemodialysis. *J Am Soc Nephrol* 13: 497-503, 2002.
377. Malatino LS, Benedetto FA, Mallamaci F, Tripepi G, Zoccali C on behalf of CREED investigators. Smoking, blood pressure and serum albumin are major determinants of carotid atherosclerosis in dialysis patients. CREED Investigators. Cardiovascular Risk Extended Evaluation in Dialysis patients. *J Nephrol* 12: 256-60, 1999.
378. Kawagishi T, Nishizawa Y, Konishi T, Kawasaki K, Emoto M, Shoji T, y cols. High resolution B-mode ultrasonography in evaluation of atherosclerosis in uremia. *Kidney Int* 48: 820-826, 1995.
379. Sakurabayashi T, Fujimoto M, Takaesu Y, y cols. Association between plasma homocysteine concentration and carotid atherosclerosis in hemodialysis patients. *Jpn Circ J* 63: 692-6, 1999.
380. Shoji T, Emoto M, Tabata T, Kimoto E, Shinohara K, Maekawa K, y cols. Advanced atherosclerosis in predialysis patients with chronic renal failure. *Kidney Int*. 61:2187-92, 2002.
381. Kato A, Takita T, Maruyama Y, Kumagai H, Hishida A. Impact of carotid atherosclerosis on long-term mortality in chronic hemodialysis patients. *Kidney Int* 64: 1472-79, 2003.
382. Hojs R. Carotid intima-media thickness and plaques in hemodialysis patients. *Artif Organs* 24:691-5, 2000.
383. Burdick L, Periti M, Salvaggio A, Bertoli S, Mangiarotti R, Castagnone D, Anguissola G. Relation between carotid artery atherosclerosis and time on dialysis. A non-invasive study in vivo. *Clin Nephrol*. 42:121-6, 1994.
384. Wesson DE. The relationship of cigarette smoking to end-stage renal disease. *Semin Nephrol* 23: 317-22, 2003.
385. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. *Nephrol Dial Transplant*. 18:1731-40, 2003.
386. Ducloux D, Kazory A, Chalopin JM. Predicting coronary heart disease in renal transplant recipients: a prospective study. *Kidney Int* 66: 441-7, 2004.
387. Aker S, Ivens K, Grabensee B, Heering P. Cardiovascular complications after renal transplantation. *Transplantation Proc* 30; 2039-42, 1998.
388. Kasiske BL, Klinger D: Cigarette smoking in renal transplant recipients. *J Am Soc Nephrol* 11: 753-759, 2000.
389. Arend SM, Mallat MJ, Westendorp RJ, van der Woude FJ, van Es LA. Patient survival after renal transplantation; more than 25 years follow-up. *Nephrol Dial Transplant*. 12:1672-9, 1997.
390. Cosio FG, Alamir A, Yim S, Pesavento TE, Falkenhain ME, Henry ML, y cols. Patient survival after renal transplantation: I. The impact of dialysis pre-transplant. *Kidney Int*. 53:767-72, 1998.
391. Hegeman RL, Hunsicker LG. Chronic rejection in renal allografts: importance of cardiovascular risk factors. *Clin Transplant*. 9:135-9, 1995.

392. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG: Obesity and the risk of heart failure. *N Engl J Med* 347: 305-313, 2002.
393. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body mass index and mortality in a prospective cohort of U.S. adults. *N Engl J Med* 341: 1097-1105, 1999.
394. Must A, Spadano J, Coakley EH, Field AE: The disease burden associated with overweight and obesity. *JAMA* 282: 1523-29, 1999.
395. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. *JAMA* 282:2131-5, 1999.
396. Keaney JF, Larson MG, Vasani RS, y cols. Framingham study; Obesity and systemic oxidative stress; clinical correlation of oxidative stress in the Framingham study. *Arterioscl Thromb Vasc Biol* 23: 434-9, 2003.
397. Hall JE, Henegar JR, Dwyer TM, Liu J, da Silva AA, Kuo JJ, y cols. Is obesity a major cause of chronic kidney disease? *Adv Renal Replac Ther* 11: 41-54, 2004.
398. Praga M. Obesity--a neglected culprit in renal disease. *Nephrol Dial Transplant*. 17:1157-9, 2002.
399. Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S. Body mass index and the risk of development of end-stage renal disease in a screened cohort. *Kidney Int* 65 :1870-8, 2004.
400. Degoulet P, Legrain M, Reach I y cols. Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. *Nephron* 31: 103-110, 1982.
401. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. *Kidney Int*. 55:648-58, 1999.
402. Kopple JD, Zhu X, Lew NL, Lowrie EG. Body weight-for-height relationships predict mortality in maintenance hemodialysis patients. *Kidney Int* 56: 1136-1148, 1999.
403. Fleischmann E, Teal N, Dudley J, May W, Bower JD, Salahudeen AK. Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients. *Kidney Int*. 55:1560-7, 1999.
404. Leavey SF, McCullough K, Hecking E, Goodkin D, Port FK, Young EW. Body mass index and mortality in 'healthier' as compared with 'sicker' haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). *Nephrol Dial Transplant*. 16:2386-94, 2001.
405. Port FK, Ashby VB, Dhingra RK y cols. Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. *J Am Soc Nephrol* 13: 1061-1066, 2002.
406. Stack AG, Murthy BV, Molony DA. Survival differences between peritoneal dialysis and hemodialysis among "large" ESRD patients in the United States. *Kidney Int*. 65:2398-408, 2004.
407. Stenvinkel P, Wanner C, Metzger T, Heimbürger O, Mallamaci F, Tripepi G, y cols. Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage? *Kidney Int*. 62:1791-8, 2002.
408. Wallen MD, Radhakrishnan, Appel G, Hodgson ME, Pablos-Mendez A. An analysis of cardiac mortality in patients with new-onset end-stage renal disease in New York State. *Clin Nephrol* 55: 101-8, 2001.
409. Wong JS, Port FK, Hulbert-Shearon TE, Carroll CE, Wolfe RA, Agodoa LY. Survival advantage in Asian American end-stage renal disease patients. *Kidney Int* 55: 2515-2523, 1999.
410. Kalantar-Zadeh K, Fouque D, Kopple JD. Outcome research, nutrition, and reverse epidemiology in maintenance dialysis patients. *J Ren Nutr* 14:64-71, 2004.
411. Beddhu S, Pappas LM, Ramkumar N, Samore MH. Malnutrition and atherosclerosis in dialysis patients. *J Am Soc Nephrol* 15: 733-42, 2004.
412. Aslam N, Bernardini J, Fried L, Piraino B. Large body mass index does not predict short-term survival in peritoneal dialysis patients. *Perit Dial Int* 22: 191-196, 2002.
413. Johnson DW, Herzog KA, Purdie DM, Chang W, Brown AM, Rigby RJ. Is obesity a favorable prognostic factor in peritoneal dialysis patients? *Perit Dial Int* 20: 715-721, 2000.
414. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. *Am J Transplant* 3:178-85, 2003.
415. Massy ZA, Kasiske BL. Posttransplant hyperlipidemia: mechanism and management. *J Am Soc Nephrol* 7: 971, 1996
416. Locsey L, Asztalos L, Kincses ZS, Berczi CS, Paragh GY. The importance of obesity and hyperlipidaemia in patients with renal transplants. *Int Urol Nephrol* 30:767-775, 1998.
417. Holley JL, Shapiro R, Lopatin WB, Tzakis AG, Hakala TR, Starzl TE. Obesity as a risk factor following cadaveric renal transplantation. *Transplantation* 49:387-389, 1990.
418. Merion RM, Twork AM, Rosenberg L, Ham JM, Burtch GD, Turcotte JG, y cols. Obesity and renal transplantation. *Surg Gynecol Obstet*. 172:367-76, 1991.
419. Gill IS, Hodge EE, Novick AC, Steinmuller DR, Garred D. Impact of obesity on renal transplantation. *Transplant Proc* 25:1047-1048, 1993.
420. Halme L, Eklund B, Salmela K Obesity and renal transplantation. *Transplant Proc*. 27:3444-5, 1995.
421. Pirsch JD, Armbrust MJ, Knechtle SJ, D'Alessandro AM, Sollinger HW, Heisey DM, y cols. Obesity as a risk factor following renal transplantation. *Transplantation* 59:631-647, 1995.
422. Modlin CS, Flechner SM, Goormastic M, y cols. Should obese patients lose weight before receiving a kidney transplant? *Transplantation* 64:599-604, 1997.
423. Orofino L, Pascual J, Quereda C, Burgos J, Marcen R, Ortuño J. Influence of overweight on survival of kidney transplant. *Nephrol Dial Transplant* 12:855, 1997.
424. Drafts HH, Anjum MR, Wynn JJ, Mulloy LL, Bowley JN, Humphries AL. The impact of pre-transplant obesity on renal transplant outcomes. *Clin Transplant*. 11:493-6, 1997.
425. Meier-Kriesche H-U, Vaghela M, Thambuganipalle R, Friedman G, Jacobs M, Kaplan B. The effect of body mass index on long-term renal allograft survival. *Transplantation* 68:1294-1297, 1999.
426. Howard RJ, Thai VB, Patton PR, y cols. Obese kidney transplant recipients have good outcomes. *Transplant Proc* 33:3420-3421, 2001.
427. Johnson DW, Isbel NM, Brown AM, Kay TD, Franzen K, Hawley CM, Campbell SB, Wall D, Griffin A, Nicol DL. The effect of obesity on renal transplant outcomes. *Transplantation*. 74:675-81, 2002.
428. Howard RJ, Thai VB, Patton PR, Hemming AW, Reed AI, Van der Werf WJ. Obesity does not portend a bad outcome for kidney transplant recipients. *Transplantation* 73:53-55, 2002.

BIBLIOGRAFÍA

429. Meier-Kriesche HU, Arndorfer JA, Kaplan B. The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. *Transplantation*. 73:70-4, 2002.
430. Marks WH, Florence LS, Chapman PH, Precht AF, Perkinson DT. Morbid obesity is not a contraindication to kidney transplantation. *Am J Surg* 187: 635-38, 2004.
431. Jindal RM, Zawada ET Jr. Obesity and kidney transplantation. *Am J Kidney Dis*.43:943-52, 2004.
432. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. *JAMA* 288:2015-22, 2002.
433. Christen WG, Ajani UA, Glynn RJ, Hennekens CH. Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual? *Arch Intern Med* 160:422-434, 2000.
434. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. *Br Med J* 325:1202-1208, 2002.
435. Refsum H, David Smith A, Ueland PM, Nexø E, Clarke R, McPartlin J, y cols. Facts and recommendations about total homocysteine determinations: An expert opinion. *Clin Chem* 50: 3-32, 2004.
436. Chauveau P, Chadefaux B, Coude M, Aupetit J, Hannedouche T, Kamoun P. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. *Kidney Int* 41 (Supl): S72-7. 1993.
437. Bostom AG, Lathrop L. Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to atherosclerotic outcomes. *Kidney Int* 52: 10-20, 1997.
438. Arnadottir M, Hultberg B, Wahlberg J, Fellstrom B, Dimeny E. Serum total homocysteine concentration before and after renal transplantation. *Kidney Int*. 54:1380-1384, 1998.
439. Bostom AG, Gohh RY, Liaugaudas G, Beaulieu AJ, Han H, Jacques PF, y cols. Prevalence of mild fasting hyperhomocysteinemia in renal transplant versus coronary artery disease patients after fortification of cereal grain flour with folic acid. *Atherosclerosis* 145:221-224, 1999.
440. Suliman ME, Stenvinkel P, Barany P, Heimburger O, Anderstam B, Lindholm B. Hyperhomocysteinemia and its relationship to cardiovascular disease in ESRD: influence of hypoalbuminemia, malnutrition, inflammation, and diabetes mellitus. *Am J Kidney Dis* 41(3 Supl 2):S89-95, 2003.
441. Födinger M, Mannhalter C, Wöfl G y cols. Mutation (677 C to T) in the methyltetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. *Kidney Int* 52: 517-23, 1997.
442. Bostom AG, Shemin D, Verhoef P, Nadeau MR, Jacques PF, Selhub J: Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients: A prospective study. *Arterioscler Thromb Vasc Biol* 17: 2554-2558, 1997.
443. Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacobsen DW y cols. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. *Circulation* 97: 138-141, 1998.
444. Mallamaci F, Zoccali C, Tripepi G, Fermo I, Benedetto FA, Cataliotti A y cols. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. *Kidney Int* 61: 609-614, 2002.
445. Haraki T, Takegoshi T, Kitoh C, Kajigami K, Wakasugi T, Hirai J y cols. Hyperhomocysteinemia, diabetes mellitus and carotid atherosclerosis independently increase atherosclerotic vascular disease outcome in Japanese patients with end-stage renal disease. *Clin Nephrol* 51: 132-139, 2001.
446. Righetti M, Ferrario GM, Milani S, Serbelloni P, La Rosa L, Uccellini M, Sessa A. Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients. *Med Sci Monitor* 9: 37-42, 2003.
447. Jungers P, Chauveau P, Bandin O, y cols. Hyperhomocysteinemia is associated with atherosclerotic occlusive arterial accidents in predialysis chronic renal failure patients. *Miner Electrolyte Metab* 23: 170-173, 1997.
448. Dierkes J, Domrose U, Westphal S, y cols. Cardiac troponin T predicts mortality in patients with end-stage renal disease. *Circulation* 102:1964-1969, 2000.
449. Koulouridis E, Tzilianos M, Katsarou A, Costimba I, Klonou E, Panagiotaki E y cols. Homocysteine and C-reactive protein levels in hemodialysis patients. *Int Urol Nephrol* 33: 207-15, 2001.
450. Bayés B, Pastor MC, Bonal J, Junca J, Hernandez JM, Riutort N, y cols. Homocysteine, C-reactive protein, lipid peroxidation and mortality in hemodialysis patients. *Nephrol Dial Transplant* 18: 106-12, 2003.
451. Sirrs S, Duncan L, Djurdjev O, y cols. Homocyst(e)ine and vascular access complications in haemodialysis patients: Insights into a complex a complex metabolic relationship. *Nephrol Dial Transplant* 14: 738-43, 1999.
452. Wrone EM, Hornberger JM, Zehnder JL, McCann L, Coplou NS, Fortmann SP. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. *J Am Soc Nephrol* 15: 420-426, 2004.
453. Kalantar-Zadeh K, Block G, Humphreys MH, McAllister CJ, Kopple JD. A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. *J Am Soc Nephrol* 15: 442-453, 2004.
454. Suliman ME, Qureshi AR, Barany P, Stenvinkel P, Filho JC, Anderstam B y cols. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. *Kidney Int* 57: 1727-1735, 2000.
455. Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R y cols. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. *Circulation* 94: 2743-2748, 1996.
456. Bachmann J, Tepel M, Raidt H, Riezler R, Graefe U, Langer K y cols. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. *J Am Soc Nephrol* 6: 121-125, 1995.
457. Manns BJ, Burgess ED, Hyndman ME, Parsons HG, Schaefer JP, Scott-Douglas NW. Hyperhomocysteinemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease. *Am J Kidney Dis* 34:669-677, 1999.
458. Kunz K, Petitjean P, Lisri M, Chantrel F, Koehl C, Wiesel ML y cols. Cardiovascular morbidity and endothelial dysfunction in chronic haemodialysis patients: is homocyst(e)ine the missing link? *Nephrol Dial Transplant* 14:1934-42, 1999.
459. Fellah H, Feki M, Hsairi M, Sanhaji H, Kaabachi N, Ben Abdallah T, Massy ZA, Ben Maiz H, Lacour B, Mebazaa A. Hyperhomocysteinemia and end-stage renal disease: determinants and association with cardiovascular disease in Tunisian patients. *Clin Chem Lab Med*. 41:675-80, 2003.

460. Kimura H, Gejyo F, Suzuki S, Miyazaki R. The C677T methylenetetrahydrofolate reductase gene mutation in hemodialysis patients. *J Am Soc Nephrol* 11: 885-893, 2000.
461. De Vecchi AF, Bamonti-Catena F, Finazzi S, Finazzi S, Patrosso C, Taioli E y cols. Homocysteine, vitamin B12, serum and erythrocyte folate in peritoneal dialysis patients. *Clin Nephrol* 55: 313-7, 2000.
462. Wrone EM, Zehnder JL, Hornberger JM, McCann LM, Coplon NS, Fortmann SP: An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease. *Kidney Int* 60: 1106-1113, 2001.
463. Ohkuma T, Minagawa T, Takada N, Ohno M, Oda H, Ohashi H. C-reactive protein, lipoprotein(a), homocysteine, and male sex contribute to carotid atherosclerosis in peritoneal dialysis patients. *Am J Kidney Dis*. 42:355-61, 2003.
464. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Fermo I, Foca A, y cols. Inflammation is associated with carotid atherosclerosis in dialysis patients. CREED Investigators. Cardiovascular Risk Extended Evaluation in Dialysis Patients. *J Hypertens* 18:1207-13, 2000.
465. Blacher J, Demuth K, Guerin AP, Vadez C, Moatti N, Safar ME, London GM. Association between plasma homocysteine concentrations and cardiac hypertrophy in end-stage renal disease. *J Nephrol*. 12:248-55, 1999.
466. Mezzano D, Pais EO, Aranda E, Panes O, Downey P, Ortiz M y cols. Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. *Kidney Int* 60: 1844-50, 2001.
467. Ducloux D, Motte G, Challier B, Gibey R, Chalopin JM y cols. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: A prospective study. *J Am Soc Nephrol* 11: 134-137, 2000.
468. Massy ZA, Chadefaux-Vekemans B, Chevalier A, Chevalier A, Bader CA, Druke TB y cols. Hyperhomocysteinemia: a significant risk factor for cardiovascular disease in renal transplant recipients. *Nephrol Dial Transplant* 9:1103-8, 1994.
469. Ducloux D, Fournier V, Rebibou JM, Bresson-Vautrin C, Gibey R, Chalopin JM. Hyperhomocyst(e)inemia in renal transplant recipients with and without cyclosporine. *Clin Nephrol* 49:232-5, 1998.
470. Franke S, Muller A, Sommer M, Busch M, Kientsch-Engel R, Stein G. Serum levels of total homocysteine, homocysteine metabolites and of advanced glycation end-products (AGEs) in patients after renal transplantation. *Clin Nephrol*. 59:88-97, 2003.
471. Hagen W, Födinger M, Heinz G, Buchmayer H, Horl WH, Sunder-Plassmann G y cols. The effect of MTHFR genotypes and hyperhomocysteinemia on patients and graft survival in kidney transplant recipients. *Kidney Int* 59(Supl 78): S253-S257, 2001.
472. Haviv YS, Shpichinetsky V, Goldschmidt N, Atta IA, Ben-Yehuda A, Friedman G. The common mutations C677T and A1298C in the human methylenetetrahydrofolate reductase gene are associated with hyperhomocysteinemia and cardiovascular disease in hemodialysis patients. *Nephron* 92:120-126, 2002.
473. Morimoto K, Haneda T, Okamoto K, Ishida H, Kikuchi K. Methylenetetrahydrofolate reductase gene polymorphism, hyperhomocysteinemia, and cardiovascular diseases in chronic hemodialysis patients. *Nephron*. 90:43-50, 2002.
474. Lim PS, Hung WR, Wei YH. Polymorphism in methylenetetrahydrofolate reductase gene: its impact on plasma homocysteine levels and carotid atherosclerosis in ESRD patients receiving hemodialysis. *Nephron*. 87:249-56, 2001.
475. Austen SK, Coombes JS, Fassett RG. Homocysteine-lowering therapy in renal disease. *Clin Nephrol* 80: 375-385, 2003.
476. van Guldener C, Lambert J, ter Wee PM, Donker AJ, Stehouwer CD. Carotid artery stiffness in patients with end-stage renal disease: no effect of long-term homocysteine-lowering therapy. *Clin Nephrol* 53: 33-41, 2000.
477. van Guldener C, Janssen MJ, Lambert J, Ter Wee PM, Jakobs C, Donker AJ. No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinemia in haemodialysis patients. *Nephrol Dial Transplant* 13; 106-112, 1998.
478. van Guldener C, Janssen MJ, Lambert J, ter Wee PM, Donker AJ, Stehouwer CD. Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: no change in endothelial function after long-term therapy. *Perit Dial Int* 18:282-9, 1998.
479. Thambyrajah J, Landray MJ, McGlynn FJ, Jones HJ, Wheeler DC, Townend JN. Does folic acid decrease plasma homocysteine and improve endothelial function in patients with pre-dialysis renal failure? *Circulation* 22: 102:871-75, 2000.
480. Bennett-Richards K, Kattenhorn M, Donald A, Oakley G, Varghese Z, Rees L, y cols. Does oral folic acid lower total homocysteine levels and improve endothelial function in children with chronic renal failure ? *Circulation* 105: 1810-15, 2002.
481. Bucciatti G, Raselli S, Baragetti I, Bamonti F, Corghi E, Novembrino C y cols. 5-methyltetrahydrofolate restores endothelial function in uraemic patients on convective haemodialysis. *Nephrol Dial Transplant* 17: 857-64, 2002.
482. Apeland T, Mansoor MA, Seljeflot I, Bronstad I, Goranson L, Strandjord RE. Homocysteine, malondialdehyde and endothelial markers in dialysis patients. *J Int Med* 252: 456-64, 2002.
483. Bayés B, Pastor MC, Bonal J, Juncà J, Romero R. Homocysteine and lipid peroxidation in haemodialysis: role of folic acid and vitamin E. *Nephrol Dial Transplant* 16: 2172-75, 2001.
484. Scholze A, Rinder C, Beige J, Riezler R, Zidek W, Tepel M. Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. *Circulation* 109: 369-74, 2004.
485. Van Telligen A, Grooteman MP, Bartels PC, Van Limbeek J, Van Guldener C, Wee PM, y cols. Long-term reduction of plasma homocysteine levels by super-flux dialyzers in hemodialysis patients. *Kidney Int* 59: 342-347, 2001.
486. De Vriese AS, Langlois M, Bernard D, Geerolf I, Stevens L, Bolaert JR, y cols. Effect of dialyser membrane pore size on plasma homocysteine levels in haemodialysis patients. *Nephrol Dial Transplant* 18: 2596-600, 2003.
487. Galli F, Benedetti S, Buoncrisiani U, Piroddi M, Conte C, Canestrari F, y cols. A. The effect of PMMA-based protein-leaking dialyzers on plasma homocysteine levels. *Kidney Int*. 64:748-55, 2003.
488. Friedman AN, Bostom AG, Levey AS, Rosenberg IH, Selhub J, Perratos A. Plasma total homocysteine levels among patients undergoing nocturnal versus standard hemodialysis. *J Am Soc Nephrol* 13: 265-268, 2002.

BIBLIOGRAFÍA

489. Maduell F, Navarro V, Torregrosa E, Rius A, Dicenta F, Cruz MC, Ferrero JA. Change from three times a week on-line hemodiafiltration to short daily on-line hemodiafiltration. *Kidney Int.* 64:305-13, 2003.
490. Galland R, Traeger J, Arkouche W, Cleaud C, Delawari E, Fouque D. Short daily hemodialysis rapidly improves nutritional status in hemodialysis patients. *Kidney Int* 60: 1555-60, 2001.
491. Marcucci R, Zanazzi M, Bertoni E, Rosatti A, Fedi S, Lenti M y cols. Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal-transplant recipients. *Transplantation* 75: 1551-5, 2003.
492. Abdelfatah A, Ducloux D, Toubin G, Motte G, Alber D, Chalopin JM. Treatment of hyperhomocysteinemia with folic acid reduces oxidative stress in renal transplant recipients. *Transplantation.* 73:663-5, 2002.
493. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.5.5. Cardiovascular risks. Hyperhomocysteinaemia. *Nephrol Dial Transplant* 17 (Supl 4):28-29, 2002.
494. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, y cols. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. *JAMA.* 291:451-9, 2004.
495. Ross R. Mechanisms of disease: atherosclerosis an inflammatory disease. *N Engl J Med* 340: 115-26, 1999.
496. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. *Circulation* 107: 363-9, 2003.
497. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy american women. *Circulation* 107: 391-7, 2003.
498. Koenig W. Update in C reactive protein as a risk marker in cardiovascular disease. *Kidney Int* 84: S58-S61, 2003.
499. Stenvinkel P, Heimbürger O, Paultre F, y cols. Strong associations between malnutrition, inflammation and atherosclerosis in chronic renal failure. *Kidney Int* 55: 1899-1911, 1999.
500. Boltom CH, Downs LG, Victory JGG, Dwight JF, Tomson CRV, Mackness MI y cols. Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines. *Nephrol Dial Transplant* 16: 1189-97, 2001.
501. Panichi V, Migliori M, De Pietro S, Taccola D, Bianchi AM, Norpoth M, y cols. C-reactive protein in patients with chronic renal diseases. *Renal Fail* 23: 551-62, 2001.
502. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA y cols. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. *Kidney Int* 65: 1009-1016, 2004.
503. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, y cols. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. *Circulation* 107:87-92,2003.
504. Stuveling EM, Hillege HL, Bakker SJ, Gans RO, De Jong PE, De Zeeuw D. C-reactive protein is associated with renal function abnormalities in a non-diabetic population. *Kidney Int.* 63:654-61, 2003.
505. Owen WF, Lowrie EG. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. *Kidney Int* 54: 773-782, 1998.
506. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. *Am J Kidney Dis* 35: 469-76, 2000.
507. Yeun JY, Kaysen GA. Acute phase proteins and peritoneal dialysate albumin loss are the main determinants of serum albumin in peritoneal dialysis patients. *Am J Kidney Dis* 30: 923-7, 1997.
508. Herbelin A, Urena P, Nguyen AT, Zingraff J, Descamps-Latscha B. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. *Kidney Int.* 39:954-60, 1991.
509. Stenvinkel P. Inflammation in end-stage renal failure: could it be treated? *Nephrol Dial Transplant* 17(supl 8): S33-S38, 2002.
510. Busch M, Franke S, Müller A, Wolf M, Gerth J, Ott U, y cols. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites and C-reactive protein. *Kidney Int* 2004; 66: 338-47.
511. Kaysen GA, Eisenrich JP. Characteristics and effects of inflammation in end-stage renal disease. *Semin Dial* 16: 438-46, 2003.
512. López-Gómez JM, Pérez Flores I, Jofré R, Carretero D, Rodríguez Benítez P, Villaverde M, y cols. The presence of a failed kidney transplant in patients returning to hemodialysis is associated with a chronic inflammatory state and erythropoietic resistance. *J Am Soc Nephrol* 2004 (en prensa)
513. Bergstrom J, Heimbürger O, Lindholm B, Qureshi AR. Elevated C-reactive protein is a strong predictor of increased mortality and low serum albumin in hemodialysis patients. *J Am Soc Nephrol* 6: 573Abstract, 1995.
514. Kimmel PL, Philips TM, Simmens SJ, Peterson RA, Weihs KL, Alleyne S y cols. Immunologic function and survival in hemodialysis patients. *Kidney Int* 54: 236-244, 1998.
515. Noh H, Lee SW, Kang SW, Shin SK, Choi KH, Lee HY, Han DS. Serum C-reactive protein: a predictor of mortality in continuous ambulatory peritoneal dialysis patients. *Perit Dial Int.* 18:387-94, 1998.
516. Iseki K, Tozawa M, Yoshi S, Fujiyama K. Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. *Nephrol Dial Transplant* 14: 1956-60, 1999.
517. Qureshi AR, Alvestrand A, Divino-Filho JC, y cols. Inflammation, malnutrition and cardiac disease as predictor of mortality in hemodialysis patients. *J Am Soc Nephrol* 13(supl 1): S28-36, 2002.
518. DeFilippi C, Wasserman S, Rosanio S, Tiblier E, Sperger H, Tcchi M y cols. Cardiac troponin and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. *JAMA* 290: 353-9, 2003.
519. Chauveau P, Level C, Lasseur C, Bonarek H, Peuchant E, Montaudon D, y cols. C-reactive protein and procalcitonin as markers of mortality in hemodialysis patients: a 2-year prospective study. *J Ren Nutr.* 13:137-43, 2003.
520. Ikizler TA, Wingard RL, Harvell J, Shyr Y, Hakim RM. Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study. *Kidney Int* 55: 1945-51, 1999.

521. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH y cols. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. *Am J Kidney Dis* 32: 469-76, 1998.
522. Kalantar-Zadeh K, Kopple JD, Humphreys MH, Block G. Comparing outcome predictability of markers of malnutrition-inflammation complex syndrome in haemodialysis patients. *Nephrol Dial Transplant* 19: 1507-1519, 2004.
523. Stolar J, Georges B, Shita A, Verbeelen D. The predictive value of cardiac troponin T measurements in subjects on regular hemodialysis. *Nephrol Dial Transplant* 14: 1961-67, 1999.
524. Ducloux D, Bresson-Vautrin C, Kribs M, Abdelfatah A, Chalopin M. C-reactive protein and cardiovascular disease in peritoneal dialysis patients. *Kidney Int* 62: 1417-22, 2002.
525. Herzig KA, Purdie DM, Chang W, Brown AM, Hawley CM, Campbell SB, y cols. Is C-reactive protein a useful predictor of outcome in peritoneal dialysis patients? *J Am Soc Nephrol*. 12:814-21, 2001.
526. Spittle MA, Hoenich NA, Handelman GJ, Adhikarla R, Homel P, Levin NW. Oxidative stress and inflammation in hemodialysis patients. *Am J Kidney Dis*. 38:1408-13, 2001.
527. Varaganam M, Finney H, Trevitt R, Sharples E, McCloskey DJ, Sinnott PJ, y cols. Pretransplantation levels of C-reactive protein predict all-cause and cardiovascular mortality, but not graft outcome, in kidney transplant recipients. *Am J Kidney Dis* 43:502-7, 2004.
528. Pawlak K, Naumnik B, Brzosko S, Pawlak D, Mysliwiec M. Oxidative stress - a link between endothelial injury, coagulation activation, and atherosclerosis in haemodialysis patients. *Am J Nephrol*. 24:154-61, 2004.
529. Bakri RS, Afzali B, Covic A, Sriskantharan R, Bharma-Ariza P, Park WH, y cols. Cardiovascular disease in renal allograft recipients is associated with elevated sialic acid or markers of inflammation. *Clin Transplant*. 18:201-4, 2004.
530. Menon V, Wang X, Greene T, Beck GJ, Kusek JW, Marcovina SM, y cols. Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease. *Am J Kidney Dis* 42: 44-52, 295.
531. Ortega O, Rodriguez I, Gallar P, Carreno A, Ortiz M, Espejo B, y cols. Significance of high C-reactive protein levels in pre-dialysis patients. *Nephrol Dial Transplant*. 17:1105-9, 2002.
532. Papayianni A, Alexopoulos E, Giamalis P, Gionanlis L, Belechri AM, Koukoudis P, y cols. Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in haemodialysis patients: association with inflammation, dyslipidaemia, and vascular events. *Nephrol Dial Transplant*. 17:435-41, 2002.
533. Papagianni A, Kalovoulos M, Kirmizis D, Vainas A, Belechri AM, Alexopoulos E y cols. Carotid atherosclerosis is associated with inflammation and endothelial cell adhesion molecules in chronic hemodialysis patients. *Nephrol Dial Transplant*. 18: 113-9, 2003.
534. Papagianni A, Kokolina E, Kalocvoulos M, Vainas A, Dimitriadis C, Memmos D. Carotid atherosclerosis is associated with inflammation, malnutrition and intercellular adhesion molecule-1 in patients on continuous ambulatory peritoneal dialysis. *Nephrol Dial Transplant* 2004 (en prensa)
535. Oh J, Wunsch R, Turzer BC y cols. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. *Circulation* 106: 100-105, 2002.
536. Leskinen Y, Groundstroem K, Virtanen V, Lehtimäki T, Huhtala H, Saha H. Risk factors for aortic atherosclerosis determined by transesophageal echocardiography in patients with CRF. *Am J Kidney Dis*. 42:277-85, 2003.
537. Stenvinkel P, Heimbürger O, Jøgestrand T. Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: association with Chlamydia pneumoniae seropositivity. *Am J Kidney Dis* 39: 274-282, 2002
538. Cardiovascular risk extended evaluation in dialysis patients research group (CREED): C-reactive protein and atherosclerosis in dialysis patients. *Nephrol Dial Transplant* 13: 2710-2711, 1998.
539. Pecoits-Filho R, Lindholm B, Stenvinkel P. The malnutrition, inflammation and atherosclerosis (MIA) syndrome. The heart of the matter. *Nephrol Dial Transplant* 17(supl 11): S28-S31, 2002.
540. Park CW, Shin YS, Kim CM, Lee SY, Yu SE, Kim SY, y cols. Increased C-reactive protein following hemodialysis predicts cardiac hypertrophy in chronic hemodialysis patients. *Am J Kidney Dis* 40: 1230-39, 2002.
541. Stenvinkel P, Andersson P, Wang T, y cols. Do ACE-inhibitors suppress tumour necrosis factor-alpha production in advanced chronic renal failure? *J Int Med* 246-503-7, 1999.
542. Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. *Am J Kidney Dis*. 39:1213-7, 2002.
543. Vernaglione L, Cristofano C, Muscogiuri P, Chimienti S. Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis? *Am J Kidney Dis*. 43: 471-8, 2004.
544. Kim SB, Lee SK, Min WK, Chi HS, Park JS. Lack of effects of low-dose aspirin on high-sensitivity C-reactive protein, hemostatic factors, and troponin T in CAPD patients. *Perit Dial Int*. 22:721-3, 2002.
545. Bloembergen WE, Hakim RM, Stannard DC, Held PJ, Wolfe RA, Agodoa LY, y cols. Relationship of dialysis membrane and cause-specific mortality. *Am J Kidney Dis*. 1999 ;33:1-10.
546. Irish A. Cardiovascular disease, fibrinogen and the acute phase response: associations with lipids and blood pressure in patients with chronic kidney disease. *Atherosclerosis* 137: 133-9, 1998.
547. Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Parlongo S, Malatino LS, y cols. Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure. *J Intern Med* 254: 132-139, 2003.
548. Koch M, Kutkuhn B, Grabensee B, Ritz E. Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: a prospective study in 412 subjects. *Nephrol Dial Transplant*. 12:2603-11, 1997.
549. Freedman BI, Iskandar SS, Appel RG: The link between hypertension and nephrosclerosis. *Am J Kidney Dis* 25: 207-221, 1995.
550. Sociedad Española de Hipertensión - Liga Española para la Lucha contra la Hipertensión Arterial (SEH-LELHA): Guía sobre el diagnóstico y el tratamiento de la hipertensión arterial en España 2002. *Hipertensión* 19 (suppl 3):1-74, 2002.
551. Jacobson HR: Ischemic renal disease: an overlooked clinical entity? *Kidney Int* 34: 729-743, 1988.
552. Alcázar JM, Rodicio JL: Ischemic nephropathy: clinical characteristics and treatment. *Am J Kidney Dis* 36: 883-893, 2000.

BIBLIOGRAFÍA

553. Scoble JE, Hamilton G: Atherosclerotic renovascular disease. *BMJ* 300: 1670-1671, 1990.
554. USRDS: the United States Renal Data System. *Am J Kidney Dis* 42 (6 suppl 5): 1-230, 2003.
555. Marín R, Fernández-Vega F, Alcázar JM, Aranda P, Díez J, Gorostidi M, y cols. en representación de los investigadores del Estudio Coparenal: Grado de control de la hipertensión arterial en pacientes con insuficiencia renal crónica atendidos en consultas externas de nefrología. Estudio Coparenal. XXXIV Congreso Nacional de la SEN. *Nefrología* 24 (suppl X), 2004, en prensa.
556. Gorostidi M, Riesgo A, Prieto MA, Marín R, Fernández-Vega F, Tranche S, y cols. en representación del Grupo Oviedo Hipertensión: La insuficiencia renal es la enfermedad de órgano diana más prevalente en la hipertensión arterial controlada en Atención Primaria. XXXIV Congreso Nacional de la SEN. *Nefrología* 24 (suppl X), 2004, en prensa.
557. Olin JW, Melia M, Young JR, Graor RA, Risius B: Prevalence of atherosclerotic renal artery stenosis in patients with atherosclerosis elsewhere. *Am J Med* 88: 46-51, 1990.
558. Harding MB, Smith LR, Himmelstein SI, Harrison K, Phillips HR, Schwab SJ, y cols. Renal artery stenosis: prevalence and associated risk factors in patients undergoing routine cardiac catheterization. *J Am Soc Nephrol* 2: 1608-1616, 1992.
559. Missouri CG, Buckenham T, Cappuccio FP, MacGregor GA: Renal artery stenosis: a common and important problem in patients with peripheral vascular disease. *Am J Med* 96: 10-14, 1994.
560. Wachtell K, Ibsen H, Olsen MH, Laybourn C, Christoffersen JK, Norgaard H, y cols. Prevalence of renal artery stenosis in patients with peripheral vascular disease and hypertension. *J Hum Hypertens* 10: 83-85, 1996.
561. Marín R, Díaz C, Cosío J, Rodríguez E, Barreiro A, Esteban JE, y cols. Estenosis de arteria renal no sospechada en pacientes con arteriopatía periférica: prevalencia, significado clínico y factores de riesgo asociados. *Nefrología* 17: 62-71, 1997.
562. Aqel RA, Zoghbi GJ, Baldwin SA, Auda WS, Calhoun DA, Coffey CS, y cols. Prevalence of renal artery stenosis in high-risk veterans referred to cardiac catheterization. *J Hypertens* 21: 1157-1162, 2003.
563. Swartbol P, Thorvinger BO, Parsson H, Norgren L: Renal artery stenosis in patients with peripheral vascular disease and its correlation to hypertension. A retrospective study. *Int Angiol* 11: 195-199, 1992.
564. Leertouwer TC, Pattinama PMT, van der Berg-Huysmans A: Incidental renal artery stenosis in peripheral vascular disease: a case for treatment? *Kidney Int* 59: 1480-1483, 2001.
565. Textor SC: Progressive hypertension in a patient with "incidental" renal artery stenosis. *Hypertension* 40: 595-600, 2002.
566. Perera G: Hypertensive vascular disease: description and natural history. *J Chronic Dis* 1: 33-42, 1955.
567. Rostand SG, Brown G, Kirk KA, Rutsky EA, Dustan HP: Renal insufficiency in treated essential hypertensives. *N Engl J Med* 320: 684-688, 1989.
568. Rosansky SJ, Hoover DR, King L, Gibson J: The association of blood pressure levels and change in renal function in hypertensive and nonhypertensive subjects. *Arch Intern Med* 150: 2073-2076, 1990.
569. Ruilope LM, Alcázar JM, Hernández E, Moreno F, Martínez MA, Rodicio JL: Does an adequate control of blood pressure protect the kidney in essential hypertension? *J Hypertens* 8: 525-532, 1990.
570. Walker GW, Neaton JD, Cutler JA, Neuwirth R, Cohen JD, for the MRFIT Research Group: Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial: racial and treatment effects. *JAMA* 268: 3085-3091, 1992.
571. Perneger TV, Nieto J, Whelton PC, Klag MJ, Comstock GW, Szklo M: A prospective study of blood pressure and serum creatinine: results for the "Clue" study and the Atherosclerosis Risk in Communities study. *JAMA* 269: 488-493, 1993.
572. Perry HM, Miller JP, Fornoff JR, Baty JD, Sambhi MP, Rutan G, y cols. Early predictors of 15-year end-stage renal disease in hypertensive patients. *Hypertension* 25: 587-594, 1995.
573. Aranda P, Ruilope LM, Marín R, Aljama P, Luque M: Estudio transversal sobre prevalencia de insuficiencia renal en la hipertensión arterial esencial. Estudio Laennec. *Nefrología* 25: 134-140, 1995.
574. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, y cols. Blood pressure and end-stage renal disease in men. *N Engl J Med* 334: 13-18, 1996.
575. Siewert-Delle A, Ljungman S, Andersson OK, Wilhelmsen L: Does treated primary hypertension lead to end-stage renal disease? A 20-year follow-up of the Primary Prevention Study in Göteborg, Sweden. *Nephrol Dial Transplant* 13: 3084-3090, 1998.
576. Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S: Blood pressure predicts risk of developing end-stage renal disease in men and women. *Hypertension* 41: 1341-1345, 2003.
577. Ljungman S: The kidney as a target of hypertension. *Curr Hypertens Rep* 1: 164-169, 1999.
578. Zucchelli P, Zuccalá A: Progression of renal failure and hypertensive nephrosclerosis. *Kidney Int* 54 (Suppl 68): S55-S59, 1998.
579. Zucchelli P, Zuccalá A: Can we accurately diagnose nephrosclerosis? *Nephrol Dial Transplant* 10 (suppl 6): S2-S5, 1995.
580. González E, Gorostidi M, Marín R: Nefroangioesclerosis. *Hipertensión* 11: 290-304, 1994.
581. Tracy RE, Strong JP, Newman WP, Malcom GT, Oalman MC, Guzman MA: Renovasculopathies of nephrosclerosis in relation to atherosclerosis at ages 25 to 54 years. *Kidney Int* 49: 564-570, 1996.
582. Zucchelli P, Zuccalá A: Hypertension and renal dysfunction. *Curr Op Nephrol Hypertens* 5: 97-101, 1996.
583. Ruilope LM, Campo C, Rodríguez-Artalejo F, Lahera V, García-Robles R, Rodicio JL: Blood pressure and renal function: therapeutic implications. *J Hypertens* 14: 1259-1263, 1996.
584. Safian RD, Textor S: Renal-artery stenosis. *N Engl J Med* 344: 431-442, 2001.
585. Alcázar JM, Marín R, Gómez-Campderá F, Orte L, Rodríguez-Jornet A, Mora-Maciá J, on behalf of the Spanish Group of Ischaemic Nephropathy (GEDENI): Clinical characteristics of ischaemic renal disease. *Nephrol Dial Transplant* 16 (Suppl 1): 74-77, 2001.

586. López G, Ruiz JC: Exploración vascular renal. En: Hernando L, Aljama P, Arias M, Caramelo C, Ejido J, Lamas S, eds. *Nefrología Clínica*. Madrid: Editorial Médica Panamericana, 139-144, 2003.
587. Rundback JH, Sacks D, Kent C, Cooper C, Jones D, Murphy T, y cols. Guidelines for the reporting of renal artery revascularization in clinical trial. *AHA Scientific Statement*. *Circulation* 106; 1572-1585, 2002.
588. Vasbinder GBC, Nelemans PJ, Kessels AGH, Kroon AA, de Leeuw PW, van Engelshoven JMA: Diagnostic tests for renal artery stenosis in patients suspected of having renovascular hypertension: a meta-analysis. *Ann Intern Med* 135: 401-411, 2001.
589. Plouin PF: Stable patients with atherosclerotic renal artery stenosis should be treated first with medical management. *Pro. Am J Kidney Dis* 42: 851-857, 2003.
590. Caps MT, Zierler RE, Polissar NL, Bergelin RO, Beach KW, Cantwell-Gab K, y cols. Risk of atrophy in kidneys with atherosclerotic renal artery stenosis. *Kidney Int* 53: 735-742, 1998.
591. Johansson M, Herlitz H, Jensen G, Rundqvist B, Friberg P: Increased cardiovascular mortality in hypertensive patients with renal artery stenosis. Relation to sympathetic activation, renal function and treatment regimens. *J Hypertens* 17: 1743-1750, 1999.
592. Kennedy DJ, Colyer WR, Brewster PS, Ankenbrandt M, Burket MW, Nemeth AS, y cols. Renal insufficiency as a predictor of adverse events and mortality after renal artery stent placement. *Am J Kidney Dis* 42; 926-935, 2003.
593. Textor SC: Stable patients with atherosclerotic renal artery stenosis should be treated first with medical management. *Con. Am J Kidney Dis* 42: 858-863, 2003.
594. Webster J, Marshall F, Abdalla M, Dominiczak A, Edwards R, Isles CG, y cols. Randomised comparison of percutaneous angioplasty vs continued medical therapy for hypertensive patients with atheromatous renal artery stenosis. *Scottish and Newcastle Renal Artery Stenosis Collaborative Group*. *J Hum Hypertens* 12: 329-335, 1998.
595. Plouin PF, Chatellier G, Darne B, Raynaud A: Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis : a randomized trial. *Essai Multicentrique Medicaments vs Angioplastie (EMMA) Study Group*. *Hypertension* 31: 823-829, 1998.
596. van de Ven PJG, Kaatee R, Beutler JJ, Beek FJA, Woittiez AJJ, Buskens E, y cols. Arterial stenting and balloon angioplasty in ostial atherosclerotic renovascular disease: a randomised trial. *Lancet* 353: 282-286, 1999.
597. van Jaarsveld BC, Krijnen P, Pieterman H, Derkx FH, Deinum J, Postma CT, y cols. The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. *Dutch Renal Artery Stenosis Intervention Cooperative Study Group*. *N Engl J Med* 342: 1007-1014, 2000.
598. Ives NJ, Wheatley K, Stowe RL, Krijnen P, Plouin PF, van Jaarsveld BC, y cols. Continuing uncertainty about the value of percutaneous revascularization in atherosclerotic renovascular disease: a meta-analysis of randomized trials. *Nephrol Dial Transplant* 18: 298-304, 2003.
599. Zuccala A, Zucchelli P: Atherosclerotic renal artery stenosis: when is intervention by PTA or surgery justified? *Nephrol Dial Transplant* 10: 585-600, 1995.
600. Navarro-Antolín J, Orte L: Enfermedad renal isquémica e hipertensión. *Hipertensión* 13: 132-144, 1996.
601. Ritz E, Mann JFE: Renal angioplasty for lowering blood pressure. *N Engl J Med* 342: 1042-1043, 2000.
602. Plouin PF, Rossignol P, Bobrie G: Atherosclerotic renal artery stenosis: to treat conservatively, to dilate, to stent, or to operate? *J Am Soc Nephrol* 12: 2190-2196, 2001.
603. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, y cols. for the African American Study of Kidney Disease and Hypertension Study Group: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. A randomised controlled trial. *JAMA* 285: 2719-2728, 2001.
604. Wright JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, y cols. for the African American Study of Kidney Disease and Hypertension Study Group: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. *JAMA* 288: 2421-2431, 2002.
605. Segura J, Campo C, Rodicio JL, Ruilope LM: ACE inhibitors and appearance of renal events in hypertensive nephrosclerosis. *Hypertension* 38 (3 Pt 2): 645-649; 2001.
606. Valderrábano F, Gómez-Campderá F, Jones EH: Hipertensión as cause of end-stage renal disease: lessons from international registries. *Kidney Int* 68 (suppl): S60-S66, 1998.
607. Vikse BE, Aasarød K, Bostad L, Iversen BM: Clinical prognostic factors in biopsy-proven benign nephrosclerosis. *Nephrol Dial Transplant* 18: 517-523, 2003.
608. Textor SC. Ischemic nephropathy. Where are we now. *J Am Soc Nephrol* 15: 1974-1982, 2004
609. Cheung CM, Wright JR, Shurrab AE, Mamtora H, Foley RN, O'Donoghue DJ, y cols. Epidemiology of renal dysfunction and patient outcome in atherosclerotic renal artery occlusion. *J Am Soc Nephrol* 13:149-157, 2002.
610. US RENAL Data System: USRDS 2001. Annual Data Report: The National Institutes of Health , National institute of Diabetes and Digestive and Kidney Disease, Bethesda. MD 2001
611. Obrador CG, Ruthazer R, Arora P, Kausz AT, Pereira BJ. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. *J Am Soc Nephrol* 10:1793-1800, 1999.
612. Coresh J, Weis GL, McQuillan G, Brancati FL, Levey AS, Jones C y cols. Prevalence of high blood pressure and elevated serum creatinine level in the United States : findings from the third National Health and Nutrition Examination Survey (1998-1994). *Am J Kidney Dis* 39:1-246, 2002.
613. Hsu CY, Chertow GM. Chronic renal confusion: insufficiency, failure, dysfunction, or disease. *Am J Kidney Dis* 39 (Suppl 1) :37-41, 2002.
614. Comité de Registro de la Sociedad de Nefrología y Registros Autonómicos. Informe de Diálisis y Trasplante de la Sociedad de Nefrología y Registros Autonómicos, correspondiente a 1999. *Nefrología* 21:246-252, 2001.
615. Röhrich B, Asmus G, Von Herrat D, Schaefer K: Is it worth performing kidney replacement therapy omn patients over 80? *Nephrol Dial Transplant* 11: 2412-2413, 1996.
616. Delano BG. Regular dialysis treatment . En *Drukker W, Parson FM, Maher JF (Eds). Replacement of renal function by dialysis*. Boston. Martinus Nijhoff, pp 391-409, 1983.
617. Frei U, Schober-Halstenberg HJ and the QuaSi Task Group for Quality Assurance in Renal Replacement Therapy. Annual Report of de the German Renal Registry 1998. *Nephrol Dial Transplant* 14:1085-1090, 1999.

BIBLIOGRAFÍA

618. Lippert J, Ritz E, Schwarzbeck A, Schneider P. The rising tide of end stage renal failure from diabetic nephropathy type-II an epidemiological analysis . *Nephrol Dial Transplant*. 10:462-467, 1995.
619. Hörl WH, de Alvaro F, Williams PF. Healthcare system and end-stage renal disease (ESRD) therapies- An international review: access to ESRD treatment . *Nephrol Dial Transplant* 14 (Suppl.6):10-15, 1999.
620. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy: The Collaborative Study Group. *N Engl J Med* 329: 1456-62, 1993.
621. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes : UKPDS 39. *BMJ* 317: 713-720, 1998.
622. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. *N Engl J Med* 345: 870-8, 2001.
623. Levey A, Coresh J, Balk E, Kausz AT, Levin A, Steffes M y cols. National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. *Ann Intern Med* 139:137-147, 2003.
624. Locatelli F, Alberti D, Graziani G, Bucciatti G, Redaelli B, Giangrande A. Prospective, randomised, multicenter trial of effect of protein restriction on progression of chronic renal insufficiency. Northern Italian Cooperative Study Group. *Lancet* 337:1299-1304, 1991.
625. Klahr S, Levey AS, Beck JG, Caggiula AW, Hunsicker L, Kusek JW y cols. The effects of dietary protein restriction and blood pressure control on the progression of renal disease. Modification of Diet In Renal Disease Study Group. *N Engl J Med* 330:877-884, 1994
626. Fouque D, Wang P, Laville M, Biossel JP. Low protein diets delay end-stage disease in non-diabetic adults with chronic renal failure. *Nephrol Dial Transplant* 15:1986-1992, 2000.
627. J Álvarez-Grande, F Alvarez-Ude, R. Marcén y ALM de Francisco. Normas de Actuación Clínica en Nefrología (NAC). Sociedad Española de Nefrología :Tratamiento sustitutivo de la insuficiencia renal crónica; nutrición, págs 5-7, 1999.
628. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D y cols. Left ventricular mass index increase in early renal disease: impact of decline in haemoglobin. *Am J Kidney Dis* 34:125-134, 1999.
629. National Kidney Foundation. Kidney Disease Outcomes Quality Initiative/DOQI. Clinical Practice Guidelines for Anemia of Chronic Kidney Disease. *Am J Kidney Dis* (suppl 1) 37:S182-S238, 2001.
630. Martínez I; Saracho R, Montenegro J and Lach F. A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism. *Nephrol Dial Transplant*. 11(Suppl 3):22-8, 1996.
631. National Kidney Foundation. K/DOQI Clinical Practice for Bone Metabolism and Disease in Chronic Kidney Disease. *Am J Kidney Dis* 42 (suppl 3): S1-S202, 2003.
632. J Cannata, E. Fernández, MT González, I. Martínez, J. Olivares, A. Palma y cols. NAC. Normas de Actuación Clínica en Nefrología. Sociedad Española de Nefrología: 79-93, 1999
633. Locatelli F, Del Vecchio. How long can dialysis be postponed by low protein diet and ACE inhibitors? *Nephrol Dial Transplant*. 14(6):1360-1364, 1999.
634. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH y cols. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med* 345 (12): 861-9, 2001.
635. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB y cols. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med* 345:851-860, 2001.
636. Martínez Castelao A, de Álvaro F, Romero R, en representación de la SEN, AENP, SED, SEEN, SEMFYC; SEH-LELHA y SEMERGEN. Documento de Consenso 2002 sobre pautas de detección, prevención y tratamiento de la nefropatía diabética en España. *Nefrología* 22:521-530,2002.
637. Brenner BM. Retarding of progression of renal disease. *Kidney Int* 64:370-378, 2003
638. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, y cols. for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group: Preserving renal function in adults with hypertension and diabetes: a consensus approach. *Am J Kidney Dis* 36: 646-661, 2000.
639. Ruggenti P, Schieppati A, Remuzzi G: Progression, remission, regression of chronic renal disease. *Lancet* 357: 1601-1608, 2001.
640. Taal MW, Brenner BM : Achieving maximal renal protection in nondiabetic chronic renal disease. *Am J Kidney Dis* 38: 1365-1371, 2001.
641. Asociación Española de Nefrología Pediátrica (AEN-PED), Sociedades Españolas de Diabetes (SEDIAB), Endocrinología y Nutrición (SEEN), Hipertensión – Liga Española para la Lucha contra la Hipertensión Arterial (SEHLELHA), Medicina Familiar y Comunitaria (SEMFYC), Medicina Rural y Generalista (SEMERGEN) y Nefrología (SEN): Pautas de detección, prevención y tratamiento de la nefropatía diabética en España. *Hipertensión* 19: 412-420, 2002.
642. Gæde P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. *N Engl J Med* 348: 383-393, 2003.
643. Mogensen CE: Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. *BMJ* 285: 685-688, 1982.
644. Parving HH, Andersen AR, Smidt UM, Svendsen PA: Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. *Lancet* 1: 1175-1179, 1983.
645. Pettinger WA, Lee HC, Reisch J, Mitchell HC: Long-term improvement in renal function after short-term "strict" blood pressure control in hypertensive nephrosclerosis. *Hypertension* 13: 766-772, 1989.
646. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, y cols. for the Modification of Diet in Renal Disease (MDRD) Study Group: Blood pressure control, proteinuria, and the progression of renal disease. *Ann Intern Med* 123: 754-762, 1995.
647. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, for the ACE Inhibition in Progressive Renal Disease Study Group: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. *Ann Intern Med* 135: 73-87, 2001.

648. Estacio RO, Jeffers BW, Gifford N, Schrier RW: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. *Diabetes Care* 23 (suppl 2): B54-B64, 2000.
649. Ruilope LM, Miranda B, Morales JM, Rodicio JL, Romero JC, Raij L: Converting enzyme inhibition in chronic renal failure. *Am J Kidney Dis* 13: 120-126, 1989.
650. Zucchelli P, Zuccalà A, Borghi M, Fusaroli M, Sasdelli M, Stallone C, y cols. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. *Kidney Int* 42: 452-458, 1992.
651. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. *N Engl J Med* 329: 1456-1462, 1993.
652. Hannedouche T, Landais P, Goldfarb B, Esper NE, Fournier A, Godin M, y cols. : Randomised controlled trial of enalapril and b blockers in non-diabetic chronic renal failure. *BMJ* 309: 833-837, 1994.
653. Ihle BU, Whitworth JA, Shahinfar S, Cnaan A, Kincaid-Smith PS, Becker GJ: Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial. *Am J Kidney Dis* 27: 489-495, 1996.
654. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Montolese M, y cols. and the Angiotensin-converting-enzyme Inhibition in Progressive Renal Insufficiency study group: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of renal insufficiency. *N Engl J Med* 334: 939-945, 1996.
655. The GISEN group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. *Lancet* 349: 1857-1863, 1997.
656. Marín R, Ruilope LM, Aljama P, Aranda P, Segura J, Díez J, on behalf of the investigators of the ESPIRAL study: A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. *J Hypertension* 19: 1871-1876, 2001.
657. Giatras I, Lau J, Levey AS, for the Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group: Effect of angiotensin-converting-enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. *Ann Intern Med* 127: 337-345, 1997.
658. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, y cols. for the AIPRD Study Group: Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. *Ann Intern Med* 139: 244-252, 2003.
659. Viberti G, Wheeldon NM; for the MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effect. *Circulation* 106: 672-678, 2002.
660. Praga M, Fernández-Andrade C, Luño J, Arias M, Poveda R, Mora J, y cols. Antiproteinuric efficacy of losartan in comparison with amlodipine in nondiabetic proteinuric renal disease: a double-blind, randomized clinical trial. *Nephrol Dial Transplant* 18: 1806-1813, 2003.
661. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. *Lancet* 361: 117-124, 2003.
662. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, y cols. for the Collaborative Study Group: Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. *Ann Intern Med* 138: 542-549, 2003.
663. American Diabetes Association: Position statement. Nephropathy in diabetes. *Diabetes Care* 27 (suppl 1): S79-S82, 2004.
664. American Diabetes Association: Position statement. Hypertension management in adults with diabetes. *Diabetes Care* 27 (suppl 1): S65-S67, 2004.
665. Hemmelgarn BR, Zarnke KB, Campbell N, Feldman RD, McKay DW, McAlister FA, y cols. for the Canadian Hypertension Education Program: The 2004 Canadian recommendations for the management of hypertension: Part I - Blood pressure measurement, diagnosis and assessment of risk. *Can J Cardiol* 20: 31-40, 2004.
666. Khan NA, McAlister FA, Campbell NRC, Feldman RD, Rabkin S, Mahon J, y cols. for the Canadian Hypertension Education Program: The 2004 Canadian recommendations for the management of hypertension: Part II - Therapy. *Can J Cardiol* 20: 41-54, 2004.
667. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, y cols. British Hypertension Society guidelines. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. *J Hum Hypertension* 18: 139-185, 2004.
668. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. *N Engl J Med* 351: 585-592, 2004.
669. Bakris GL, Weir MR: Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine. Is this a cause for concern? *Arch Intern Med* 160: 685-693, 2000.
670. Vogt L, Navis G, de Zeeuw D. Renoprotection: A matter of blood pressure reduction or agent-characteristics? *J Am Soc Nephrol* 13: S202-S207; 2002.
671. Lebovitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Sica DA, Broadstone V, y cols. Renal protective effect of enalapril in hypertensive NIDDM: Role of baseline albuminuria. *Kidney Int* 45 (Suppl): S150-S155; 1994.
672. Laffel LMB, McGill J, Gans D. The beneficial effects of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. *Am J Med* 99: 497-503; 1995.
673. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin dependent diabetes mellitus: A 7-year follow-up study. *Arch Intern Med* 156: 286-289; 1996.
674. Praga M, Hernandez E, Montoyo c, Andres A, Ruilope LM, Rodicio JL. Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria. *Am J Kidney Dis* 20: 240-248; 1992.
675. Ruggenti P, Perna A, Gherardi G, Benini R, Remuzzi G. Chronic proteinuric nephropathies: Outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. *Am J Kidney Dis* 35: 1155-1165; 2000.
676. Himmelmann A, Hansson L, Hansson BG, Hedstrand H, Skogstrom K, Ohrvik J, y cols. ACE inhibition preserves renal

BIBLIOGRAFÍA

- function better than beta-blockade in the treatment of essential hypertension. *Blood Press* 4: 85-90; 1995.
677. Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE. Antiproteinuric effect of blood-pressure-lowering agents: A meta-analysis of comparative trials. *Nephrol Dial Transplant* 10:1963-1974; 1995.
 678. Kashirsagar AV, Joy MS, Hogan SL, Falk RJ, Colindres RE. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: A systematic overview of randomised placebo-controlled trials. *Am J Kidney Dis* 35: 695-707; 2000.
 679. Parving HH, Hovind P. Microalbuminuria in type 1 and type 2 diabetes mellitus: evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy. *Curr Hypertens Rep* 4:387-393; 2002.
 680. Parving HH, Andersen S, Jacobsen P, Christensen PK, Rossing K, Hovind P, y cols. Angiotensin receptor blockers in diabetic nephropathy: Renal and cardiovascular end points. *Semin Nephrol* 24:147-157; 2004.
 681. Praga M, Andrade CF, Luño J, Arias M, Poveda R, Mora J, y cols. Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial. *Nephrol Dial Transplant* 18:1806-1813; 2003.
 682. Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K, y cols.; Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study Investigators. Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study. *Clin Exp Nephrol* 7:221-230; 2003.
 683. Ellis D, Vats A, Moritz ML, Reitz S, Grosso MJ, Janosky JE. Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria. *J Pediatr* 143:89-97; 2003.
 684. Panos J, Michelis MF, DeVita MV, Lavie RH, Wilkes BM. Combined converting enzyme inhibition and angiotensin receptor blockade reduce proteinuria greater than converting enzyme inhibition alone: insights into mechanism. *Clin Nephrol* 60:13-21; 2003.
 685. Komine N, Khang S, Wead LM, Blantz RC, Gabbai FB. Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels. *Am J Kidney Dis* 39:159-164; 2002.
 686. Agarwal R, Siva S, Dunn SR, Sharma K. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels. *Am J Kidney Dis* 39:486-492; 2002.
 687. Hollenberg NK, Price DA, Fisher ND, Lansang MC, Perkins B, Gordon MS, y cols. Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. *Kidney Int* 63:172-178; 2003.
 688. Jacobsen P, Andersen S, Jensen BR, Parving HH. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. *J Am Soc Nephrol* 14:992-999; 2003.
 689. Rossing K, Jacobsen P, Pietraszek L, Parving HH. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. *Diabetes Care* 26:2268-2274; 2003.
 690. Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M y cols. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. *Am J Kidney Dis* 38: 18-25; 2001.
 691. Woo KT, Lau YK, Wong KS, Chiang GS. ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis. *Kidney Int* 58: 2485-2491; 2000.
 692. Ferrari P, Marti HP, Pfister M, Frey FJ. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. *J Hypertens* 20: 125-130; 2002.
 693. Berger ED, Bader BD, Ebert C, Risler T, Erley CM. Reduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition. *J Hypertens* 20: 739-743; 2002.
 694. Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw D. Dual renin-angiotensin system blockade at optimal doses for proteinuria. *Kidney Int* 62: 1020-1025; 2002.
 695. Ruilope LM, Aldigier J, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. *J Hypertens* 18: 89-95; 2000.
 696. Segura J, Praga M, Campo C, Rodicio JL, Ruilope LM. Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses. *J Renin Angiotensin Aldosterone Syst* 4:43-47; 2003.
 697. Luño J, Barrio V, Goicoechea MA, González C, García de Vinuesa S, Gómez F, y cols. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies. *Kidney Int* 62 (Suppl 82): S47-S52; 2002.
 698. Kincaid-Smith P, Fairley K, Packman D. Randomised controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. *Nephrol Dial Transplant* 17: 597-601; 2002.
 699. Mangrum AJ, Bakris GL. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues. *Semin Nephrol* 24:168-175; 2004.
 700. Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? *Arch Intern Med* 158:26-32; 1998.
 701. Palmer FB. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. *N Engl J Med* 351: 585-92; 2004.
 702. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. US Renal Data System, USRDS 2000 Annual Data Report. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: 2000.
 703. Foley RN, Changchun W, Collins AJ. Cardiovascular risk factor profiles and kidney function stage in the United States general population. The NHANES Study. United States Renal Data System, Minneapolis Medical Research Foundation, University of Minnesota Twin Cities. United States Renal Data System: USRDS 2003.
 704. Kasiske BL. Risk factors for accelerated atherosclerosis in renal transplant recipients. *Am J Med* 84: 985-992, 1998
 705. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. *J Am Soc Nephrol* 10: 1606-1615, 1999

706. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS y cols. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. *Kidney Int* 47: 884-890, 1995.
707. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP y cols. Cardiovascular disease risk status in elderly persons with renal insufficiency. *Kidney Int* 62: 997-1004, 2002
708. Wannamethee SG, Shaper AG, Perry IJ. Serum creatinine concentration and risk of cardiovascular disease: a possible marker for increased risk of stroke. *Stroke* 28: 557-563, 1997
709. Culleton BF, Hemmelgarn BR. Is chronic kidney disease a cardiovascular disease risk factor? *Semin Dialysis* 16: 95-100, 2003
710. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL y cols. Level of kidney function as a risk factor for atherosclerotic cardiovascular disease in the community. *J Am Coll Cardiol* 41: 47-55, 2003
711. O'Brien MM, Gonzales R, Shroyer AL, Grunwald GK, Daley J, Henderson WG y cols. Modest serum creatinine elevation affects adverse outcome after general surgery. *Kidney Int* 62: 585-592, 2002
712. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, y cols. Chronic kidney disease as a risk factor for cardiovascular disease and all cause mortality: a pooled analysis of community based studies. *J Am Soc Nephrol* 15: 1307-1315, 2004.
713. Messent JW, Elliott TG, Hill RD, Jarrett RJ, Keen H, Viberti GC y cols. Prognostic significance of microalbuminuria in insulin dependent diabetes mellitus : a twenty three year follow up study. *Kidney Int* 41: 836-839, 1992
714. Stehouwer CD, Lambert J, Donker AJ, van Hinsbergh VW. Endothelial dysfunction and pathogenesis of diabetic angiopathy. *Cardiovasc Res* 34: 55-68, 1997
715. Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Inflammation and microalbuminuria in non diabetic and type 2 diabetic subjects: the insulin resistance atherosclerosis study. *Kidney Int* 58: 1703-1710, 2000
716. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH y cols. Increased urinary albumin excretion, endothelial dysfunction, and chronic low grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. *Diabetes* 51: 1157-1165, 2002
717. Mombouli JV, Vanhoutte PM. Endothelial dysfunction: From physiology to therapy. *J Mol Cell Cardiol* 31: 61-74, 1999
718. Demuth K, Blacher J, Guerin AP, Benoit MO, Moatti N, Safar ME, y cols. Endothelin and cardiovascular remodelling in end stage renal disease. *Nephrol Dial Transplant* 13: 375-383, 1998
719. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. *Kidney Int* 62: 1524-1538, 2002
720. Arici M, Walls J. End stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? *Kidney Int* 2001; 59: 407-414
721. Massy Z, Nguyen-Khoa T. Oxidative stress and chronic renal failure. Markers and management. *J Nephrol* 15: 336-341, 2002
722. Stenvinkel P. Interactions between inflammation, oxidative stress, and endothelial dysfunction in end stage renal disease. *J Ren Ntr* 13: 144-148, 2003
723. Locatelli F, Canaud B, Eckardt K-U, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end stage renal: an emerging threat to patient outcome. *Nephrol Dial Transplant* 18: 1272-1280, 2003
724. Rattazzi M, Puato M, Faggini E, Bertipaglia B, Grego F, Pauletto P y cols. New markers of accelerated atherosclerosis in end stage renal disease. *J Nephrol* 16: 11-20, 2003
725. Ruilope LM. Kidney Dysfunction: a sensitive predictor of cardiovascular risk. *Am J Kidney Dis. Am J Hypertens* 14 (6 Pt 2): S213-S217, 2001
726. Levin A. Prevalence of cardiovascular damage in early renal disease. *Nephrol Dial Transplant* 16 (suppl 2): 7-11, 2001
727. National Kidney Foundation K/DOQI clinical practice guidelines on managing dyslipidemias in chronic kidney disease. *Am J Kidney Dis* 41 (suppl 3): S1-S77, 2003
728. Samuelsson O, Mulec H, Knight-Gibson C, Attman PO, Kron B, Larsson R y cols. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. *Nephrol Dial Transplant* 12: 1908-1915, 1997
729. Keane WF. The role of lipids in renal disease: Future challenges. *Kidney Int* 57 (suppl 75): S27-S31, 2000
730. Kasiske BL. Hyperlipidemia in patients with chronic renal disease. *Am J Kidney Dis* 32 (suppl 3): S142-S156, 1998
731. Warwick GL, Packard CJ. Lipoprotein metabolism in the nephrotic syndrome. *Nephrol Dial Transplant* 8: 385-396, 1993
732. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ y cols. Plasma lipids and risk of developing renal dysfunction: The Atherosclerosis Risk in Communities Study. *Kidney Int* 58: 293-301, 2000
733. López Revuelta K, Saracho R, García López F, Gentil MA, Castro P, Castilla J y cols. Informe de diálisis y trasplante año 2001 de la Sociedad Española de Nefrología y Registros Autonómicos. *Nefrología* 24: 21-33, 2004
734. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. *Am J Kidney Dis* 39(2 suppl 1): S1-S266, 2002
735. Instituto Nacional de Estadística. Definiciones según la causa de muerte 1999. Madrid. INE 2002
736. Sahadevan M, Kasiske B. Hyperlipidemia in kidney disease: causes and consequences. *Curr Opin Nephrol* 11:323-329, 2002
737. Attman PO; Alaupovic P, Tavella M, Knight-Gibson C. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure. *Nephrol Dial Transplant* 11: 63-69, 1996
738. Craig WY, Neveux LM, Palomaki GE, Cleveland MM, Haddow JE. Lipoprotein(a) as a risk factor for ischemic heart disease : metaanalysis of prospective studies. *Clin Chem* 44: 2301-2306, 1998
739. Kronenberg F, Kuen E, Ritz E, Junker R, König P, Kraatz G, y cols. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. *J Am Soc Nephrol* 11: 105-115, 2000
740. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF y cols. Lipoprotein(a) is an independent risk factor

BIBLIOGRAFÍA

- for cardiovascular disease in hemodialysis patients. *Circulation* 86: 475-482, 1992
741. Kuboyama M, Ageta M, Ishihara T, Fujiura Y, Kashio N, Ikushima I. Serum lipoprotein(a) concentration and Apo(a) isoform under the condition of renal dysfunction. *J Atheroscler Thromb* 10: 283-289, 2003
 742. Samuelsson O, Attman P-O, Knight-Gibson C, Kron B, Larsson R, Mulec H, y cols. Lipoprotein abnormalities without hyperlipidemia in moderate renal insufficiency. *Nephrol Dial Transplant* 9: 1580-1585, 1994
 743. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Metaanalysis of prospective studies. *Circulation* 102: 1082-1085, 2000
 744. Kovesdy CP, Astor BC, Longenecker JC, Coresh J. Association of kidney function with serum lipoprotein(a) level: the third National Health and Nutrition Examination Survey (1991-1994). *Am J Kidney Dis* 40: 899-908, 2002
 745. Attman PO, Samuelsson O, Johansson AC, y cols. Dialysis modalities and dyslipidemia. *Kidney Int* 63(suppl 84): S110-S112, 2003
 746. Jungers P, Massy ZA, Nguyen Khoa T, Fumeron C, Labrunie M, Lacour B y cols. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients. A prospective study. *Nephrol Dial Transplant* 12: 2597-2602, 1997
 747. Landrat MJ, Thambyrajah J, Mc Glynn FJ, Jones HJ, Baigent C, Kendall MJ y cols. Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment. *Am J Kidney Dis* 38: 537-546, 2001
 748. Tonelli M, Bohm C, Pandeya S, Gill J, Levin A, Kiberd BA. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. *Am J Kidney Dis* 37: 484-489, 2001
 749. Levin A, Djurdjev O, Barrett B, Burgess E, Carlisle E, Ethier J y cols. Cardiovascular disease in patients with chronic kidney disease: Getting to the heart of the matter. *Am J Kidney Dis* 38: 1398-1407, 2001
 750. Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ y cols. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. *Kidney Int* 61: 297-304, 2002
 751. Control de la Colesterolemia en España, 2000. Un instrumento para la prevención cardiovascular. Ministerio de Sanidad y Consumo. Madrid 2000.
 752. Gutiérrez-Fuentes JA, Gómez-Gerique J, Gómez de la Cámara A, Rubio MA, García A, Arístegui I. Dieta y riesgo cardiovascular en España (DRECE II). Descripción de la evolución del perfil cardiovascular. *Med Clin (Barc)* 115: 726-729, 2000
 753. Wood D, de Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K y cols. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and others Societies on Coronary Prevention. *Eur Heart J* 19: 1434-1503, 1998
 754. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment panel III). *JAMA* 285: 2486-2497, 2001
 755. European Guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. *European Journal of Cardiovascular Prevention and Rehabilitation* 10 (suppl 1): S1-S78, 2003
 756. Genest J, Frohlich J, Fodor G, McPherson R (the Working Group on Hypercholesterolemia and other dyslipidemias). Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. *CMAJ* 169: 921-924, 2003
 757. Harmonized Clinical Guidelines on Prevention of Atherosclerotic Vascular Disease. International Atherosclerosis Society. <http://www.athero.org>
 758. The Expert Panel: Report of the national cholesterol education program expert panel on detection, evaluation and treatment of high blood cholesterol in adults. *Arch Intern Med* 148: 36-69, 1998
 759. Schaefer EJ, Lamon-Fava S, Cohn SD, Schaefer MM, Ordoval JM, Castelli WP y cols. Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study. *J Lipid Res* 35: 779-792, 1994
 760. Wanner C. Importance of hyperlipidaemia and therapy in renal patients. *Nephrol Dial Transplant* 15(suppl5): 92-96, 2000
 761. Joven J, Villabona C, Vilella E. Pattern of hyperlipoproteinemia in human nephrotic syndrome: influence of renal failure and diabetes mellitus. *Nephron* 64: 565-569, 1993
 762. Uhlig K, Levey A, Sarnak M. Traditional cardiac factors in individuals chronic kidney disease. *Semin Dialysis* 16: 118-127, 2003
 763. Tonelli M, Moyé L, Sacks F, Kiberd B, Curhan G; Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. *Ann Intern Med* 138:98-104, 2003
 764. Tonelli M, Moyé L, Sacks F, Cole T, Curhan GC; Cholesterol and Recurrent Events Trial Investigators. Effect of Pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. *J Am Soc Nephrol* 14: 1605-1613, 2003
 765. Jungst D, Caselmann H, Kutschera P, Weisweiler P. Relation of hyperlipidemia in serum and loss of high density lipoproteins in urine in the nephrotic syndrome. *Clin Chim Acta* 168: 159-167, 1987
 766. Takegoshi T, Kitoh C, Haba T, Hirai J, Wakasugi T, Saga T y cols. A study of the clinical significance of lipoprotein(a) in nephrotic syndrome. *Jpn J Med* 30: 21-25, 1991
 767. Kaysen GA, Gambertoglio J, Felts J, Hutchison FN. Albumin synthesis, albuminuria and hyperlipemia in nephrotic patients. *Kidney Int* 31: 1368-1376, 1987
 768. Joven J, Rubiés-Prat J, Espinel E, Ras MR, Piera L. High density lipoproteins in untreated idiopathic nephrotic syndrome without renal failure. *Nephrol Dial Transplant* 2: 149-153, 1987
 769. Clemens MR, Bursa-Zanetti Z. Lipid abnormalities and peroxidation of erythrocytes in nephrotic syndrome. *Nephron* 53: 325-329, 1989
 770. Faucher C, Doucet C, Baumelou A, Chapman J, Jacobs C, Thillet J. Elevated lipoprotein (a) levels in primary nephrotic syndrome. *Am J Kidney Dis* 22: 808-813, 1993
 771. Attman PO, Nyberg G, William-Olsson T, Knight-Gibson C, Alaupovic P. Dyslipoproteinemia in diabetic renal failure. *Kidney Int* 42: 1381-1389, 1992

772. Quaschnig T, Schömig M, Wanner C, Thiery J, Nauck M, Schollmeyer P y cols. Non insulin dependent diabetes mellitus and hypertriglyceridemia impair lipoprotein metabolism in chronic hemodialysis patients. *J Am Soc Nephrol* 10: 332-341, 1999
773. Appel GB, Blum CB, Chien S, Kunis CL, Appel AS. The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity. *N Engl J Med* 312: 1544-1548, 1985.
774. Ordóñez JD, Hiatt RA, Killebrew EJ, Fireman BH. The increased risk of coronary artery disease associated with nephrotic syndrome. *Kidney Int* 44: 638-642, 1993
775. De Sain-van der Velden MG, Kaysen GA, Barrett HA, Stellaard F, Gadellaa MM, Voorbij HA y cols. Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis. *Kidney Int* 53: 994-1001, 1998
776. Radhakrishnan J, Appel AS, Valeri A, Appel GB. The nephrotic syndrome, lipids, and risk factors for cardiovascular disease. *Am J Kidney Dis* 22: 135-142, 1993
777. Nickolas TL, Radhakrishnan J, Appel GB. Hyperlipidemia and Thrombotic complications in patients with membranous nephropathy. *Seminars in Nephrology* 23: 406-411, 2003
778. Kronenberg F, König P, Neyer U, Auinger M, Pribasniq A, Lang U y cols. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. *J Am Soc Nephrol* 6:110-120, 1995
779. Covic A, Gusbeth-Tatomir P, Goldsmith D. The challenge of cardiovascular risk factors in end stage renal disease. *J Nephrol* 16: 476-486, 2003
780. Prichard S. Impact of dyslipidemia in end stage renal disease. *J Am Soc Nephrol* 14: S315-S320, 2003
781. Horkko S, Huttunen K, Kesaniemi YA. Decreased clearance of low density lipoprotein in uremic patients under dialysis treatment. *Kidney Int* 47: 1732-1740, 1995
782. Pedro-Botet J, Senti M, Rubies Prat J, Pelegri A, Romero R. When to treat dyslipidaemia of patients with chronic renal failure on haemodialysis? A need to define specific guidelines. *Nephrol Dial Transplant* 11: 308-313, 1996
783. Hernández E, Praga M, Alamo C, Araque A, Morales JM, Ruilope LM, Rodicio JL. Lipoprotein(a) and vascular access survival in patients on chronic hemodialysis. *Nephron* 72: 145-149, 1996
784. Shoji T, Nishizawa Y, Kawagishi T, Tanaka M, Kawasaki K, Tabata T, Seccia M, Bellomo G. Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with renal failure treated by hemodialysis. *Atherosclerosis* 131: 229-236, 1997
785. Maggi E, Bellazzi R, Gazo A, y cols. Autoantibodies against oxidatively modified LDL in uremic patients undergoing dialysis. *Kidney Int* 46: 869-876, 1994
786. Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ. Atherogenic lipoprotein phenotype in end stage renal failure. Origin and extent of small dense low density lipoprotein formation. *Am J kidney Dis* 35: 852-862, 2000
787. Ramos R, Gómez Gerique N, Martínez Castela A, Estrés oxidativo de las lipoproteínas y efecto antioxidante de la vitamina C un año después de iniciar hemodiálisis. *Nefrología* 2004, en prensa.
788. Kronenberg F, Lingenhel A, Neyer U, Lhotta K, König P, Auinger M y cols. Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients. *Kidney Int* 63 (suppl 84): S113-S116, 2003
789. Harris K, Thomas M, Short C, Moore R. Assessment of the efficiency of treatment of dyslipidaemia in renal outpatients. *J Nephrol* 15: 263-269, 2002
790. Attman PO, Samuelsson O, Moberly J, Johansson AC, Ljungman S, Weiss LG y cols. Apolipoprotein B containing lipoproteins in renal failure. The relation to mode of dialysis. *Kidney Int* 1536-1542, 1999
791. Moberly JB, Attman PO, Samuelsson O, Johansson AC, Knight-Gibson C, Alaupovic P. Alterations in lipoprotein composition in peritoneal dialysis patients. *Periton Dialysis Int* 22:1-9, 2002
792. Wheeler DC. Abnormalities of lipoprotein metabolism in CAPD patients. *Kidney Int* 50 (suppl 56): S41-S46, 1996
793. Johansson AC, Samuelsson O, Attman PO, Haraldsson B, Moberly J, Knight-Gibson C y cols. Dyslipidemia in peritoneal dialysis relation to dialytic variables. *Periton Dialysis Int* 20: 306-314, 2000
794. Llopart R, Donate T, Oliva JA, Roda M, Rousaud F, Gonzalez-Sastre F y cols. Triglyceride rich lipoprotein abnormalities in CAPD treated patients. *Nephrol Dial Transplant* 10: 537-540, 1995
795. Bredie SJ, Bosch FH, Demacker PN, Stalenhoef AF, van Leusen R. Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism. *Periton Dialysis Int* 21: 275-281, 2001.
796. Castela AM, Barbera MJ, Blanco A, Fiol C, Grino JM, Bover J, y cols. Lipid metabolic abnormalities after renal transplantation under cyclosporine and prednisone immunosuppression. *Transplant Proc* 24: 96-98, 1992.
797. Gonyea JE, Anderson CF. Weight change and serum lipoproteins in recipients of renal allografts. *Mayo Clinic Proc* 67: 653-657, 1992
798. Aakhus S, Dahl K, Wideroe TE. Hyperlipidaemia in renal transplant patients. *J Intern Med* 239: 407-415, 1996
799. Brown JH, Murphy BG, Douglas AF, Short CD, Bhatnagar D, Mackness MI y cols. Influence of immunosuppressive therapy on lipoprotein(a) and others lipoproteins following renal transplantation. *Nephron* 75: 277-282, 1997
800. Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. *Transplantation* 63: 331-338, 1997
801. Marcen R, Pascual J. Enfermedades cardiovasculares en el trasplante renal. *Nefrología* 21: 104-114, 2001.
802. Hricik DE, Mayes JT, Schulak JA. Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia. *Am J Kidney Dis* 18: 353-358, 1991
803. Ligtenberg G, Hene RJ, Blankestijn PJ, Koomans HA. Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus. *J Am Soc Nephrol* 12: 368-373, 2001
804. Collins AJ, Li S, Ma JZ, Herzog C. Cardiovascular disease in end stage renal disease patients. *Am J Kidney Dis* 38 (4 suppl 1): S26-S29, 2001
805. Hoogeveen RC, Ballantyne CM, Pownall HJ, Opekun AR, Hachey DL, Jaffe JS y cols. Effect of sirolimus on the metabolism of ApoB100 containing lipoproteins in renal transplant patients. *Transplantation* 72: 1244-1250, 2001

BIBLIOGRAFÍA

806. Morrisett JD, Abdel-Fattah G, Hoogeveen R, Mitchell E, Ballantyne CM, Pownall HJ y cols. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. *J Lipid Res* 43: 1170-1180, 2002
807. McCune TR, Thacker LR, Peters TG, Mulloy L, Rohr MS, Adams PA, y cols. Effects of tacrolimus on hyperlipidemia after successful renal transplantation: A Southeastern Organ Procurement Foundation multicenter clinical study. *Transplantation* 65: 87-92, 1998
808. Johnson C, Ahsan N, Gonwa T, Halloran P, Stegall M, Hardy M, y cols. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil after cadaveric kidney transplantation. *Transplantation* 69: 834-841, 2000
809. Vanrenterghem Y, Lebranchu Y, Hene R, Oppenheimer F, Ekberg H. Double blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. *Transplantation* 70: 1352-1359, 2000
810. Breyer JA, Bain RP, Evans JK, Nahman NS Jr, Lewis EJ, Cooper M, y cols. Predictors of the progression of renal insufficiency in patients with insulin dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group. *Kidney Int* 50: 1651-1658, 1996.
811. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. *Arch Intern Med* 158: 998-1004, 1998
812. Shearer GC, Stevenson FT, Atkinson DN, Jones H, Staprans I, Kaysen GA. Hypoalbuminemia and proteinuria contribute separately to reduce lipoprotein catabolism in the nephritic syndrome. *Kidney Int* 59: 179-189, 2001
813. Murdoch SJ, Breckenridge WC. Influence of lipoproteinlipase and hepatic lipase on the transformation of VLDL and HDL during lipólisis of VLDL. *Atherosclerosis* 118: 193-212, 1995
814. Sasaki A, Goldberg IJ. Lipoprotein lipase release from BCF-1 beta adipocytes. Effects of triglyceride rich lipoproteins and lipolysis products. *J Biol Chem* 267: 15198-15204, 1992
815. Liang K, Vaziri ND. Down regulation of hepatic lipase expression in experimental nephritic syndrome. *Kidney Int* 51: 1933-1937, 1997
816. Lambert G, Sakai N, Vaisman BL, Neufeld EB, Marteyn B, Chan CC, y cols. Analysis of glomerulosclerosis in lecithin cholesterol acyltransferase deficient mice. *J Biol Chem* 276: 15090-15098, 2001
817. Apple G. Lipid abnormalities in renal disease. *Kidney Int* 39: 169-183, 1991
818. De Sain van der Velden MG, Reijngoud D, Kaysen GA, Gadellaa MM, Voorbij H, Stellaard F, y cols. Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. *J Am Soc Nephrol* 9: 1474-1481, 1998
819. Noel LH. Morphological features of primary focal and segmental glomerulosclerosis. *Nephrol Dial Transplant* 14 (suppl 3): 53-57, 1999
820. Magil AB. Interstitial foam cells and oxidized lipoprotein in human glomerular disease. *Mod Pathol* 12: 33-40, 1999
821. Suzuki S, Takahashi H, Sato H, Takashima N, Arakawa M, Gejyo F. Significance of glomerular deposition of apolipoprotein(a) in various glomerulopathies. *Am J Nephrol* 17: 499-504, 1997
822. Galle J, Stunz P, Schollmeyer P, Wanner C. Oxidized LDL and lipoprotein(a) stimulate renin release of yuxtaglomerular cells. *Kidney Int* 47: 45-52, 1995
823. Keane WF, O'Donnell MP, Kasiske BL, Kim Y. Oxidative modification of low density lipoproteins by mesangial cells. *J Am Soc Nephrol* 4: 187-194, 1993
824. Galle J, Heermeier K. Angiotensin II and oxidized LDL. An unholy alliance creating oxidative stress. *Nephrol Dial Transplant* 14: 2585-2589, 1999
825. Wheeler DC, Chana RS. Interactions between lipoproteins, glomerular cells an matrix. *Miner Electrolyte Metab* 19: 149-164, 1993
826. Palmer BF, Alpern RJ. Treating dyslipidemia to show the progresión of chronic renal failure. *Am J Med* 114: 411-412, 2003
827. Abrass CK. Cellular lipid metabolism and the role of lipids in progressive renal disease. *Am J Nephrol* 24: 46-53, 2004
828. Atchley DH, Lopes Virella MF, Zheng D, Kenny D, Virella G. Oxidized LDL antioxidantized LDL immune complexes and diabetic nephropathy. *Diabetologia* 45: 1562-1571, 2002
829. Yorioka N, Taniguchi Y, Nishida Y, Okushin S, Amimoto D, Yamakido M. Low density lipoprotein apheresis for focal glomerular sclerosis. *Ther Apher* 1: 370-371, 1997
830. Yokoyama K, Sakai S, Sigematsu T, Takemoto F, Hara S, Yamada A y cols. LDL adsorption improves the response of focal glomerulosclerosis to corticosteroid therapy. *Clin Nephrol* 50: 1-7, 1998
831. Walker WG. Hypertension related renal injury: A major contributor to end stage renal disease. *Am J Kidney Dis* 22: 164-173, 1993
832. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW y cols. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. *Kidney Int* 51: 1908-1919, 1997
833. Klein R, Klein BE, Moss SE, Cruickshanks KJ, Brazy PC. The 10 year incidence of renal insufficiency in people with type 1 diabetes. *Diabetes Care* 22: 743-751, 1999
834. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH. y cols. Progression of diabetic nephropathy. *Kidney Int* 59: 702-709, 2001.
835. Massy ZA, Khoa TN, Lacour B, Descamps-Latscha B, Man NK, Jungers P. Dyslipidaemia and the progression of renal disease in chronic renal failure patients. *Nephrol Dial Transplant* 14: 2392-2397, 1999
836. Samuelsson O, Attman PO, Knight-Gibson C, Larsson R, Mulec H, Wedel H y cols. Plasma level of lipoprotein(a) do not predict progression of human chronic renal failure. *Nephrol Dial Transplant* 11: 2237-2243, 1996
837. Yokoyama H, Tomonaga O, Hirayama M, Ishii A, Takeda M, Babazono T y cols. Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin converting enzyme inhibitors in NIDDM patients. *Diabetologia* 40: 405-411, 1997
838. Locatelli F, Marcelli D, Comelli M, Alberti D, Graziani G, Buccianti G y cols. Proteinuria and blood pressure as causal components of progression to end stage renal failure. *Nephrol Dial Transplant* 1996; 11: 461-467, 1996
839. Orchard TJ, Forrest KY, Kuller LH, Becker DJ; y cols. Pittsburgh Epidemiology of Diabetes Complications Study. Lipid and blood pressure treatment goals for type 1 diabetes: 10 year incidence data from the Pittsburgh Epidemiology of

- Diabetes Complications Study. *Diabetes Care* 24: 1053-1059, 2001
840. Kohler KA, Mc Clellan WM, Ziemer DC, Kleinbaum DG, Boring JR. Risk factors for microalbuminuria in black Americans with newly diagnosed type 2 diabetes. *Am J Kidney Dis* 36: 903-913, 2000
841. Font J, Ramos-Casals M, Cervera R, Garcia-Carrasco M, Torras A, Siso A y cols. Cardiovascular risk factors and the long term outcome of lupus nephritis. *QJM* 94: 19-26, 2001
842. Manttari M, Tiula E, Alikoski T, Manninen V. Effects of hypertension and dyslipidemia on the decline in renal function. *Hypertension* 26: 670-675, 1995
843. Nielsen S, Schmitz A, Rehling A, Mogensen CE. The clinical course of renal function in NIDDM patients with normo and microalbuminuria. *J Intern Med* 241: 133-141, 1997
844. Cappelli P, Liberato L, Albertazzi A. Role of dyslipidemia in the progression of chronic renal disease. *Ren Fail* 20: 391-397, 1998
845. Gall MA, Nielsen FS, Smidt UM, Parving HH. The course of kidney function in type 2 (non insulin dependent) diabetic patients with diabetic nephropathy. *Diabetologia* 36: 1071-1078, 1993
846. Crook ED, Thallapureddy A, Migdal S, Flack JM, Greene EL, Salahudeen A y cols. Lipid abnormalities and renal disease: is Dyslipidemia a predictor of progression of renal disease? *Am J Med Sci* 325(6): 340-348, 2003
847. Wanner C, Krane V. Uremia specific alterations in lipid metabolism. *Blood Purificat* 20: 451-453, 2002
848. Kronenberg F, Neyer U, Lhotta K, Trenkwalder E, Auinger M, Pribasnik A y cols. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patient: A prospective follow up. *J Am Soc Nephrol* 10: 1027-1036, 1999
849. Iseki K, Uehara H, Nishime K, Tokuyama K, Yoshihara K, Kinjo K, y cols. Impact of the initial levels of laboratory variables on survival in chronic dialysis patients. *Am J Kidney Dis* 28: 541-548, 1996
850. Koda Y, Nishi S, Suzuki M, Hirasawa Y. Lipoprotein(a) is a predictor for cardiovascular mortality of hemodialysis patients. *Kidney Int (Suppl 71)*: S251-S253, 1999
851. Fujisawa M, Haramaki R, Miyazaki H, Imaizumi T, Okuda S. Role of lipoprotein(a) and TGF-beta1 in atherosclerosis of hemodialysis patients. *J Am Soc Nephrol* 11: 1889-1895, 2000
852. Longenecker JC, Coresh J, Marcovina SM, Powe NR, Levey AS, Giaculli F y cols. Lipoprotein(a) and prevalent cardiovascular disease in a dialysis population: the choices for healthy outcomes in caring for ESRD (CHOICE) study. *Am J Kidney Dis* 42: 108-116, 2003
853. Koch M, Kutkuhn H, Trenkwalder E, Ritz E. Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a), phenotypes predict coronary artery disease in hemodialysis patients. *J Am Soc Nephrol* 8: 1889-1898, 1997
854. Nishizawa Y, Shoji T, Kakiya R, Tsujimoto Y, Tabata T, Ishimura E y cols. Non high density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end stage renal disease. *Kidney Int* 63(suppl 84): S117-S120, 2003
855. Kates DM, Haas L, Brunzell J, Sherrard DJ. Risk factors for cardiovascular disease in end stage renal failure patients. A 21 year study. *J Am Soc Nephrol* 6: 540 (abstract), 1995
856. Tschöpe W, Koch M, Thomas B, Ritz E. Serum lipids predict cardiac death in diabetic patients on maintenance hemodialysis. Results of a prospective study. The German Study Group Diabetes and Uremia. *Nephron* 64: 354-358, 1993
857. Shoji T, Kimoto E, Shinohara K, Emoto M, Ishimura E, Miki T y cols. The association of antibodies against oxidized low-density lipoprotein with atherosclerosis in hemodialysis patients. *Kidney Int* 63(suppl 84): S128-S130, 2003
858. Bairaktari E, Elisaf M, Tzallas C, Karabina SA, Tselepis AD, Siamopoulos KC y cols. Evaluation of five methods for determining low density lipoprotein cholesterol (LDL-C) in hemodialysis patients. *Clin Biochem* 34: 593-602, 2001
859. Smith SC Jr, Blair SN, Bonow RO, y cols. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. *Circulation* 104: 1577-1579, 2001.
860. Nauck M, Kramer-Guth A, Bartens W, Marz W, Wieland H, Wanner C. Is the determination of LDL cholesterol according to Friedewald accurate in CAPD and HD patients? *Clin Nephrol* 46: 319-325, 1996
861. Hirsch GA, Vaid N, Blumenthal RS. Perspectives: The significance of measuring non-HDL-cholesterol. *Prev Cardiol* 5: 156-159, 2002
862. Lu W. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: The strong heart study. *Diabetes Care* 26: 240-242, 2003.
863. Shoji T, Nishizawa Y, Kawagishi T, Kawasaki K, Taniwaki H, Tabata T, y cols. Intermediate density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. *J Am Soc Nephrol* 9: 1277-1284, 1998
864. Shoji T, Ishimura E, Inaba M, Tabata T, Nishizawa Y. Atherogenic lipoproteins in end stage renal disease. *Am J Kidney Dis* 38 (suppl 1): S30-S33, 2001
865. Belani S, Goldberg A, Coyne D. Ability of non-high-density lipoprotein cholesterol and calculated intermediate density lipoprotein to identify non-traditional lipoprotein subclass risk factors in dialysis patients. *Am J Kidney Dis* 43: 320-329, 2004.
866. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. *Am J Kidney Dis* 25: 458-482, 1990
867. Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in the cohort of chronic hemodialysis patients. *Kidney Int* 61: 1887-1893, 2002
868. Webb AT, Brown EA. Prevalence of symptomatic arterial disease and risk factors for its development in patients on continuous ambulatory peritoneal dialysis. *Perit Dial Int* 13 (suppl 2): S406-S408, 1993
869. Olivares J, Cruz C, Gas JM, Prados MC, Perdiguero M, Caparros G, y cols. Evolution of lipid profiles in long term peritoneal dialysis. *Adv Perit Dial* 8: 373-375, 1992
870. Kronenberg F, Stühlinger M, Trenkwalder E, Geethanjali FS, Pachinger O, von Eckardstein A, y cols. Low apolipoprotein A-IV plasma concentrations in men with coronary artery disease. *J Am Coll Cardiol* 36: 751-757, 2000
871. Kronenberg F, Kuen E, Ritz E, König P, Kraatz G, Lhotta K y cols. Apolipoprotein A-IV serum concentrations are elevated in mild and moderate renal failure. *J Am Soc Nephrol* 13: 461-469, 2002

BIBLIOGRAFÍA

872. Druke TB, Abdulmassih Z, Lacour B, Bader C, Chevalier A, Kreis H. Atherosclerosis and lipid disorders after renal transplantation. *Kidney Int* 39 (suppl 31): S24-S28, 1991.
873. Abdulmassih Z, Chevalier A, Bader C, y cols. Role of lipid disturbances in the atherosclerosis of renal transplant patients. *Clin Transplant* 6: 106-113, 1992
874. Aker S, Ivens K, Grabensee B, Heering P. Cardiovascular risk factor and diseases after renal transplantation. In *Urol Nephrol* 30: 777-788, 1998
875. Aakhus S, Dahl K, Winderoe TE. Cardiovascular morbidity and risk factors in renal transplant patients. *Nephrol Dial Transplant* 14: 648-654, 1999
876. Ong CS, Pollock CA, Cateson RJ, Mahony JF, Waugh DA, Ibelis LS. hyperlipidemia in renal transplant recipients: Natural history and response to treatment. *Medicine* 1994; 73: 215-223, 1994
877. Barbagallo CM, Pinto A, Gallo S, Parrinello G, Caputo F, Sparacino V y cols. Carotid atherosclerosis in renal transplant recipients: relationships with cardiovascular risk factors and plasma lipoproteins. *Transplantation* 67: 366-371, 1999
878. Massy ZA, Mamzer-Bruneel MF, Chevalier A, Millet P, Helenon O, Chadeaux-Vekemans B, y cols. Carotid atherosclerosis in renal transplant recipients. *Nephrol Dial Transplant* 13: 1792-1798, 1998
879. Dimeny E, Fellström B, Larsson E, Tufveson G, Lithell H. Hyperlipoproteinemia in renal transplant recipients: is there a linkage with chronic vascular rejection? *Transplant Proc* 25: 2065-2066, 1993
880. Dimeny E, Fellström B, Larsson E, y cols. Chronic vascular rejection and hyperlipoproteinemia in renal transplant patients. *Clin Transplant* 7:482-490, 1993
881. Isoniemi H, Nurminen M, Tikkanen MJ, von Willebrand E, Krogerus L, Ahonen J y cols. Risk factors predicting chronic rejection of renal allografts. *Transplantation* 57: 68-72, 1994
882. Massy ZA, Guijarro C, Wiederkehr MR, Ma JZ, Kasiske BL. Chronic allograft rejection: immunologic and non immunologic risk factors. *Kidney Int* 49: 518-524, 1996
883. Roodnat JL, Mulder PG, Zietse R, Rischen-Vos J, van Riemsdijk IC, Ijzermans JN y cols. Cholesterol as an independent predictor of outcome after renal transplantation. *Transplantation* 69: 1704-1710, 2000
884. Kronenberg F, König P, Lhotka K, Ofner D, Sandholzer C, Margreiter R y cols. Apolipoprotein(a) phenotype associated decrease in lipoprotein(a) plasma concentrations after renal transplantation. *Arterioscler Thromb* 14: 1399-1404, 1994
885. Black JW, Wilcken DE. Decreases in apolipoprotein(a) after renal transplantation: implications for lipoprotein(a) metabolism. *Clin Chem* 38: 353-357, 1992
886. Webb AT, Plant M, Reaveley DA, O'Donnell M, Luck VA, O'Connor B, y cols. Lipid and lipoprotein(a) concentrations in renal transplant patients. *Nephrol Dial Transplant* 7: 636-641, 1992
887. Holdaas H, Fellström B, Jardine A, Holme I, Nyberg G, Fauchald P, y cols. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. *Lancet* 361: 2024-2031, 2003
888. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients. A report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney disease Outcomes Quality Initiative. National Kidney Foundation Work Group Members: B. Kasiske, F.G. Cosio, J. Beto, K. Bolton, B.M. Chavers, R. Grimm Jr. A. Levin, B. Masri, R. Parekh, C. Wanner, D.C. Wheeler and P.W.F. Wilson. *Am J Transplant* 4(suppl 7): 13-53, 2004
889. Kasiske BL, O'Donnell MP, Cleary MP, Keane WF. Treatment of hyperlipidemia reduces glomerular injuries in obese Zucker rats. *Kidney Int* 33: 667-672, 1988
890. Kasiske BL, O'Donnell MP, Garvis WJ, Keane WF. Pharmacological treatment of hyperlipidemia reduces glomerular injury in 5/6 nephrectomy rat model of CRF. *Circ Res* 62: 367-374, 1988
891. Harris KPG, Pukerson ML, Yates J, Klahr S. Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephritic syndrome. *Am J Kidney Dis* 50: 16-23, 1990
892. Zoja C, Corna D, Rottoli D, Cattaneo D, Zanchi C, Tomasoni S, y cols. Effect of combining ACE inhibitor and statin in severe experimental nephropathy. *Kidney Int* 61: 1635-1645, 2002
893. Zoja C, Corna D, Camozzi D, Cattaneo D, Rottoli D, Batani C, y cols. How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. *J Am Soc Nephrol* 13: 2898-2908, 2002
894. Fried L, Orchard T, Kasiske B. Effect of lipid reduction on the progression of renal disease; a metaanalysis. *Kidney Int* 59: 260- 269, 2001
895. Owada A, Suda S, Hata T. Antiproteinuric effect of niceritrol, a nicotinic acid derivate, in chronic renal disease with hyperlipidemia: a randomized trial. *Am J Med* 114: 347-353, 2003
896. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high risk individuals: a randomised placebo controlled trial. *Lancet* 360: 7-22, 2002
897. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG y cols. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. *N Engl J Med* 335: 1001-1009, 1996
898. Scandinavian Simvastatin Survival study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet* 344: 1383-1389, 1994
899. Long Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. *N Engl J Med* 339: 1349-1357, 1998
900. Shepherd J, Cobbe S, Ford I, Isles CG, Lorimer AR, MacFarlane PW y cols. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. *N Engl J Med* 333:1301-1307, 1995
901. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA y cols. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS Air Force/Texas Coronary Atherosclerosis prevention Study. *JAMA* 279: 1615-1622, 1998
902. Waters D, Schwartz G, Olsson A. The Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) trial: a new frontiers for statins? *Curr Control Trials Cardiovascular Med* 2: 111-114, 2001

903. Simpson RJ Jr. Placing PRINCE in perspective. *JAMA* 286:91-93, 2001
904. Shepherd J, Blauw G, Murphy M, Bollen EL, Buckley BM, Cobbe SM y cols. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet* 360: 1623-1630, 2002
905. Gresser U, Gathof BS. Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies. *Eur J Med Res* 9: 1-17, 2004.
906. Nissen S, Tuzcu E, Schoenhagen P, Brown BG, Ganz P, Vogel RA, y cols. Effect of intensive compared with moderate lipid lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. *JAMA* 291: 1071-1080, 2004
907. Cannon CP, Braunwald E, McCabe DJ, Rouleau JL, Belder R y cols. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med* 350: 1495-1504, 2004.
908. Athyros V, Elisaf M, Papageorgiou A, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, y cols. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) Study. *Am J Kidney Dis* 43: 589-599, 2004.
909. Grundy S, Cleeman J, Baird Merz C, Brewer HB Jr, Clark LT, Hunninghake DB y cols. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. *Circulation* 110: 227-239, 2004
910. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Clinical review 145: pleiotropic effects of statins, lipid reduction and beyond. *J Clin Endocrinol Metab* 87: 1451-1458, 2002
911. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, y cols. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. *N Engl J Med* 344: 1959-1965, 2001
912. Albert MA, Danielson E, Rifai N, Ridker PM. PRINCE Investigators: Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. *JAMA* 286: 64-70, 2001
913. Gotto AM, Farmer JA. Pleiotropic effects of statins: Do they matter? *Curr Opin Lipidol* 12: 391-394, 2001
914. Munford RS. Statins and the acute phase response. *N Engl J Med* 344: 2016-2018, 2001
915. Di Garbo V, Bono M, Di Raimondo D, De Simone R, Raneli G, Avellone G. Non lipid dose dependent effects pravastatin treatment on hemostatic system and inflammatory response. *Eur J Clin Pharmacol* 56: 277-248, 2000
916. Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A. Non lipid related effects of statins. *Ann Med* 32: 164-176, 2000
917. Sotiriou CG, Cheng JW. Beneficial effects of statins in coronary artery disease beyond lowering cholesterol. *Ann Pharmacother* 2000; 34: 1432-1439
918. Ichihara A, Hayashi M, Ryuzaki M, Handa M, Furukawa T, Saruta T. Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. *Nephrol Dial Transplant* 17: 1513-1517, 2002
919. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M. Statin sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. *Circulation* 100: 2131-2134, 1999
920. Borghi C, Dormi A, Veronesi M, Immordino V, Ambrosioni E. Use of lipid lowering drugs and blood pressure control in patients with arterial hypertension. *J Clin Hypertens* 4: 277-285, 2002
921. Aviram M, Dankner G, Cogan O, Hochgraf E, Brook JG. Lovastatin inhibits LDL oxidation and alters its fluidity and uptake by macrophages, in vitro and in vivo studies. *Metabolism* 41: 229-235, 1992.
922. Goppelt-Struete M, Hahn A; Iwanciw D, Rehm M, Banas B. Regulation of connective tissue growth factor gene expression in human mesangial cells by HMG-CoA reductase inhibitors. *Mol Pathol* 54: 176-179, 2001
923. Yoshimura A, Inui K, Nemoto T, Uda S, Sugeno Y, Watanabe S, y cols. Simvastatin suppresses glomerular cell proliferation and macrophage infiltration in rats with mesangial proliferative nephritis. *J Am Soc Nephrol* 9: 2027-2039, 1998
924. Grandaliano G, Biswas P, Choudhury GG, Abboud HE. Simvastatin inhibits PDGF induced DNA synthesis in human glomerular mesangial cells. *Kidney Int* 44: 503-508, 1993
925. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. *Am J Kidney Dis* 41: 565-570, 2003
926. Sasaki T, Kurata H, Nomura, Utsunomiya K, Ikeda Y. Amelioration of proteinuria with pravastatin in hypercholesterolemia patients with diabetes mellitus. *Jpn J Med* 29: 156-163, 1990
927. Tonolo G, Melis MG, Formato M, Angius MF, Carboni A, Brizzi P y cols. Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. *Eur J Clin Invest* 30: 980-987, 2000
928. Martínez-Castelao A, Ramos R, González MT, Castineiras MJ. Dyslipidemia and cardiovascular risk in type 2 diabetes mellitus patients with associated diabetic nephropathy. *Nefrología* 22: 51-58, 2002
929. Park JK, Muller DN, Mervaala, Dechend R, Fiebeler A, Schmidt F y cols. Cerivastatin prevents angiotensin II induced renal injury independent of BP and cholesterol lowering effects. *Kidney Int* 58: 1420-1430, 2000
930. Prasad GV, Ahmed A, Nash M, Zaltzman J. Blood pressure reduction with HMG-CoA reductase inhibitors in renal transplant recipients. *Kidney Int* 63: 360-364, 2003
931. MRC/BHF Heart Protection Study of Cholesterol lowering with simvastatin in 5963 people with diabetes. A randomized placebo controlled trial. *Lancet* 361: 2005-2016, 2003
932. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI y cols. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease evaluation (GREACE) study. *J Clin Pathol* 57: 728-734, 2004
933. Dimitriadis A, Antoniou S, Hatzisavvas N, Pastore F, Kaldi I, Stangou M. The effect of simvastatin on dyslipidemia in continuous ambulatory peritoneal dialysis patients. *Periton Dialysis Int* 13: S434-S436, 1993
934. Harris KP, Wheeler DC, Chong CC. A placebo controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. *Kidney Int* 61: 1469-1474, 2002

BIBLIOGRAFÍA

935. Fiorini F, Patrone E, Castelluccio A. Clinical investigation on the hypolipidemic effect of simvastatin versus probucol in hemodialysis patients. *Clin Ther* 145: 213-217, 1994
936. Nishikawa O, Mune M, Miyano M, Nishide T, Nishide I, Maeda A, y cols. Effect of simvastatin on the lipid profile of hemodialysis patients. *Kidney Int* 56(suppl 71): S219-S221, 1999
937. Nishizawa Y, Shoji T, Emoto M, y cols. Reduction of intermediate density lipoprotein by pravastatin in hemo and peritoneal dialysis patients. *Clin Nephrol* 43: 268-277, 1995.
938. Robson RA, Collins J, Johnson R, Kitching R, Searle M, Walker R, y cols. Effects of simvastatin and enalapril on serum lipoprotein concentrations and left ventricular mass in patients on dialysis. The PERFECT Study Collaborative Group. *J Nephrol* 10: 33-40, 1997
939. Saltissi D, Morgan C, Rigby R, Westhuyzen J. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. *Am J Kidney Dis* 39: 283-290, 2002
940. Matthys E, Schurgers M, Lamberigts G, Lameire N, Vandecasteele N, Labeur C y cols. Effect of simvastatin on the dyslipoproteinemia in CAPD patients. *Atherosclerosis* 86: 183-192, 1991
941. Hufnagel G, Michel C, Vrtošnik F, Queffeuol G, Kossari N, Mignon F. Effects of atorvastatin on dyslipidaemia in uraemic patients on peritoneal dialysis. *Nephrol Dial Transplant* 15: 684-688, 2000
942. van den Akker JM, Bredie SJ, Diepenveen SH, van Tits LJ, Stalenhoef AF, van Leusen R. Atorvastatin and simvastatin in patients on hemodialysis: Effects on lipoproteins, C-reactive protein and in vivo oxidized LDL. *J Nephrol* 16: 238-244, 2003
943. Seliger S, Stehman-Breen C. Are HMG-CoA reductase inhibitors underutilized in dialysis patients? *Semin Dialysis* 16: 179-185, 2003
944. Diercks GF, Janssen WM, van Boven AJ, Bak AA, de Jong PE, Crijs HJ y cols. Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of RENal and Vascular ENdstage Disease Intervention Trial (PREVEND IT)). *Am J Cardiol* 86: 635-638, 2000
945. Wanner C, Krane V, Ruf G, Marz W, Ritz E. Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. *Kidney Int* 71: S222-S226, 1999.
946. Baigent C, Wheeler DC. Should we reduce blood cholesterol to prevent cardiovascular disease among patients with chronic renal failure? *Nephrol Dial Transplant* 15: 1118-1119, 2000.
947. Landray M, Baigent C, Leaper C and the UK-HARP Steering Committee. Biochemical safety and efficacy of co-administration of ezetimibe and simvastatin among patients with chronic kidney disease: the second UK-Heart and renal protection (UK-HARP-II) study. *Circulation* 108 (17, suppl. IV): 736, 2003
948. Baigent C, Landray M. Study of Heart and Renal Protection (SHARP). *Kidney Int* 63 (suppl 84): S207-S210, 2003.
949. Kasiske BL, Tortorice KL, Heim-Duthoy KL, Goryance JM, Rao KV. Lovastatin treatment of hypercholesterolemia in renal transplant recipients. *Transplantation* 49: 95-100, 1990.
950. Katznelson S, Wilkinson AH, Kobashigawa JA, Wang XM, Chia D, Ozawa M, y cols. The effect of pravastatin on acute rejection after kidney transplantation. A pilot study. *Transplantation* 61: 1469-1474, 1996
951. Kliem V, Wanner C, Eisenhauer T, Olbricht CJ, Doll R, Boddaert M, y cols. Comparison of pravastatin and lovastatin in renal transplantation patients receiving cyclosporine. *Transplant Proc* 1996; 28: 3126-3128, 1996
952. Arnadóttir M, Eriksson LO, Germershausen JL, Thysell H. Low dose simvastatin is a well tolerated and efficacious cholesterol lowering agent in cyclosporine treated kidney transplant recipients: Double blind, randomized, placebo controlled study in 40 patients. *Nephron* 68: 57-62, 1994
953. Martínez Hernández BE, Persaud JW, Varghese Z, Moorhead JF. Low dose simvastatin is safe in hyperlipidaemic renal transplant patients. *Nephrol Dial Transplant* 8: 637-641, 1993
954. Castro R, Queiros J, Fonseca I, Pimentel JP, Henriques AC, Sarmiento AM y cols. Therapy of post renal transplantation hyperlipidaemia: comparative study with simvastatin and fish oil. *Nephrol Dial Transplant* 12: 2140-2143, 1997
955. Sahu K, Sharma R, Gupta A, Gulati S, Agarwal D, Kumar A y cols. Effect of lovastatin, an HMGCoA reductasa inhibitor, on acute renal allograft rejection. *Clin Transplant* 15: 173-175, 2001
956. Renders L, Mayer-Kadner I, Koch C, Scharffe S, Burkhardt K, Veelken R, y cols. Efficacy and drugs interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA treated renal transplant recipients. *Nephrol Dial Transplant* 16: 141-146, 2001.
957. Kasiske BL, Heim-Duthoy KL, Singer GG, Watschinger B, Germain MJ, Bastani B. The effects of lipid lowering agents on acute renal allograft rejection. *Transplantation* 72: 223-227, 2001.
958. Martínez-Castelao A, Grinyo JM, Gil-Vernet S, Seron D, Castineiras MJ, Ramos R, y cols. Lipid lowering long term effects of six different statins in hypercholesterolemic renal transplant patients under cyclosporine immunosuppression. *Transplant Proc* 34: 398-400, 2002.
959. Holdaas H, Jardine AG, Wheeler DC, Brekke IB, Conlon PJ, Fellstrom B y cols. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. *Kidney Int* 60: 1990-1997, 2001
960. Igel M, Sudhop T, von Bergmann K. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins). *Eur J Clin Pharmacol* 47: 357-364, 2001
961. Stern R, Yang B, Horton M, Moore S, Abel RB, Olson SC. Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin. *J Clin Pharmacol* 37: 816-819, 1997
962. Appel-Dingemanse S, Smith T, Merz M. Pharmacokinetics of fluvastatin in subjects with renal impairment and nephrotic syndrome. *J Clin Pharmacol* 2002; 42: 312-318, 2002
963. Gehr TW, Sica DA, Slugg PH, Hammett JL, Raymond R, Ford NF. The pharmacokinetics of pravastatin in patients of chronic hemodialysis. *Eur J Clin Pharmacol* 53: 117-121, 1997
964. Sica DA, Gehr TW. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: considerations in the renal failure patient. *Curr Opin Nephrol Hypertens* 11: 123-133, 2002

965. Shek A, Ferrill MJ. Statin-fibrate combination therapy. *Ann Pharmacother* 35: 908-917, 2001
966. Blum CB. Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framingham risk model. *Am J Transplant* 2: 551-559, 2002
967. Asberg A, Hartmann A, Fjeldsa E, Bergan S, Holdaas H. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. *Am J Transplant* 1: 382-386, 2001
968. Olbricht C, Wanner C, Eisenhauer T, Kliem V, Doll R, Boddaert M, y cols. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine treated kidney graft patients after multiple doses. *Clin Pharmacol Ther* 62: 311-321, 1997
969. Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. *Clin Pharmacol Ther* 1998; 64: 177-182, 1998
970. Kantola T, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. *Clin Pharmacol Ther* 64: 58-65, 1998
971. Mazzu AL, Lasseter KC, Shamblem EC, Agarwal V, Lettieri J, Sundareshan P. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. *Clin Pharmacol Ther* 68: 391-400, 2000
972. Pasternak R, Smith S, Grundy S, y cols. ACC/AHA/NHLBI Clinical Advisory on the use and safety of statins. *J Am Coll Cardiol* 40: 567-572, 2002
973. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB y cols. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. *N Engl J Med* 341: 410-418, 1999
974. Anderson P, Norbeck HE. Clinical pharmacokinetic of bezafibrate in patients with impaired renal function. *Eur J Clin Pharmacol* 21:209-214, 1981
975. Desager JP, Costermans J, Verberckmoes R, Harvenct C. Effect of hemodialysis on plasma kinetics of fenofibrate in chronic renal failure. *Nephron* 31: 51-54, 1982
976. Evans JR, Forland SC, Cutler RE. The effect of renal function on the pharmacokinetics of gemfibrozil. *J Clin Pharmacol* 27: 994-1000, 1987
977. Chertow GM, Burke SK, Lazarus JM, Stenzel KH, Wombolt D, Goldberg D y cols. Poly allylamine hydrochloride (Renagel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. *Am J Kidney Dis* 29: 66-71, 1997
978. Braunlin W, Sorbo E, Guo A, Apruzzese W, Xu Q, Hook P, y cols. Bile acid binding to sevelamer HCl. *Kidney Int* 62: 611-619, 2002
979. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. *Kidney Int* 62: 245-252, 2002
980. Soroka N, Silverberg DS, Gremland M, Birk Y, Blum M, Peer G, y cols. Comparison of a vegetable based (soya) and an animal based low protein diet in predialysis chronic renal failure patients. *Nephron* 79: 173-180, 1998
981. Khajehdehi P. Effect of vitamins on the lipid profile of patients on regular hemodialysis. *Scand J Urol Nephrol* 34: 62-66, 2000
982. Khajehdehi P. Lipid lowering effect of polyunsaturated fatty acids in hemodialysis patients. *J Ren Nutr* 10: 191-195, 2000
983. Golper TA, Wolfson M, Ahmad S, Hirschberg R, Kurtin P, Katz LA, y cols. Multicenter trial of L-carnitine in maintenance hemodialysis patients. Carnitine concentrations and lipid effects. in renal transplantation. *Kidney Int* 38: 904-911, 1990.
984. Bennett WM, Carpenter CB, Shapiro ME, Strom TB, Hefty D, Tillman M, y cols. Delayed omega-3 fatty acid supplements in renal transplantation. A double blind placebo controlled study. *Transplantation* 59: 352-356, 1995
985. Urakaze M, Hamazaki T, Yano S, Kashiwabara H, Oomori K, Yokoyama T. Effect of fish oil concentrate on risk factors of cardiovascular complications in renal transplantation. *Transplant Proc* 21: 2134-2136, 1989
986. Ingram AJ, Parbtani A, Churchill DN. Effects of two low flux cellulose acetate dialysers on plasma lipids and lipoproteins. A cross over trial. *Nephrol Dial Transplant* 13: 1452-1457, 1998
987. Seres DS, Strain GW, Hashim SA, Goldberg JJ, Levin NW. Improvement of plasma lipoprotein profile during high flux dialysis. *J Am Soc Nephrol* 3: 1409-1415, 1993
988. Blankestijn PJ, Vos PF, Rabelink TJ, van Rijn HJ, Jansen H, Koomans HA. High flux dialysis membranes improve lipid profile in chronic hemodialysis patients. *J Am Soc Nephrol* 5: 1703-1708, 1995.
989. Goldberg JJ, Kaufman AM, Lavarias VA, Vanni-Reyes T, Levin NW. High flux dialysis membranes improve plasma lipoprotein profiles in patients with end stages renal disease. *Nephrol Dial Transplant* 11 (suppl 2): 104-107, 1996.
990. The USRDS dialysis Morbidity and Mortality Study: Wave 2: United States Renal Data System. *Am J Kidney Dis* 30 (suppl 1): S67-S85, 1997
991. Prichard S. Coronary artery disease in end stage renal disease: Risk factors and treatment strategies. *J Jpn Soc Dial Ther* 33: 159-164, 2000
992. Krauss RM, Eckel RH, Howard B, Appel LJ, Daniels SR, Deckelbaum RJ, y cols. AHA Dietary Guidelines: Revision 2000: A Statement for healthcare professionals from the Nutrition Committee of the American Heart Association. *Circulation* 102: 2284-2299, 2000
993. Yu-Poth S, Zhao G, Etherton T, Naglak M, Jonnalagadda S, Kris-Etherton PM y cols. Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention program on cardiovascular disease risk factors: A metaanalysis. *Am J Clin Nutr* 69: 632-646, 1999.
994. Physical activity and cardiovascular health. NIH Consensus Development Panel on Physical Activity and Cardiovascular Health. *JAMA* 276: 241-246, 1996
995. National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice Guidelines for Nutrition in Chronic Renal Failure. *Am J Kidney Dis* 35 (suppl 2): S1-S140, 2000
996. Castaneda C, Grossi L, Dweyer J. Potential benefits of resistance exercise training on nutritional status in renal failure. *J Ren Nutr* 8: 2-10, 1998.
997. McCullough PA. Cardiovascular risk: an important clinical intersection. *Rev Cardiovasc. Med.* 3:71-76, 2002.
998. Rabelink TJ: Cardiovascular risk in patients with renal disease: treating the risk or treating the risk factor? *Nephrol. Dial. Transplant.* 19:23-26, 2004.

BIBLIOGRAFÍA

999. Gorge MP, Neild GH: Platelet function in uraemia. *Platelets*. 2:115-123, 1991.
1000. Castillo R, Lozano T, Escolar G, Revert L, Lopez J, Ordinas A: Defective platelet adhesion on vessel subendothelium in uremic patients. *Blood*. 68:337-42, 1986.
1001. Moia M, Mannucci PM, Vizzotto L, Casati S, Cattaneo M, Ponticelli C: Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. *Lancet* 2:1227-1229, 1987.
1002. Cases A, Escolar G, Reverter JC, Ordinas A, Lopez-Pedret J, Revert L, y cols. Recombinant human erythropoietin treatment improves platelet function in uremic patients. *Kidney International*. 42:668-672, 1992.
1003. Livio M, Benigni A, Vigano G, Mecca G, Remuzzi G: Moderate doses of aspirin and risk of bleeding in renal failure. *Lancet* 1:414-416, 1986.
1004. Gaspari F, Vigano G, Orisio S, Bonati M, Livio M, Remuzzi G: Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition. *J Clin. Invest* 79:1788-1797, 1987.
1005. Sanchez Perales MC, Vazquez E, Garcia Cortes MJ, Borrego FJ, Borrego J, Perez DB y cols. Platelet antiaggregation and hemorrhagic risk in hemodialysis. *Nefrologia*. 22:456-462, 2002.
1006. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. *Nature New Biol* 23:232-235, 1971.(Abstract)
1007. Moncada S, Vane JR: Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A₂, and prostacyclin. *Pharmacol.Rev.* 30:293-331, 1979.
1008. Antiplatelet Trialists' Collaboration: Collaborative overview of randomised trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. *BMJ* 308:81-106, 1994.
1009. Ridker PM, Manson JE, Buring JE, Goldhaber SZ, Hennekens CH: The Effect of Chronic Platelet Inhibition with Low-Dose Aspirin on Atherosclerotic Progression and Acute Thrombosis - Clinical Evidence from the Physicians' Health Study. *Am Heart J* 122:1588-1592, 1991.
1010. Ford CM, Ejerblad E, Lindblad P, Fryzek JP, Dickman PW, Signorello LB, y cols. Acetaminophen, aspirin, and chronic renal failure. *N Engl J Med*. 345:1801-1808, 2001.
1011. ISIS-2 Collaborative Group: Randomised trial of intravenous streptokinase, oral aspirin, oth, or neither amongst 17,187 cases of suspected acute myocardial infarction: ISIS-2. *Lancet* 2:349-360, 1988.
1012. Harker LA: Therapeutic inhibition of platelet function in stroke. *Cerebrovascular.Diseases*. 8:8-18, 1998.
1013. Eidelman RS, Hebert PR, Weisman SM, Hennekens CH: An update on aspirin in the primary prevention of cardiovascular disease. *Arch.Intern.Med*. 163:2006-2010, 2003.
1014. Antiplatelet Trialists' Collaboration: Collaborative overview of randomised trials of antiplatelet therapy II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. *BMJ* 308:159-168, 1994.
1015. Escolar G, Heras M: Clopidogrel: A selective inhibitor of platelet ADP receptors. *Drugs of today* 36:187-199, 2000.
1016. Herbert JM: Clopidogrel and antiplatelet therapy. *Expert Opin Invest Drug* 3:449-455, 1994.
1017. Schror K: Clinical pharmacology of the adenosine diphosphate (ADP) receptor antagonist, clopidogrel. *Vasc.Med*. 3:247-251, 1998.
1018. CAPRIE Steering Committee.: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). *Lancet* 348:1329-1339, 1996.
1019. Herbert JM, Frehel D, Vallee E, Kieffer G, Gouy D, Berger Y, y cols. Clopidogrel, a novel antiplatelet and antithrombotic agent. *Cardiovasc.Drug.Rev*. 2:180-198, 1993.
1020. Hankey GJ, Sudlow CL, Dunbabin DW: Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials. *Stroke* 31:1779-1784, 2000.
1021. CURE Steering Committee. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. *N Engl J Med*. 345, 494-502. 2001.
1022. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, Investigators FT: Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). *Circulation* 102:624-629, 2000.
1023. Steinhubl SR, Berger PB, Mann JT, III, Fry ET, DeLago A, Wilmer C, y cols. (CREDO Trial): Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. *JAMA* 288:2411-2420, 2002.
1024. Topol EJ, Byzova TV, Plow EF: Platelet GPIIb-IIIa blockers. *Lancet* 353:227-231, 1999.
1025. Gold HK, Gimple LW, Yasuda T, Leinbach RC, Werner W, Holt R, y cols. Pharmacodynamic Study of F(Ab')₂ Fragments of Murine Monoclonal Antibody-7E3 Directed Against Human Platelet Glycoprotein- IIb/IIIa in Patients with Unstable Angina Pectoris. *J.Clin.Invest*. 86:651-659, 1990.
1026. Brener SJ, Ellis SG, Schneider J, Apperson-Hansen C, Topol EJ: Abciximab-facilitated percutaneous coronary intervention and long-term survival--a prospective single-center registry. *Eur.Heart J* 24:630-638, 2003.
1027. Best PJ, Lennon R, Gersh BJ, Ting HH, Rihal CS, Bell MR, y cols. Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. *Am.Heart J* 146:345-350, 2003.
1028. The EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein IIb-IIIa receptor in high-risk coronary angioplasty. *N Engl J Med*. 330:956-961, 1994.
1029. The CAPTURE Investigators: Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. *Lancet* 349:1429-1435, 1997.
1030. The EPILOG Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. *N Engl J Med*. 336:1689-1696, 1997.
1031. The EPISTENT Investigators: Randomised controlled trial to assess safety of coronary stenting with use of abciximab. *Lancet* 352:85-90, 1998.
1032. Scarborough RM, Naughton MA, Teng W, Rose JW, Phillips DR, Nannizi L, y cols. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. *J.Biol.Chem*. 268:1066-1073, 1993.

1033. Scarborough RM: Development of eptifibatide. *Am.Heart J.* 138:1093-1104, 1999.
1034. Heras M, Escolar G: Eptifibatide: A cyclic peptide that selectively inhibits platelet glycoprotein IIb/IIIa. *Drugs of today* 36:295-311, 2000.
1035. Phillips DR, Scarborough RM: Clinical pharmacology of eptifibatide. *Am.J.Cardiol.* 80:11B-20B, 1997.
1036. Tcheng JE: Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. *Am.J.Cardiol.* 78:35-40, 1996.
1037. The PURSUIT Trial Investigators.: Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. *N.Engl.J.Med.* 339:436-443, 1998.
1038. The IMPACT-II Investigators: Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. *Lancet* 349:1422-1428, 1997.
1039. Ohman EM, Kleiman NS, Gacioch G, Worley SJ, Navetta FI, Talley JD, y cols. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. *IMPACT-AMI Investigators. Circulation* 95:846-854, 1997.
1040. Theroux P: Tirofiban. *Drugs of today* 35:59-73, 1999.
1041. Lynch JJ, Cook JJ, Sitko GR, Holahan MA, Ramjit DR, Mellott MJ, y cols. Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383. *J.Pharmacol.Exp.Ther.* 272:20-32, 1995.
1042. Peerlinck K, Delepeleire I, Goldberg M, Farrell D, Barrett J, Hand E, y cols. MK-383 (I-700,462), a selective nonpeptide platelet glycoprotein- IIb/IIIa antagonist, is active in man. *Circulation.* 88:1512-1517, 1993.
1043. Barrett JS, Murphy G, Peerlinck K, Lepeleire ID, Gould RJ, Panebianco D, y cols. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. *Clinical Pharmacology & Therapeutics.* 56:377-388, 1994.
1044. Umemura K, Kondo K, Ikeda Y, Nakashima M: Enhancement by ticlopidine of the inhibitory effect on in vitro platelet aggregation of the glycoprotein IIb/IIIa inhibitor tirofiban. *Thrombosis.and Haemostasis* 78:1381-1384, 1997.
1045. The PRISM Study Investigators: A combination of aspirin plus tirofiban with aspirin plus heparin for unstable angina. *N Engl J Med.* 338:1498-1505, 1998.
1046. The PRISM-PLUS Study Investigators: Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. *N Engl J Med.* 338:1488-1497, 1998.
1047. The RESTORE Investigators: Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. *Circulation* 96:1445-1453, 1997.
1048. Hirsh J, Fuster V: Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart Association [published erratum appears in *Circulation* 1995 Jan 15;91(2):A55-A56]. *Circulation* 89:1469-1480, 1994.
1049. Choonara IA, Malia RG, Haynes BP, Hay CR, Cholerton S, Breckenridge AM, y cols. The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin. *Br.J.Clin.Pharmacol.* 25:1-7, 1988.
1050. O'Reilly R, Aggeler P: Determinants of the response to oral anticoagulant drugs in man. *Pharmacology Review* 22:35-96, 1970.
1051. Kim SB, Lee SK, Park JS, Chi HS, Hong CD, Yang WS: Effects of fixed low-dose warfarin on hemostatic factors in continuous ambulatory peritoneal dialysis patients. *Am.J Kidney Dis.* 37:343-347, 2001.
1052. McMahan DA, Smith DM, Carey MA, Zhou XH: Risk of major hemorrhage for outpatients treated with warfarin. *J Gen.Intern.Med.* 13:311-316, 1998.
1053. Tomson C: Vascular calcification in chronic renal failure. *Nephron Clin.Pract.* 93:c124-c130, 2003.
1054. Schurgers LJ, Dissel PE, Spronk HM, Soute BA, Dhore CR, Cleutjens JP, y cols. Role of vitamin K and vitamin K-dependent proteins in vascular calcification. *Z.Kardiol.* 90 Suppl 3:57-63, 2001.
1055. McLean J: The thromboplastic action of cephalin. *American Journal of Physiology* 41:250-257, 1916.
1056. Brinkhous KM, Smith HP, Warner ED, Seegers WH: The inhibition of blood clotting: an unidentified substance which acts in conjunction with heparin to prevent the conversion of prothrombin into thrombin. *Am J Phys* 125:683-687, 1939.
1057. Abildgaard U: Highly purified antithrombin 3 with heparin cofactor activity prepared by disc electrophoresis. *Scan J Clin Lab Invest* 21:89-91, 1968.
1058. Hirsh J, Fuster V: Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association. *Circulation* 89:1449-1468, 1994.
1059. Handeland GF, Abildgaard U, Holm HA, Arnesen KE: Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. *Eur.J.Clin.Pharmacol.* 39:107-112, 1990.
1060. Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J: Establishing a therapeutic range for heparin therapy. *Ann.Intern.Med.* 119:104-109, 1993.
1061. Thorevska N, Amoateng-Adjepong Y, Sabahi R, Schiopescu I, Salloum A, Muralidharan V, y cols. Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin. *Chest* 125:856-863, 2004.
1062. King DJ, Kelton JG: Heparin-associated thrombocytopenia. *Ann.Intern.Med.* 100:535-540, 1984.
1063. Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM: Low-molecular-weight heparins: pharmacologic profile and product differentiation. *Am.J.Cardiol.* 82:3L-10L, 1998.
1064. Hirsh J: Heparin. *N.Engl.J.Med.* 324:1565-1574, 1991.
1065. Hirsh J: Low-molecular-weight heparin for the treatment of venous thromboembolism. *Am.Heart J.* 135:S336-S342, 1998.
1066. Fareed J: Current trends in antithrombotic drug and device development. *Semin.Thromb.Hemost.* 22 Suppl 1:3-8, 1996.
1067. Farooq V, Hegarty J, Chandrasekar T, Lamerton EH, Mitra S, Houghton JB, y cols. Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. *Am.J Kidney Dis.* 43:531-537, 2004.
1068. Von Visger J, Magee C: Low molecular weight heparins in renal failure. *J Nephrol.* 16:914-916, 2003.

BIBLIOGRAFÍA

1069. Turpie AG: Can we differentiate the low-molecular-weight heparins? *Clin.Cardiol.* 23 Suppl 1:14-172000.
1070. The FRAX.I.S.Study Group: Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of infractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. *European Heart Journal* 20:1553-1562, 1999.
1071. Monrad ES: Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction. *Am.J.Cardiol.* 85:2C-9C, 2000.
1072. Lefkowitz J, Topol EJ: Direct thrombin inhibitors in cardiovascular medicine. *Circulation* 90:1522-1536, 1994.
1073. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators: A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. *N.Engl.J.Med.* 335:775-782, 1996.
1074. The OASIS-2: Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. *Lancet* 353:429-438, 1999.
1075. Nowak G, Bucha E, Gock T, Thielier H, Markwardt F: Pharmacology of r-hirudin in renal impairment. *Thromb.Res.* 66:707-715, 1992.
1076. Vanholder R, Camez A, Veys N, Van Loo A, Dhondt AM, Ringoir S: Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. *Thromb.Haemost.* 77:650-655, 1997.
1077. Fischer KG: Hirudin in renal insufficiency. *Semin. Thromb. Hemost.* 28:467-482, 2002.
1078. Eriksson UG, Johansson S, Attman PO, Mulec H, Frison L, Fager G, y cols. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. *Clin.Pharmacokinet.* 42:743-753, 2003.
1079. Olsson SB: Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. *Lancet* 362:1691-1698, 2003.
1080. Zanchetti A, Hansson L, Dahlof B, Julius S, Menard J, Warnold I, y cols. Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk. *J Hypertens.* 20:2301-2307, 2002.
1081. Trovati M, Cavalot F: Optimization of hypolipidemic and antiplatelet treatment in the diabetic patient with renal disease. *J Am.Soc.Nephrol* 15 Suppl 1:S12-S202004.
1082. American Diabetes Association. Aspirin therapy in diabetes. *Diabetes Care* (26 (suppl 1)), S87-S88. 2003.
1083. McCullough PA, Sandberg KR, Borzak S, Hudson MP, Garg M, Manley HJ: Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. *Am.Heart J* 144:226-232, 2002.
1084. Berger AK, Duval S, Krumholz HM: Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. *J Am.Coll.Cardiol.* 42:201-208, 2003.
1085. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P: Antithrombotic and thrombolytic therapy for ischemic stroke. *Chest* 119:300S-320S, 2001.
1086. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. *J Neurol.Sci.* 143:1-13, 1996.
1087. Kaufman JS, O'Connor TZ, Zhang JH, Cronin RE, Fiore LD, Ganz MB, y cols. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. *J Am.Soc.Nephrol* 14:2313-2321, 2003.
1088. Uldall R: Prevention of thrombosis in arteriovenous fistulas. *Blood Purif.* 3:89-93, 1985.
1089. Windus DW, Santoro SA, Atkinson R, Royal HD: Effects of antiplatelet drugs on dialysis-associated platelet deposition in polytetrafluoroethylene grafts. *Am.J Kidney Dis.* 29:560-564, 1997.
1090. Obialo CI, Conner AC, Lebon LF: Maintaining patency of tunneled hemodialysis catheters--efficacy of aspirin compared to warfarin. *Scand.J Urol.Nephrol* 37:172-176, 2003.
1091. Saran R, Dykstra DM, Wolfe RA, Gillespie B, Held PJ, Young EW: Association between vascular access failure and the use of specific drugs: the Dialysis Outcomes and Practice Patterns Study (DOPPS). *Am.J Kidney Dis.* 40:1255-1263, 2002.
1092. Da Silva AF, Escofet X, Rutherford PA: Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. *Cochrane.Database.Syst.Rev.* CD0027862003.
1093. Schon D, Mishler R: Salvage of occluded autologous arteriovenous fistulae. *Am.J Kidney Dis.* 36:804-810, 2000.
1094. Clase CM, Crowther MA, Ingram AJ, Cina CS: Thrombolysis for restoration of patency to haemodialysis central venous catheters: a systematic review. *J Thromb.Thrombolysis.* 11:127-136, 2001.
1095. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA, Jr. Wheeler HB: Prevention of venous thromboembolism. *Chest* 119:132S-175S, 2001.
1096. Tveit DP, Hypolite I, Bucci J, Hshieh P, Cruess D, Agodoa LY, y cols. Risk factors for hospitalizations resulting from pulmonary embolism after renal transplantation in the United States. *J Nephrol* 14:361-368, 2001.
1097. Tveit DP, Hypolite IO, Hshieh P, Cruess D, Agodoa LY, y cols. Chronic dialysis patients have high risk for pulmonary embolism. *Am.J Kidney Dis.* 39:1011-1017, 2002.
1098. Tveit DP, Hshieh P, Cruess D, Agodoa LY, Welch PG, Abbott KC: Risk factors for pulmonary embolism in chronic dialysis patients. *J Nephrol* 15:241-247, 2002.
1099. Antiplatelet Trialists'Collaboration: Collaborative overview of randomised trials of antiplatelet therapy-III:Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. *BMJ* 308:235-246, 1994.
1100. Pulmonary Embolism Prevention (PEP) Trial: Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. *Lancet* 355:1295-1302, 2000.
1101. Fuster V, Ryden LE, Asinger RW, Cannon DS, Crijns HJ, Frye RL, y cols. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the

- European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology. *J Am.Coll.Cardiol.* 38:1231-1266, 2001.
1102. Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B, y cols. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. *Eur.Heart J.* 25:166-181, 2004.
1103. TDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 14. *JAMA* 268, 1292-1300. 1992.
1104. Juul-Moller S, Edvardsson N, Jahnmatz B, Rosen A, Sorensen S, Omblus R: Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. *Lancet* 340:1421-1425, 1992.
1105. Popma JJ, Ohman EM, Weitz J, Lincoff AM, Harrington RA, Berger P: Antithrombotic therapy in patients undergoing percutaneous coronary intervention. *Chest* 119:321S-336S, 2001.
1106. The GUSTO IV-ACS investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. *Lancet* , 1915-1924. 2001.
1107. Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, y cols. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. *Circulation* 98:734-741, 1998.
1108. Neumann FJ, Kastrati A, Schmitt C, Blasini R, Hadamitzky M, Mehilli J, y cols. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. *J Am.Coll.Cardiol.* 35:915-921, 2000.
1109. Stone GW, Grines CL, Cox DA, Garcia E, Tchong JE, Griffin JJ, Gy cols. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. *N Engl J Med.* 346:957-966, 2002.
1110. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, y cols. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. *New England Journal of Medicine* 344:1895-1903, 2001.
1111. Stein PD, Dalen JE, Goldman S, Theroux P: Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts. *Chest* 119:278S-282S, 2001.
1112. Jackson MR, Clagett GP: Antithrombotic therapy in peripheral arterial occlusive disease. *Chest* 119:283S-299S, 2001.
1113. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijsns HJ, Frye RL, y cols. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. *Eur.Heart J* 22:1852-1923, 2001.
1114. Salem DN, Daudelin HD, Levine HJ, Pauker SG, Eckman MH, Riff J: Antithrombotic therapy in valvular heart disease. *Chest* 119:207S-219S, 2001.
1115. Guyatt G, Schunemann H, Cook D, Jaeschke R, Pauker S, Bucher H: Grades of recommendation for antithrombotic agents. *Chest* 119:3S-7S, 2001.
1116. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, y cols. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. *N Engl J Med.* 345:1809-1817, 2001.
1117. Januzzi JL, Jr. Snapinn SM, DiBattiste PM, Jang IK, Theroux P: Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. *Circulation* 105:2361-2366, 2002.
1118. Jardine AG, McLaughlin. Cardiovascular complications of renal disease. *Heart* 86: 459-466, 2001.
1119. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. *Lancet* 356:147-52,2000.
1120. Sarnak MJ, Levey AS. Epidemiology of cardiac disease in dialysis patients.*Semin Dial* 12:69-76,1999.
1121. Informe preliminar de diálisis y trasplante año 2002 de la Sociedad Española de Nefrología. Congreso Nacional de la Sociedad Española de Nefrología. Palma de Mallorca (2003).
1122. U.S Renal Data System: USRDS 2002/2000 Annual Data Report. Bethesda MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases 2002 /2000
1123. Rostand SG. Coronary heart disease in chronic renal insufficiency: some management considerations. *J Am Soc Nephrol* 11:1948-1956,2000.
1124. Gheorghide M, Bonow RO. Chronic heart failure in the United States: A manifestation of coronary artery disease. *Circulation* 97:282-289, 1998.
1125. Joki N, Hase H, Nakamura R, Yamaguchi T. Onset of coronary artery disease prior to initiation of haemodialysis in patients with end-stage renal disease. *Nephrol Dial Transplant* 12:718-723, 1997.
1126. Sarnak MK. Cardiovascular complications in chronic kidney disease. *Am J Kidney Dis* 41(Suppl 5):11-17, 2003
1127. Schunkert H, Hense HW. A heart price to pay for anaemia. *Nephrol Dial Transplant* 16:445-448, 2001.
1128. Rostand SG, Kirk KA, Rutsky EA. Dialysis-associated ischemic heart disease: Insights from coronary angiography. *Kidney Int* 25:653-659, 1984.
1129. Schwarz U, Buzello M, Ritz , Stein G, Raabe G, Wiest G y cols. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. *Nephrol Dial Transplant* 17:218-23, 2000.
1130. London GM, Marchais SJ, Guerin AP, Metivier F, Adda H. Arterial structure and function in end-stage renal disease. *Nephrol Dial Transplant* 17:1713-1724, 2002.
1131. Klassen PS, Lowrie EG, Reddan DN, DeLong ER, Coladonato JA, Szczech LA y cols. Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. *JAMA* 287:1548-1555, 2002.

BIBLIOGRAFÍA

1132. Alexander RW. Hypertension and the pathogenesis of atherosclerosis: Oxidative stress and the mediation of arterial inflammatory response. A new perspective. *Hypertension* 25:155-161, 1995.
1133. London GM, Marchais SJ, Safar ME, Genest AF, Guerin AP, Metvier F, y cols. Aortic and large artery compliance in end-stage renal failure. *Kidney Int* 37:137-142, 1990.
1134. Zager PG, Nikolic J, Brown RH, Campbell MA, Hunt WC, Peterson D y cols. "U" curve association of blood pressure and mortality in hemodialysis patients. *Kidney Int* 54:561-569, 1998.
1135. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cottini E, Giaccone G, y cols. Prediction of left ventricular geometry by clinic, pre-dialysis and 24- h ambulatory BP monitoring in hemodialysis patients: CREED investigators. *J Hypertens* 17: 1751-1758, 1999.
1136. Wu M-S, Yu C-C, Yang C-W, Wu C-H, Huang J-Y, Hong J-J y cols. Poor pre-dialysis glycaemic control is a predictor of mortality in type II diabetic patients on maintenance haemodialysis. *Nephrol Dial Transplant* 12:2105-2110, 1997.
1137. Schmidt AM, Yan SD, Wautier J-L, Stern D. Activation of receptor por advanced glycation end products: A mechanism of chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. *Circ Res* 84:489-497, 1999.
1138. King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. *Br J Clin Pharmacol* 48: 643-8, 1999.
1139. Attman P-O, Alaupovic P. Lipid an apolipoprotein profiles of uremic dyslipoproteinemia-Relation to renal function and dialysis. *Nephron* 57:401-410, 1991.
1140. Brown G, Albers JJ, Fisher LD, Schaeffer SM, Lin J-T, Kaplan C y cols. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. *N Engl J Med* 323:1289-1298, 1990.
1141. Metvier F, Marchais SJ, Guerin AP, Pannier B, London GM. Pathophysiology of anaemia: Focus on the heart and blood vessels. *Nephrol Dial Transplant* 15:14-18, 2000.
1142. Fellner SK, Lang RM, Neumann A, Korcarz C, Borow KM: Cardiovascular consequences of correction of the anemia of renal failure with erythropoietin, *Kidney Int* 44:1309-1315, 1993.
1143. Besarab A, Bolton WK, Nissenson AR, Schwab SJ, Goodkin DA. The Normal Haematocrit Trial in dialysis patients with cardiac disease. *Nephrol Dial Transplant* 14:2043-2044, 1999.
1144. Rostand SG, Drüeke TB. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. *Kidney Int* 56: 383-392, 1999.
1145. Watson KE, Abrolat ML, Malone LL, Hoeg JM, Doherty T, Detrano R y cols. Active serum vitamin D levels are inversely correlated with coronary calcification. *Circulation* 96:1755-1760, 1997.
1146. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphorus product with mortality risk in chronic hemodialysis patients: A national study. *Am J Kidney Dis* 31:607-617, 1998.
1147. Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S. Homocysteine and cardiovascular disease. A critical review of the epidemiologic evidence. *Ann Intern Med* 131:363-375, 1999.
1148. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. *N Engl J Med* 337:230-236, 1997.
1149. Ross R. Atherosclerosis-An inflammatory disease. *N Engl J Med* 40:115-126, 1999.
1150. Libby P, Ridker PM. Novel inflammatory markers of coronary risk: Theory versus practice. *Circulation* 100:1148-1150, 1999.
1151. Herrington DM. The HERS trial results: Paradigms lost? *Ann Intern Med* 131:463-466, 1999.
1152. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. *JAMA* 21;288(7):872-81, 2002.
1153. Stehman-Breen CO, Gillen D, Gipson D. Prescription of hormone replacement therapy in postmenopausal women with renal failure. *Kidney Int* 56: 2243-2247, 1999.
1154. Kenny A, Sutters M, Evans DB, Shapiro LM. Effects of hemodialysis on coronary blood flow. *Am J Cardiol* 74:291-294, 1994.
1155. Van der Sande FM, Cheriex EC, van Kuijk W, Leuissen K. Effect of dialysate calcium concentration on intradialytic blood pressure course in cardiac-compromised patients. *Am J Kidney Dis* 32:1125-1131, 1998.
1156. Alpert MA, Wizeman V, Holph KD, Van Stone J, Culpepper MC. Hemodialysis and the heart. *Am J Med Sci* 309:110-121, 1995.
1157. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC y cols. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. *Kidney Int* 47:186-92, 1995.
1158. Mehta BR, Ireland MA, Shiu MF. Echocardiographic evaluation of cardiac size and function in dialysis patients. *Clin Nephrol* 20:61-66, 1993.
1159. Ikram H, Lynn KL, Bacley RR, Little PJ. Cardiovascular changes in chronic hemodialysis patients. *Kidney Int* 24:371-6, 1983.
1160. London GM, Fabiani F, Marchais SJ, de Vernejoul MC, Guerin AP, Safar ME y cols. Uremic cardiomyopathy. An inadequate left ventricular hypertrophy. *Kidney Int* 31:973-980, 1987.
1161. Straumann E, Bertel O, Meyer B. Symmetric and asymmetric left ventricular hypertrophy in patients with end-stage renal failure on long-term hemodialysis. *Clin Cardiol* 21:672-678, 1998.
1162. London GM, Guerin AP, Marchais SJ. Pressure-overload cardiomyopathy in end-stage renal disease. *Curr Opin Nephrol Hypertens* 8:179-186, 1999.
1163. London GM, Guerin AP, Marchais SJ. Pathophysiology of left ventricular hypertrophy in dialysis patients. *Blood Purif* 12:277-283, 1994.
1164. Meeus F, Kourilsky O, Guerin AP, Gaudry C, Marchais SJ, London GM. Pathophysiology of cardiac disease in hemodialysis patients. *Kidney Int* 76 (suppl 1): 140-147, 2000.
1165. Canziani ME, Cendoroglo Neto M, Saragoca MA, Cassiolato JL, Ramos OL, Ajzen H y cols. Hemodialysis versus continuous ambulatory peritoneal dialysis: effects on the heart. *Artif Organs* 19:241-244, 1995.
1166. Amann K, Breitbach M, Ritz E, Mall G. Myocyte/capillary mismatch in the heart of uremic patients. *J Am Soc Nephrol* 9:1018-1022, 1998.

1167. Rostand SG, Gretes KC, Kirk KA, Rutsky EA, Andreoli TE. Ischemic heart disease in patients with uremia undergoing maintenance hemodialysis. *Kidney Int* 16:600-611, 1979.
1168. Amann U, Ritz E, Wiest G, Klaus G, Mall G. A role of parathyroid hormone in the genesis of interstitial cell activation. *J Am Soc Nephrol* 4:1814-1819, 1994.
1169. Vlahakos DV, Hahalis G, Vasillakos P, Marathias KP, Geroulanos S. Relationship between left ventricular hypertrophy and plasma renin activity in chronic hemodialysis patients. *J Am Soc Nephrol* 8:1764-1770, 1997.
1170. Washio M, Okuda S, Mizoue T, Kiyama S, Ando T, Sanai T y cols. Risk factors for left ventricular hypertrophy in chronic hemodialysis patients. *Clin Nephrol* 47:362-366, 1997.
1171. Harnett JD, Kent GM, Barre PE, Taylor R, Parfrey PS. Risk factors for the development of left ventricular hypertrophy in a prospective followed cohort of dialysis patients. *J Am Soc Nephrol* 1994;4:1486-1490, 1994.
1172. Mallamaci F, Zoccali C, Tripepi G, Benedetto FA, Parlongo S, Cataliotti A y cols.; CREED Investigators. The Cardiovascular Risk Extended Evaluation. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. *Kidney Int* 59:1559-1566, 2001.
1173. Ozkahya M, Toz H, Özerkan F, Duman S, Ok E, Basci A y cols. Impact of volume control on left ventricular hypertrophy in dialysis patients. *J Nephrol* 15:655-660, 2002.
1174. Tucker B, Fabbian F, Giles M. Reduction of left ventricular mass with blood pressure reduction in chronic renal failure. *Clin Nephrol* 52:377-382, 1999.
1175. Roithinger FX, Punzengrubere C, Wallner M, Ulbrich W, Pachinger O, Kramar R y cols. The influence of ACE inhibition on myocardial mass and diastolic function in chronic hemodialysis patients with adequate control of blood pressure. *Clin Nephrol* 42:309-314, 1994.
1176. Portoles J, Torralbo A, Martin P, Rodrigo J, Herrero JA, Barrientos A. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. *Am J Kidney Dis* 29:541-548, 1997.
1177. Wizemann V, Shafer R, Kramer W. Follow-up of cardiac change in normotensive hemodialysis patients with left ventricular hypertrophy. *Nephron* 69:202-206, 1993.
1178. Low-Friedrich I, Gruntzmacher P, Marz W, Bergmann M, Schoeppe W. Therapy with recombinant human erythropoietin reduces cardiac size and improves heart function in chronic hemodialysis patients. *Am J Nephrol* 11:54-60, 1991.
1179. Pascual J, Teruel DL, Moya JL, Liano F, Jimenez-Mena M, Ortuno J. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis. *Clin Nephrol* 35:280-287, 1991.
1180. Massimetti C, Pontillo D, Feriozzi S, Costantini S, Capezzuto A, Ancarani E. Impact of recombinant human erythropoietin treatment on left ventricular hypertrophy and cardiac function in dialysis patients. *Blood Purif* 16:317-324, 1998.
1181. Rademacher J, Koch KM. Treatment of renal anemia by erythropoietin substitution. The effects on the cardiovascular system. *Clin Nephrol* 44 (suppl 1): 856-860, 1995.
1182. Kasiske BL, Cangro CB, Hariharan S, Hricik ED, Kerman RH, Roth D y cols. The evaluation of renal transplantation candidates: Clinical practice guidelines. *Am J Transplant* 1(suppl 2):1-95, 2002.
1183. Gaston RS, Danovitch GM, Adams PL, Wynn JJ, Merion RM, Deierhoi H, y cols. The report of a National Conference on the wait list for kidney transplantation. *Am J Transplant* 3:775-785, 2003.
1184. Ix JH, Shlipak MG, Liu HH, Schiller NB, Whooley MA. Association between renal insufficiency and inducible ischemia in patients with coronary artery disease: The Heart and Soul Study. *J Am Soc Nephrol* 14:3233-3238, 2003.
1185. Rostand SG, Rutsky EA. Cardiac disease in dialysis patients. In: *Clinical Dialysis*, 3rd ED, edited by Nissenson AR, Fine RN, Gentile DE, Norwalk CT, Appleton and Lange. pp 652-698, 1995.
1186. Manske CL, Wang Y, Rector T, Wilson RF, White CW. Coronary revascularization in insulin-dependent diabetic patients with chronic renal failure. *Lancet* 340:998-1002, 1992.
1187. Murphy SW, Foley RN, Parfrey RS. Screening and treatment for cardiovascular disease in patients with chronic renal disease. *Am J Kidney Dis* 32: S184-99, 1998.
1188. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to know? Where do we go from here? Special report from the National Kidney Foundation Task Force on Cardiovascular Disease. *Am J Kidney Dis* 32 (suppl 3): S1-199, 1998.
1189. Zawada ET Jr, Stinson JB, Done G. New perspectives on coronary artery disease in hemodialysis patients. *South Med J* 75:694-6, 1982.
1190. Elsner D. How to diagnose and treat coronary artery disease in the uremic patient: an update. *Nephrol Dial Transplant* 16:1103-8, 2001.
1191. Ridker P, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. *N Engl J Med* 347:1557-1565, 2002.
1192. Wanner C, Metzger T. C-reactive protein a marker for all-cause and cardiovascular mortality in haemodialysis patients. *Nephrol Dial Transplant* 17 (suppl 8); 29-32, 2002.
1193. Stevinkel P, Alvestrand P. Inflammation in end-stage renal disease: Sources, consequences and therapy. *Semin Dial* 15:330-338, 2002.
1194. Herzog CA. How to manage the renal patient with coronary heart disease: The Agony and the Ecstasy of Opinion-Based Medicine. *J Am Soc Nephrol* 14:2556-2572, 2002.
1195. Apple FS, Murakami MM, Pearce LA, Herzog CA. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. *Circulation* 106:2941-2945, 2002.
1196. Mallamaci F, Zoccali C, Parlongo S, Tripepi G, Benedetto FA, Cutrupi S y cols. Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. *Am J Kidney Dis* 40:68-75, 2002.
1197. Setsusa K, Seino Y, Takahashi N, Ogawa T, Sasaki K, Harada A y cols. Clinical significance of elevated levels of cardiac troponin T in patients with chronic heart failure. *Am J Cardiol* 84:608-611, 1999.
1198. Goicoechea M, Garcia de Vinuesa MS, Gómez-Campderá F, Gutierrez MJ, Blanco P, Amann R y cols. Clinical significance of cardiac troponin T levels in chronic kidney disease patients: predictive value for cardiovascular risk. *Am J Kidney Dis* 43:846-853, 2004.
1199. Aviles RJ, Askari AT, Lindahl B, Wallentin L, Jia G, Ohman M y cols. Troponin T levels in patients with acute coronary syndromes with or without renal dysfunction. *N Engl J Med* 346:2047-2052, 2002.

BIBLIOGRAFÍA

1200. Conlon PJ, Krucoff MW, Minda S, Schumm D, Schwab SJ. Incidence and long-term significance of transient ST segment deviation in hemodialysis patients. *Clin Nephrol* 49:236-9, 1998.
1201. Marwick TH, Steinhilber DR, Underwood DA, Hobbs RE, Go RT, Swift C y cols. Ineffectiveness of dipyridamole SPECT thallium imaging as a screening technique for coronary artery disease in patients with end-stage renal failure. *Transplantation* 49:100-103, 1990.
1202. Vandenberg BF, Rossen JD, Grover-McKay M, Shammass NW, Burns TL, Rezai K. Evaluation of diabetic patients for renal and pancreas transplantation: Noninvasive screening for coronary artery disease using radionuclide methods. *Transplantation* 62:1230-1235, 1996.
1203. Rabbat CG, Treleaven DJ, Russell JD, Ludwin D, Cook DJ. Prognostic value of myocardial perfusion studies in patients with end-stage renal disease assessed for kidney or kidney-pancreas transplantation: a meta-analysis. *J Am Soc Nephrol* 14:431-439, 2003.
1204. Rostand SG, Rutsky EA. Ischemic heart disease in chronic renal failure: Management considerations. *Semin Dial* 2:98-101, 1989.
1205. Herzog CA MT, Pheley AM, White CW, White CW, Rao VK, Dick CD. Dobutamine stress echocardiography for the detection of significant coronary artery disease in renal transplant candidates. *Am J Kidney Dis* 33:1080-90, 1999.
1206. Reis GMP, Leichtman AB, Merion RM, Merion RM, Fay WP, Werns SW, y cols. Usefulness of dobutamine stress echocardiography in detecting coronary artery disease in end-stage renal disease. *Am J Cardiol* 75:707-10, 1995.
1207. Keeley EC, McCullough PA. Coronary revascularization in patients with end-stage renal disease: Risks, Benefits and Optimal Strategies. *Rev Cardiovasc Med* 4:125-130, 2003.
1208. Opsahl JA, Husebye DG, Helseth HK, Collins AJ. Coronary artery bypass surgery in patients on maintenance dialysis: long-term survival. *Am J Kidney Dis* 12:271-274, 1988.
1209. Kadakia RA, McCullough PA, Soman S. Does percutaneous revascularization confer a long-term survival benefit in patients with chronic renal failure? *J Invasive Cardiol* 12(11): P1, 2000.
1210. Charra B, Calemard M, Laurent G. Importance of treatment time and blood pressure control in achieving long-term survival on dialysis. *Am J Nephrol* 16:35-44, 1996.
1211. Witzmann V. Points to remember when dialysing the patient with coronary disease. *Nephrol Dial Transplant* 11:236-238, 1996.
1212. Herzog CA, Ma JZ, Collins AJ. Long-term survival of dialysis patients receiving thrombolytic therapy for acute myocardial infarction in the U.S. *Circulation* 100 (suppl 1): 304 (abstract), 1999.
1213. Gottlieb SS, McCarter RJ, Vogel RA. Effect of betablockade on mortality among high-risk and low-risk patient after myocardial infarction. *N Engl J Med* 339:489-493, 1998.
1214. Cice G, Ferrara L, Di Benedetto A, Russo PE, Marinelli G, Pavese F, Iacono A. Dilated cardiomyopathy in dialysis-patients beneficial effects of carvedilol: A double-blind, placebo-controlled trial. *J Am Coll Cardiol* 37: 407-411, 2001.
1215. Cice G, Ferrara L, D'Andrea A, D'Isa S, Di Benedetto A, Cittadini A y cols. Carvedilol increases two-year survival in patients with dilated cardiomyopathy. A prospective, placebo-controlled trial. *J Am Coll Cardiol* 41:1438-1444, 2003.
1216. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. *N Engl J Med* 345:494-502, 2001.
1217. Kong TQ, Dacanay S, Hsieh AA. Features of acute myocardial infarction in patients on chronic hemodialysis (abstract). *Circulation* 88(suppl 1): 1-49, 1993.
1218. Amann K, Ritz E. Cardiac disease in chronic uremia. *Pathophysiology. Adv Renal Replace Ther* 4:212-224, 1997.
1219. Ritz E, Amann Törnig J, Schwarz U, Stein G. Some cardiac abnormalities in renal failure. *Adv Nephrol Necker Hosp* 27:85-103, 1997.
1220. Amann K, Buzello M, Simonaviciene A, Miltenberger-Miltenyi G, Koch A, Nabokov A, Gross ML, Gless B, Mall G, Ritz E. Capillary/myocyte mismatch in the heart in renal failure-A role for erythropoietin? *Nephrol Dial Transplant* 15:964-969, 2000.
1221. Herzog CA. Cardiac arrest in dialysis patients: Approaches to alter an abysmal outcome. *Kidney Int* 84: S197-S200, 2003.
1222. Bleyer AK, Russell GB, Satko SG. Sudden an cardiac death rates in hemodialysis patients. *Kidney Int* 55: 1553-1559, 1999.
1223. Karnik JA, Young BS, Lew NL, Herget M, Dubinsky C, Lazarus JM y cols. Cardiac arrest and sudden death in dialysis units. *Kidney Int* 60:350-357, 2001.
1224. Stevinkel P, Pecoito-Filho R, Lindholm B. Coronary artery disease in end-stage renal disease: No longer a simple plumbing problem. *J Am Soc Nephrol* 14:1927-1939, 2003.
1225. Chang JW, Yang WS, Min WK, Lee SK, Park JD, Kim SB. Effects of statins on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. *Am J Kidney Dis* 39:1213-1217, 2002.
1226. Dogra GK, Watts GF, Hermann S, Thomas MA, Irish AB. Statin therapy improves brachial artery endothelial function in nephrotic syndrome. *Kidney Int* 62:550-557, 2002.
1227. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases and cell death in human carotid plaques: Implications for plaque stabilisation. *Circulation* 103:926-933, 2001.
1228. De Cavanagh EM, Ferder L, Carrasquedo F, Scrivero D, Wasserman A, Fraga CG y cols. Higher levels of antioxidant defensors in enalapril-treated versus non-enalapril-treated hemodialysis patients. *Am J Kidney Dis* 34:445-455, 1999.
1229. Steinberg D, Witztum JL. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? *Circulation* 105:2107-2111, 2002.
1230. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A y cols. Secondary prevention with antioxidants of cardiovascular disease in end-stage renal disease (SPACE): randomised placebo-controlled trial. *Lancet* 356:1213-1218, 2000.
1231. Tepel M, van der GM, Statz M, Jankowski K, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: A randomized, controlled trial. *Circulation* 107:992-995, 2003.
1232. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. *Circulation* 106: 679-684, 2002.

1233. Chertow GM, Normand SL, Silva LR, McNeil BJ. Survival after acute myocardial infarction in patients with end-stage renal disease: Results from the Cooperative Cardiovascular Project. *Am J Kidney Dis* 35: 1044-1051, 2000.
1234. Aronow WS, Ahn C, Mercado AD, Epstein S: Prevalence of coronary artery disease, complex ventricular arrhythmias, and silent myocardial ischemia and incidence of new coronary events in older persons with chronic renal insufficiency and with normal renal function. *Am J Cardiol* 86:1142-1143, 2000.
1235. Wizerman V, Kaufmann J, Kramer W. Effect of erythropoietin on ischemia tolerance in anemic hemodialysis patients with confirmed coronary artery disease. *Nephron* 62:161-165, 1992.
1236. Herzog CA, Ma JZ, Collins AJ. Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting and coronary artery bypass surgery and impact of diabetes. *Circulation* 106:2207-2211, 2002.
1237. Herzog CA, Ma JZ, Collins AJ. Survival of dialysis patients in the United States after percutaneous versus surgical coronary revascularization: Is there a clear choice? *Circulation* 106 (suppl II): II-492 (abstract), 2002.
1238. Marso S, Gimple LW, Philbrick JT, Dimarco JP. Effectiveness of percutaneous coronary interventions to prevent recurrent coronary events inpatients on chronic hemodialysis. *Am J Cardiol* 82:378-380, 1998.
1239. Sanai T, Kimura G, Inenaga T, Nonogi H, Haze K, Omae T. Efficacy of percutaneous transluminal coronary angioplasty for patients on hemodialysis: comparison with those not on dialysis. *Am J Nephrol* 19:38-44, 1999.
1240. Le Feuvre C, Dambrin G, Helft G, Tabet S, Beygui F, Legendre C y cols. Comparison of clinical outcome following coronary stenting or balloon angioplasty in dialysis versus non-dialysis patients. *Am J Coll Cardiol* 85:1365-1368, 2000.
1241. Koyanagi T, Nishida H, Kitamura M, Endo M, Koyanagi H, Kawaguchi M, y cols. Comparison of clinical outcomes of coronary artery bypass grafting and percutaneous transluminal coronary angioplasty in renal dialysis patients. *Ann Thorac Surg* 61:1793-1796, 1996.
1242. Morice M, Serruys P, Constantini C, Wuelfert E, Wijns W, Fajadet J y cols. Two-year follow-up of the RAVEL study: A randomized study with the sirolimus-eluting Bx velocity stent in the treatment of patients with the-novo native coronary artery lesions (abstract). *J Am Coll Cardiol* 41 (suppl A): 32A, 2002.
1243. Gruberg L, Waksman R, Ajani AE, Kim HS, White RL, Pinnow E y cols. The effect of intracoronary radiation for the treatment of recurrent in stent restenosis in patients with chronic renal failure. *J Am Coll Cardiol* 38:1049-1053, 2001.
1244. Herzog CA, Ma JZ, Collins AJ: Long-term outcome of dialysis patients in the United States with coronary revascularization procedures. *Kidney Int* 56:324-332, 1999.
1245. Rinehart AL, Herzog CA, Collins AJ, Flack JM, Ma JZ, Opsahl JA. A comparison of coronary angioplasty and coronary artery bypass grafting outcomes in chronic dialysis patients. *Am J Kidney Dis* 25:281-290, 1995.
1246. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC. Electrom beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. *Am J Kidney Dis* 27:394-401, 1996.
1247. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D y cols. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. *N Engl J Med* 342: 1478-1483, 2000.
1248. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness and cardiovascular risk in end-stage renal disease. *Hypertension* 38:938-942, 2001.
1249. Hujairi NMA, Afzali B, Goldsmith DJA. Cardiac calcification in renal patients: What we do and don't know. *Am J Kidney Dis* 2: 234-243, 2004.
1250. Proudfoot D, Shanahan CM. Biology of calcification in vascular cells: intima versus media. *Herz* 26:245-51, 2001.
1251. Shioi A, Taniweki H, Hono S, Okuno Y, Koyama H, Mori K y cols. Monckeberg's medial sclerosis and inorganic phosphate in uremia. *Am J Kidney Dis* 38(supl 1): S47-S49, 2001.
1252. Lanzer P. Monckeberg media calcinosis. *Z Kardiol* 87:586-593, 1998.
1253. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. *Nephrol Dial Transplant* 15:1014-021, 2000.
1254. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK y cols. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? *J Am Coll Cardiol* 39:695-701, 2002.
1255. Blacher J, Safar ME, Guerin AP, Pannier B, Marchais SJ, London GM. Aortic pulse wave velocity index and mortality in end-stage renal disease. *Kidney Int* 63:1852-1860, 2003.
1256. Rajamannan NM, Subramaniam M, Rickard D, Stock SR, Donovan J, Springett M y cols. Human aortic valve calcification is associated with an osteoblast phenotype. *Circulation* 107:2181-2184, 2003.
1257. Mohler ER III, Adam LP, McClelland P, Graham L, Hathaway DR. Detection of osteopontin in calcified human aortic valves. *Arterioscler Thromb Vasc Biol* 17:547-552, 1997.
1258. Ahmed S, O'Neill KD, Hood AF, Evan AP, Moe SM. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. *Am J Kidney Dis* 37:1267-1276, 2001.
1259. Moe SM, O'Neill KD, Duan D, Ahmed S, Chen NX, Leapman SB y cols. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. *Kidney Int* 61:638-647, 2002.
1260. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K y cols. Phosphate regulation of vascular smooth muscle cell calcification. *Circ Res* 87: E10-E17, 2000.
1261. Sattler AM, Schoppet M, Schaefer JR, Hofbauer LC. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. *Calcif Tissue Int* 74:103-106, 2004.
1262. Cozzolino M, Dusso AS, Slatopolsky E. Role of calcium-phosphate product and bone associated proteins on vascular calcification in renal failure. *J Am Soc Nephrol* 12:2511-2516, 2001.
1263. Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, y cols. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. *J Clin Invest* 112:357-366, 2003.
1264. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnen AH, Bohm R y cols. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality.

BIBLIOGRAFÍA

- lity in patients on dialysis: A cross-sectional study. *Lancet* 361:827-833, 2003.
1265. Ketteler M, Vermeer C, Wanner C, Westenfeld R, Jahn-Dechent W, Floege J. Novel insights into uremic vascular calcification. *Blood Purif* 20:473-476, 2002.
1266. Stompor T, Pasowicz M, Sulowicz W, Dembinska-Kiez, A, Janda K, Wójcik K y cols. An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis. *Am J Kidney Dis* 41:203-211, 2003.
1267. Alexander RW. Inflammation and coronary artery disease. *N Engl J Med* 331:468-469, 1994.
1268. Davies MR, Lund RJ, Hruska KA. BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. *J Am Soc Nephrol* 14:1559-1567, 2003.
1269. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases. The role of oxidant stress. *Circ Res* 87:840-844, 2000.
1270. Rubel JR, Milford EL. The relationship between serum calcium and phosphate levels and cardiac valvular procedures in the hemodialysis population. *Am J Kidney Dis* 41:411-421, 2003.
1271. Block G. How should hyperphosphatemia be managed in dialysis patients? *Semin Dial* 15:315-317, 2002.
1272. Chertow GM, Burke SK, Raggi P, for the Treat-to-Goal Working Group: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. *Kidney Int* 62:245-252, 2002.
1273. Achenbach S, Ropers D, Pohle K, Leber A, Thilo C, Knez A y cols. Influence of lipid-lowering therapy on the progression of coronary artery calcification: A prospective evaluation. *Circulation* 106:1077-1082, 2002.
1274. Wilson PW, Kauppila LI, O'Donnell CJ, Kiel DP, Hannan M, Polak JM y cols. Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality. *Circulation* 103:1529-34, 2001.
1275. Kagawishi T, Nishizawa Y, Konishi T. High resolution B-mode ultrasonography in evaluation of atherosclerosis in uremia. *Kidney Int* 48: 820-826, 1995.
1276. Nishizawa Y, Shoji T, Maekawa K, Nagasue K, Okuno S, Kim M y cols. Intima-media thickness of carotid artery predicts cardiovascular mortality in hemodialysis patients. *Am J Kidney Dis* 41:S76-S79, 2003.
1277. Lindroos M, Kupari M, Heikkilä J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly. An echocardiographic study of a random population sample. *J Am Coll Cardiol* 321:1220-1225, 1993.
1278. Straumann E, Meyer B, Misteli M, Blumberg A, Jenzer HR. Aortic and mitral valve disease in patients with end-stage renal failure in long-term hemodialysis. *Br Heart J* 67:236-9, 1992.
1279. Cohen JL, Barooah B, Segal KR, Batuman V. Two-dimensional echocardiographic findings in patients on hemodialysis for more than six months. *Am J Cardiol* 60:743-745, 1987.
1280. Umana E, Ahmed Waqas, Alpert MA. Valvular and perivalvular abnormalities in end-stage renal disease. *Am J Med Sci* 325:237-242, 2003.
1281. Wang A, Wang M, Woo J, Lam C, Li P, Lui S-F y cols. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients. *J Am Soc Nephrol* 14:159-168, 2003.
1282. Boon A, Cheriez E, Lodder J, Kessels F. Cardiac valve calcification: characteristics of patients with calcification of the mitral annulus or aortic valve. *Heart* 78:472-4, 1997.
1283. Urena P, Malergue MC, Goldfarb B, Prieur P, Guedon-Rapoud C, Petrover M. Evolutive aortic stenosis in hemodialysis patients: analysis of risk factors. *Nephrologie* 20:217-25, 1999.
1284. Maher ER, Pazianas M, Curtis JR. Calcific aortic stenosis: a complication of chronic uraemia. *Nephron* 47:119-22, 1987.
1285. Raine AEG. Acquired aortic stenosis in dialysis patients. *Nephron* 68:159-68, 1994.
1286. Fujise K, Amerling R, Sherman W. Rapid progression of mitral and aortic stenosis in a patient with secondary hyperparathyroidism. *Br Heart J* 70:282-4, 1993.
1287. Perkovic V, Hunt D, Griffin SV, du Plessis M, Becker GJ. Accelerated progression of calcific aortic stenosis in dialysis patients. *Nephron Clin Pract* 94:c40-c45, 2003.
1288. Pellikka PA, Hishimura RA, Bailey KR, Tajik AJ. The natural history of adults with asymptomatic hemodynamically significant aortic stenosis. *J Am Coll Cardiol* 15:1012-1017, 1990.
1289. Schott CR, Koller MN, Parry WR, Segal BL. Mitral annular calcification. *Arch Intern Med* 137:1143-50, 1977.
1290. Huting J. Mitral valve calcification as an index of left ventricular dysfunction in patients with end-stage renal disease on peritoneal dialysis. *Chest* 105:383-8, 1994.
1291. Edwards FH, Peterson ED, Coombs LP, DeLong ER, Jamieson WR, Shroyer ALW y cols. Prediction of operative mortality after valve replacement surgery. *J Am Coll Cardiol* 37:885-92, 2001.
1292. Bonow RO, Carabello B, de Leon AC, Edmunds LH Jr, Fedderly BJ, Freed MD y cols. Guidelines for the management of patients with valvular disease: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with valvular heart disease). *Circulation* 98:1949-1984, 1998.
1293. Herzog CA, Ma JZ, Collins AJ. Long-term Survival of dialysis patients in the United States with prosthetic heart valves. Should ACC/AHA guidelines on valve selection be modified? *Circulation* 105:1336-1341, 2002.
1294. Eggers PW, Gohdes D, Pugh J. Nontraumatic lower extremity amputations in the Medicare end-stage renal disease population. *Kidney Int* 56: 1524-1533, 1999.
1295. United States Renal Data System. Annual Data Report. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Division of Kidney, Urologic, and Hematologic Diseases, pp 339-348, 2000.
1296. Rocco MV, Soucie JM, Reboussin DM, McClellan WM. Risk factors for hospital utilization in chronic dialysis patients: Southeastern Kidney Council (Network 6). *J Am Soc Nephrol* 7: 889-896, 1996.
1297. Barrett BJ, Parfrey PS, Morgan J, Barre P, Fine A, Goldstein MB y cols. Prediction of early death in end-stage renal disease patients starting dialysis. *Am J Kidney Dis* 29: 214-222, 1997.
1298. O'Hare A, Johansen K. Lower-extremity peripheral arterial disease among patients with end-stage renal disease. *J Am Soc Nephrol* 12:2838-2847, 2001.

1299. Webb AT, Franks PJ, Reaveley DA, Greenhalgh RM, Brown EA. Prevalence of intermittent claudication and risk factors for its development in patients on renal replacement therapy. *Eur J Vasc Surg* 7: 523–527, 1993.
1300. Criqui MH, Fronck A, Klauber MR, Barrett-Connor E, Gabriel S. The sensitivity, specificity, and predictive value of traditional clinical evaluation of peripheral arterial disease: Results from noninvasive testing in a defined population. *Circulation* 71: 516–522, 1985.
1301. McGrae McDermott M, Kerwin DR, Liu K, Martin GJ, O'Brien E, Kaplan H, y cols. Prevalence and significance of unrecognized lower extremity peripheral arterial disease in general medicine practice. *J Gen Intern Med* 16: 384–390, 2001.
1302. Möhler ER. Peripheral arterial disease. *Arch Intern Med* 163: 2306–2314, 2003.
1303. Fiegleson HS, Criqui MH, Fronck A, Langer RD, Molgaard CA. Screening for peripheral arterial disease: The sensitivity, specificity, and predictive value of noninvasive tests in a defined population. *Am J Epidemiol* 140: 526–534, 1994.
1304. Ono K, Tsuchida A, Kawai H, Matsijo H, Wakamatsu R, Maezawa A y cols. for the GUNMA dialysis and ASO study group. Ankle-brachial blood pressure index predicts all-cause and cardiovascular mortality in hemodialysis patients. *J Am Soc Nephrol* 14:1591-1598, 2003.
1305. Richbourg MJ. Whatever happened to foot care? Preventing amputations in patients with end stage renal disease. *EDTNA ERCA J* 24: 4–10, 1998.
1306. Carter SA, Tate RB. Value of toe pulse waves in addition to systolic pressures in the assessment of the severity of peripheral arterial disease and critical limb ischemia. *J Vasc Surg* 24: 258–265, 1996.
1307. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). *J Vasc Surg*, (suppl 1), 31:S1-S44, 2000.
1308. Ramsey DE, Manke DA, Sumner DS. Toe blood pressure: A valuable adjunct to ankle pressure measurement for assessing peripheral arterial disease. *J Cardiovasc Surg* 24:43-48, 1983.
1309. Makisalo H, Lepantalo M, Halme L, Lund T, Peltonen S, Salmela K y cols. Peripheral arterial disease as a predictor of outcome after renal transplantation. *Transplant Int* 11 [Suppl 1]: S140–S143, 1998.
1310. Hiatt WR, Jones DN. The role of hemodynamics and duplex ultrasound in the diagnosis of peripheral arterial disease. *Curr Opin Cardiol* 7:805-810, 1992.
1311. Foster AVM, Snowden S, Grenfell A, Watkins PJ, Edmonds ME. Reduction of gangrene and amputations in diabetic renal transplant patients: The role of a special foot clinic. *Diabet Med* 12: 632–635, 1995
1312. Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication [Cochrane Review]. In: *The Cochrane Library* 4, edited by Oxford, UK, Update Software, 2000
1313. Painter P, Johansen K. Physical functioning in end-stage renal disease: Introduction: A call to activity. *Adv Ren Replace Ther* 6: 107–109, 1999.
1314. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: Meta-analysis of randomised trials. *BMJ* 321: 983–986, 2000.
1315. Fowkes FGR, Gillespie IN: Angioplasty (versus non surgical management) for intermittent claudication [Cochrane Review]. In: *The Cochrane Library* 4, edited by Oxford, UK, Update Software, 2000
1316. Harrington EB, Harrington ME, Schanzer H, Haimov M. End-stage renal disease: Is infrainguinal limb revascularization justified? *J Vasc Surg* 12: 691–695, 1990.
1317. Simsir SA, Cabellon A, Kohlman-Trigoboff D, Smith BM. Factors influencing limb salvage and survival after amputation and revascularization in patients with end-stage renal disease. *Am J Surg* 170: 113–117, 1995.
1318. Leskinen Y, Salenius J, Lehtimäki T, Huhtala H, Saha H. The prevalence of peripheral arterial disease and medial arterial calcification in patients with chronic renal failure: Requirements for diagnostics. *Am J Kidney Dis* : 40 : 472-9; 2002
1319. Beale HR, Piotrowski JJ, Yuhás J, Anderson C, Alexander J. Infrainguinal bypass in patients with end-stage renal disease. *Surgery* 117: 319–324, 1995.
1320. Johnson BL, Glickman MH, Bandyk DF, Esses GE. Failure of foot salvage in patients with end-stage renal disease after surgical revascularization. *J Vasc Surg* 22: 280–285, 1995.
1321. Sanchez LA, Goldsmith J, Rivers SP, Panetta TF, Wengerter KR, Veith FJ. Limb salvage surgery in end stage renal disease: Is it worthwhile? *J Cardiovasc Surg (Torino)* 33: 344–348, 1992.
1322. Edwards JM, Taylor LM Jr, Porter JM. Limb salvage in end-stage renal disease (ESRD): Comparison of modern results in patients with and without ESRD. *Arch Surg* 123: 1164–1168, 1988.
1323. Mills JL, Gahtan V, Fujitani RM, Taylor SM, Bandyk D. The utility and durability of vein bypass grafts originating from the popliteal artery for limb salvage. *Am J Surg* 168: 646–651, 1994.
1324. Isiklar MH, Kulbaski M, MacDonald MJ, Lumsden AB. Infrainguinal bypass in end-stage renal disease: When is it justified? *Semin Vasc Surg* 10: 42–48, 1997.
1325. Koskas F, Cluzel P, Deray G, Petitclerc T, Barrou B, Bitker M y cols. Management of peripheral arterial disease among end-stage renal failure patients. In: *Cardiovascular Disease in End-Stage Renal Failure*, edited by Lozcalzo J, London GM, Oxford, UK, Oxford University Press, pp 421–442, 2000.
1326. Bruni T, Ghizzi M, Tedoli M, Bellani A, Paladini R. Treatment of chronic critical ischemia of the lower limbs with spinal cord electrostimulation. *Chir Ita* 51: 53–58, 1999.
1327. Moncada S, Higgs EA. Prostaglandins in the pathogenesis and prevention of vascular disease. *Blood Rev* 1: 141–145; 1987.
1328. Ruggenti P, Vigano G, Mecca G, Cassina G, Remuzzi G. Failure of prostacyclin to improve peripheral arterial disease in dialysis patients. *Nephron* 54: 93–94, 1990.
1329. Dossa CD, Shepard AD, Amos AM, Kupin WL, Reddy DJ, Elliott JP y cols. Results of lower extremity amputations in patients with end-stage renal disease. *J Vasc Surg* 20: 14–19, 1994.
1330. Hankey G, Warlow C. Treatment and secondary prevention of stroke: evidence, costs and effects on individuals and populations. *Lancet* 354:1457-1463, 1999.
1331. Toyoda K, Fukii K, Ando T, Kumai Y, Ibayashi s, Lida M. Incidence, etiology, and outcome of stroke in patients on continuous ambulatory peritoneal dialysis. *Cerebrovasc Dis* 17:98-105, 2004.

BIBLIOGRAFÍA

1332. Sacco RL, Benjamin EJ, Broderick JP, Howard G, Kittner SJ, Manolio TA y cols. American Heart Association Prevention Conference. Prevention and Rehabilitation of stroke. Risk factors stroke 28:1507-17, 1997.
1333. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. *N Engl J Med* 340:14-22, 1999.
1334. Amarenco P, Cohen A, Tzourion C, Bertrand B, Hommel M, Besson G, y cols. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. *N Engl J Med* 331:1474-9, 1994.
1335. Iseki K, Kinjo K, Kimura Y, Osawa A, Fukiyama K, Nishime K y cols. Evidence for high risk of cerebral hemorrhage in chronic dialysis patients. *Kidney Int* 44:1086-1090, 1993.
1336. Onoyama K, Kumagai H, Miishima T, Tsuruda H, Tomooka S, Motomura K y cols. Incidence of strokes and its prognosis in patients on maintenance hemodialysis. *Jpn Heart J* 27:685-691, 1986.
1337. Nakatani T, Naganuma T, Uchida J, Masuda C, Wada S, Sugimura T, y cols. Silent cerebral infarction in hemodialysis patients. *Am J Nephrol* 23:86-90, 2003.
1338. Fisher CM. Lacunar strokes and infarcts: A review. *Neurology* 32:871-876, 1982.
1339. Howard G, Wagenknecht LE, Cai J, Cooper L, Kaut MA, Toole JF. Cigarette smoking and other risks factor for silent cerebral infarction in the general population. *Stroke* 29:913-917, 1998.
1340. Furie K. Stroke prevention. *N Engl J Med* 346:213-214, 2001.
1341. Mc Mahon S, Rodgers A. Blood pressure, antihypertensive treatment and stroke risk. *J Hypertens* 12(supl 10): S5-S14, 1994.
1342. Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G y cols. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. *Circulation* 103:163-182, 2001.
1343. Gorelick PB. Stroke prevention therapy beyond antithrombotics: unifying mechanisms in ischemic stroke pathogenesis and implication for therapy. *Stroke* 33:862-875, 2002.
1344. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. *JAMA* 275:1571-1576, 1996.
1345. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks US population data. *Arch Int Med* 153:598-615, 1993.
1346. Seliger SL, Gillern DL, Tirschwell D, Wasse H, Kestenbaum BR, Stehman-Breen CO. Risk factors for incident stroke among patients with end-stage renal disease. *J Am Soc Nephrol* 14:2623-2631, 2003.
1347. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. *Stroke* 22:312-318, 1991.
1348. Iseki K, Fukiyama K. Predictors of stroke in patients receiving chronic hemodialysis. *Kidney Int* 50:1672-1675, 1996.
1349. Gorelick PB. New horizons for stroke prevention: PROGRESS and HOPE. *Lancet Neurology* 1:149-56, 2002.
1350. Kiyohara Y, Ueda K, Hasuo Y, Fujii I, Yanai T, Wada J y cols. Hematocrit as a risk factor of cerebral infarction: Long-term prospective population survey in a Japanese rural community. *Stroke* 17:687-692, 1986.
1351. Vederchia P, Porcellati C, Reboldi G, Gattobigio R, Gorgioni C, Pearson TA y cols. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. *Circulation* 104:2039-2044, 2001.
1352. Leys D, Deplanque D, Mounier-Vehier C, Mackowiak-Cordoliani MA, Lucas C, Border R. Stroke prevention: Management of modifiable risk factors. *J Neurol* 249:507-517, 2002.
1353. Combe C, Chauveau P, Laville M, Fouque D, Azar R, Cano N y cols. Influence of nutritional factors and hemodialysis adequacy on the survival of 1,610 French patients. *Am J Kidney Dis* 37:s81-s88, 2001.
1354. Pifer TB, McCullough KP, Port FK, Goodkin DA, Maroni BJ, Held PJ, y cols. Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. *Kidney Int* 62:2238-2245, 2002.
1355. Stevinkel . Malnutrition and chronic inflammation as risk factors for cardiovascular disease in chronic renal failure. *Blood Purif* 19:143-151, 2001.
1356. Kalantar-Zadeh K, Kopple J. Relative contributions of nutrition and inflammation to clinical outcome in dialysis patients. *Am J Kidney Dis* 38:1342-1350, 2001.
1357. Benjamin EF, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levey D. Impact of atrial fibrillation on the risk of the death. The Framingham Heart Study. *Circulation* 98:946-952, 1998.
1358. Korzets A, Ory Y, Herman M. Serum potassium levels and atrial fibrillation in hemodialysis patients. *Nephrol Dial Transplant* 16:1090, 2001.
1359. McNamara RL, Tamariz LJ, Segal JB, Bass EB. Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion and echocardiography. *Ann Intern Med* 39:1018-1033, 2002.
1360. Heidbüchel H. A paradigm shift in treatment for atrial fibrillation: from electrical to structural therapy. *Eur Heart J* 24:2077-2078, 2003.
1361. Pascazio L, Bianco F, Giorgini A, Galli G, Curri G, Panzetta G. Echo color Doppler imaging of carotid vessels in hemodialysis patients: evidence of high levels of atherosclerosis lesions. *Am J Kidney Dis* 28:713-20, 1996.
1362. Benedetto FA, Mallamaci F, Tripepi G, Zoccali C. Prognostic value of ultrasonographic measurement of carotid intima media thickness in dialysis patients. *J Am Soc Nephrol* 12: 2458-64, 2001.
1363. Maeda N, Sawayama Y, Tatsukawa M, Okada K, Furusyo N, Shigematsu M y cols. Carotid artery lesions and atherosclerotic risk factors in Japanese hemodialysis patients. *Atherosclerosis* 169:183-192, 2003.
1364. Cheigh JS, Milite C, Sullivan JF, Rubin AL, Stenzel KH. Hypertension is not adequately controlled in hemodialysis patients. *Am J Kidney Dis* 19:453-459, 1992.
1365. Rahman M, Dixit A, Donley V, Gupta S, Hanslik T, Lacson E y cols. Factors associated with inadequate blood pressure control in hypertensive hemodialysis patients. *Am J Kidney Dis* 33:498-506, 1999.
1366. Mailloux LU, Haley WE. Hypertension in the ESRD patient: Pathophysiology, therapy, outcomes and future directions. *Am J Kidney Dis* 32:705-719, 1998.
1367. Cruz JM, Piera L, Bragg-Gresham JL, Feldman H, Port FK. Resultados del estudio internacional de hemodiálisis DOPPS en Europa y España. *Nefrología* 23: 437-43, 2003.

1368. Zucchelli P, Santoro A, Zuccala A. Genesis and control of hypertension in hemodialysis patients. *Semin Nephrol* 8:163-168, 1998.
1369. 1368. 1573. Rahman M, Fu P, Sehgal AR, Smith MC. Interdialytic weight gain, compliance with dialysis regimen, and age are independent predictors of blood pressure in hemodialysis patients. *Am J Kidney Dis* 35:257-265, 2000.
1370. Tomita J, Kimura G, Inoue T, Inenaga T, Sanai T, Kawano Y y cols. Role of systolic BP in determining prognosis of hemodialyzed patients. *Am J Kidney Dis* 25:405-412, 1995.
1371. Tozawa M, Iseki K, Iseki C, Takishita S. Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis. *Kidney Int* 61: 717-726, 2002.
1372. Amar J, Vernier I, Rossignol E, Bongard V, Arnaud C, Conte JJ, Salvador M, Chamontin B. Nocturnal blood pressure and 24-hour pulse pressure are potent indicators of mortality in hemodialysis patients. *Kidney Int* 57: 2485-2491, 2000.
1373. Gunal AI, Duman S, Ozkahya M, Toz H, Asci G, Akcicek F, Basci A. Treatment of hypertension in dialysis patients by ultrafiltration: Role of cardiac dilatation and time factor. *Am J Kidney Dis*;37:588, 2001.
1374. Lins RL, Elseviers M, Rogiers P, Van Hoeyweghen RJ, De Raedt H, Zachee P, Daelemans RA. Importance of volume factors in dialysis related hypertension. *Clin Nephrol* 48:29-33, 1997.
1375. Dionisio P, Valenti M, Bergia R, Caramello E, Stramignoni E, Berto IM, y cols. Influence of the hydration state on blood pressure values in a group of patients on regular maintenance hemodialysis. *Blood Purif* 15:25-33, 1997.
1376. Salem MM. Hypertension in the hemodialysis population: A survey of 649 patients. *Am J Kidney Dis* 26:461-468, 1995.
1377. Hörl MP, Hörl WH. Hemodialysis-Associated hypertension: pathophysiology and therapy. *Am J Kidney Dis* 39:227-244, 2002.
1378. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F y cols. Sympathetic overactivity in patients with chronic renal failure. *N Engl J Med* 327:1912-1928, 1992.
1379. Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F y cols. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. *N Engl J Med* 340:1321-1328, 1999.
1380. Grekas D, Kalevrosoglou I, Karamouzis M, Geropoulou E, Kabouris H, Tourkantonis A. Effect of sympathetic and plasma renin activity on hemodialysis hypertension. *Clin Nephrol* 55:115-120, 2001.
1381. Shichiri M, Hirata Y, Ando K, Emori T, Ohta K, Kimoto S y cols. Plasma endothelin levels in hypertension and chronic renal failures. *Hypertension* 15:493, 1990.
1382. Koyama H, Tabata T, Nishizawa Y, Inoue T, Morii H, Yamaji T. Plasma endothelin levels in patients with uremia. *Lancet* 1:991, 1989.
1383. Suzuki N, Matsumoto H, Miyauchi T. Endothelin-3 concentrations in human plasma: The increased concentrations in patients undergoing hemodialysis. *Biochem Biophys Res Commun* 169:809, 1999.
1384. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. *Lancet* 339:572-575, 1992.
1385. Kielstein JT, Böger RH, Bode-Böger SM, Schäffer J, Barbey M, Koch KM, y cols. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: Relationship to treatment method and atherosclerotic disease. *J Am Soc Nephrol* 10:594-600, 1999.
1386. Anderstam B, Katzarski K, Bergström J. Serum levels of NG, NG-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. *J Am Soc Nephrol* 8:1437-1442, 1997.
1387. Morris ST, Jardine AG. The vascular endothelium in chronic renal failure. *J Nephrol* 13:96-105, 2000.
1388. Morris STW, McMurray JJV, Rodger RSC, Jardine AG. Impaired endothelium-dependent vasodilatation in uraemia. *Nephrol Dial Transplant* 15:1194-1200, 2000.
1389. Raine AE, Roger SD. Effects of erythropoietin on blood pressure. *Am J Kidney Dis* 18 (suppl 1):76-83, 1991.
1390. Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW. Hypertension following erythropoietin therapy in anemic hemodialysis patients. *Am J Hypertension* 3:947-955, 1990.
1391. Abraham PA, Macres MG. Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. *J Am Soc Nephrol* 2:927-936, 1991.
1392. Canadian Erythropoietin Study Group. Effect of recombinant human erythropoietin therapy on blood pressure in haemodialysis patients. *Am J Nephrol* 11:23-26;1991
1393. Kaupke CJ, Kim S, Vaziri ND. Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy. *J Am Soc Nephrol* 4:1874-1878, 1994.
1394. Torralbo A, Herrero JA, Portoles J, Fontanellas A, Barrientos A. Activation of the sympathetic nervous system in hemodialyzed patients treated with EPO. *Nephron* 69:350 (letter), 1995.
1395. Berns JS, Rudnick MR, Cohen RM, Bower JD, Wood BC. Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease. *Kidney Int* 56:253-260, 1999
1396. Massry SG, Iseki K, Campese VM. Serum calcium, parathyroid hormone and blood pressure. *Am J Nephrol* 6:119-128, 1986.
1397. Ifudu O, Matthew JJ, Macey LJ, Hong JS, Sumrani N, Sommer BG y cols. Parathyroidectomy does not correct hypertension in patients on maintenance hemodialysis. *Am J Nephrol* 18:28-34, 1998.
1398. Raine AE, Bedford L, Simpson AW, Ashley CC, Brown R, Woodhead JS, y cols. Hyperparathyroidism, platelet intracellular free calcium and hypertension in chronic renal failure. *Kidney Int* 43:700-705, 1993.
1399. Goldsmith DJ, Covic AA, Venning MC, Ackrill. Blood pressure reduction after patients for secondary hyperparathyroidism: Further evidence implicating calcium homeostasis in blood pressure regulation. *Am J Kidney Dis* 27:819-825, 1996.
1400. Fliser D, Franek E, Fode P, Stefanski A, Schmitt CP, Lyons M y cols. Subacute infusion of physiological doses of parathyroid hormone raises blood pressure in humans. *Nephrol Dial Transplant* 12:933-938, 1997.
1401. Coomer RW, Schulman G, Breyer JA, Shyr Y. Ambulatory blood pressure monitoring in dialysis patients and estimation of mean interdialytic blood pressure. *Am J Kidney Dis* 29:678-684, 1997.

BIBLIOGRAFÍA

1402. Agarwal R. Role of home blood pressure monitoring in hemodialysis patients. *Am J Kidney Dis* 33:682-687, 1999
1403. Rodby RA, Vonesh EF, Korbet SM. Blood pressures in hemodialysis and peritoneal dialysis using ambulatory blood pressure monitoring. *Am J Kidney Dis* 23:401-411, 1994.
1404. Huisman RM, de Bruin C, Klont D, Smith AJ. Relationship between blood pressure during haemodialysis and ambulatory blood pressure in between dialyses. *Nephrol Dial Transplant* 10:1890-1894, 1995.
1405. Conlon PJ, Walshe JJ, Heinle SK, Minda S, Krucoff M, Schwab SJ. Predialysis systolic blood pressure correlates strongly with mean 24-hour systolic blood pressure and left ventricular mass in stable hemodialysis patients. *J Am Soc Nephrol* 7:2658-2663, 1996.
1406. Nystrom F, Malmqvist K, Ohman KP, Kahan T. Nurse-recorded and ambulatory blood pressure predicts treatment-induced reduction of left ventricular hypertrophy equally well in hypertension: results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA) study. *J Hypertens* 20: 1527-1533, 2002.
1407. Kooman JP, Gladziwa U, Bocker G, Wijnen JAG, Bortel LV, Luik AJ. Blood pressure during the interdialytic period in haemodialysis patients: Estimation of representative blood pressure values. *Nephrol Dial Transplant* 7:917-923, 1992.
1408. Covic A, Goldsmith DJ. Ambulatory blood pressure monitoring in nephrology: focus on BP variability. *J Nephrol* 12: 220-229, 1999.
1409. Covic A, Goldsmith D. Ambulatory blood pressure monitoring: an essential tool for blood pressure assessment in uraemic patients. *Nephrol Dial Transplant* 17:1737-1741, 2002.
1410. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. *Circulation* 99: 2434-2439, 1999.
1411. Asmar RG, London GM, O'Rourke ME, Safar ME. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. *Hypertension* 38: 922-926, 2001.
1412. Covic A, Goldsmith DJ, Panaghiu L, Covic M, Sedor J. Analysis of the effect of hemodialysis on peripheral and central arterial pressure waveforms. *Kidney Int* 57: 2634-2643, 2000.
1413. Zoccali C. Cardiovascular risk in uraemic patients-is it fully explained by classical risk factors? *Nephrol Dial Transplant* 15: 454-457, 2000.
1414. Schomig M, Eisenhardt A, Ritz E. Controversy on optimal blood pressure on haemodialysis: normotensive blood pressure values are essential for survival. *Nephrol Dial Transplant* 16: 469-474, 2001.
1415. London GM. Controversy on optimal blood pressure on haemodialysis. Lower is not always better. *Nephrol Dial Transplant* 16:475-479, 2001.
1416. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs. *Lancet* 356:1955-1964, 2000.
1417. Ogden LG, He J, Lydick E, Whelton PK. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. *Hypertension* 35:539-543, 2000.
1418. Duranti E, Imperiali P, Sasdelli M. Is hypertension a mortality risk factor in dialysis? *Kidney Int* 55: S173-S17, 1996.
1419. Charra B, Calemard E, Ruffet M, Chazot C, Terrat JC, Vanel T y cols. Survival as an index of adequacy of dialysis. *Kidney Int* 41: 1286-1291, 1992.
1420. Port FK, Hulbert-Shearon TE, Wolfe RA, Bloembergen WE, Golper TA, Agodoa LY y cols. Pre-dialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. *Am J Kidney Dis* 33: 507-517, 1999.
1421. Iseki K, Miyasato F, Tokuyama K, Nishime K, Uehara H, Shiohira Y, y cols. Low diastolic blood pressure, hypoalbuminemia, and risk of death in a cohort of chronic hemodialysis patients. *Kidney Int* 51: 1212-1217, 1997.
1422. Salem MM. Hypertension in the haemodialysis population: Any relationship to 2-years survival? *Nephrol Dial Transplant* 14:125-128, 1999.
1423. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. *Kidney Int* 49: 1379-1385, 1996.
1424. Savazzi GM, Cusmano F, Bergamaschi E, Vinci S, Allegri L, Garini G. Hypertension as an etiopathological factor in the development of cerebral atrophy in hemodialyzed patients. *Nephron* 81:17-24, 1999.
1425. Foley RN, Parfrey PS. Cardiovascular disease and mortality in ESRD. *J Nephrol* 11:239-245, 1998.
1426. Mazzuchi N, Carbonell E, Fernandez-Cean J. Importance of blood pressure control in hemodialysis patient survival. *Kidney Int* 58: 2147-2154, 2000.
1427. Mailloux LU. Hypertension in chronic renal failure and ESRD. Prevalence, pathophysiology, and outcomes. *Semin Nephrol* 21:146-156, 2001.
1428. Shaldon S. Can antihypertensive medications control BP in haemodialysis patients? *Nephrol Dial Transplant* 15:736 (letter), 2000.
1429. Vertes V, Cangiano JL, Berman LB, Gould A. Hypertension in end-stage renal disease. *N Engl J Med* 280:978-981, 1969.
1430. Blumberg A, Nelp WB, Hegstrom RM, Scribner BH. Extracellular volume in patients with chronic renal disease treated for hypertension by sodium restriction. *Lancet* 2:69-73, 1967.
1431. Özkahya M, Töz H, Ünsal A, Özerkan F, Asci G, Gürgün C y cols. Treatment of hypertension in dialysis patients by ultrafiltration. Role of cardiac dilatation and time factor. *Am J Kidney Dis* 34:218-221, 1999.
1432. Thomson GE, Waterhouse K, McDonald HP, Jr, Friedman EA. Hemodialysis for chronic renal failure. Clinical observations. *Arch Intern Med* 120:153-167, 1967.
1433. Jaeger JQ, Mehta RL. Assessment of dry weight in hemodialysis: An overview. *J Am Soc Nephrol* 10:392, 1999.
1434. Katzarski KS, Nisell J, Randmaa I, Danielsson A, Freyschuss U, Bergstrom J. A critical evaluation of ultrasound measurement of inferior vena cava diameter in assessing dry weight in normotensive and hypertensive hemodialysis patients. *Am J Kidney Dis* 30:459, 1997.
1435. Charra B, Laurent G, Chazot C, Calemard E, Terrat JC, Vanel T y cols. Clinical assessment of dry weight. *Nephrol Dial Transplant* 11:16-19, 1996.
1436. Wizemann V, Schilling M. Dilemma of assessing volume state-the use and the limitations of a clinical score. *Nephrol Dial Transplant* 10: 2114-2117, 1995.
1437. De Zeeuw D, Janssen WM, de Jong PE. Atrial natriuretic factor: Its pathophysiological significance in humans. *Kidney Int* 41:1115-1133, 1992.

1438. Kohse KP, Feifel K, Mayer-Wehrstein R. Differential regulation of brain and atrial natriuretic peptides in hemodialysis patients. *Clin Nephrol* 40:83-90, 1993.
1439. Fishbane S, Natke E, Maesaka JK. Role of volume overload in dialysis-refractory hypertension. *Am J Kidney Dis* 28:257, 1996.
1440. Zoccali C, Mallamaci F, Benedetto FA, Tripepi G, Parlongo S, Cataliotti A, y cols. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. *J Am Soc Nephrol* 12:1508-1515, 2001.
1441. Charra B, Bergstrom J, Scribner BH. Blood pressure control in dialysis patients: importance of the lag phenomenon. *Am J Kidney Dis* 32: 720-724, 1988.
1442. Khosla UM and Johnson RJ. Hypertension in the hemodialysis patient and the "Lag Phenomenon": Insights into pathophysiology and clinical management. *Am J Kidney Dis* 43:739-751, 2004.
1443. Freis ED, Reda DJ, Materson BJ. Volume (weight loss) and blood pressure response following thiazide diuretics. *Hypertension* 12:244, 1988.
1444. Charra B, Laurent G, Caemard E. Survival in dialysis and blood pressure control. *Contrib Nephrol* 106: 179-185, 1994.
1445. 1444. 1658. Luik AJ, van der Sande FM, Weideman P, Cheriex E, Kooman JP, Leunissen KM. The influence of increasing dialysis treatment time reducing dry weight on blood pressure control in haemodialysis patients: a prospective study. *Am J Nephrol* 21: 471-478, 2001.
1446. Charra B, Caemard E, Laurent G. Importance of treatment time and blood pressure control in achieving long-term survival on dialysis. *Am J Nephrol* 16:35-44, 1996.
1447. Krautzig S, Janssen U, Koch KM, Granolleras C, Shaldon S. Dietary salt restriction and reduction of dialysate sodium to control hypertension in maintenance haemodialysis patients. *Nephrol Dial Transplant* 13:552-553, 1998.(letter)
1448. Sang GL, Kovithavongs C, Ulan R, Kjellstrand CM. Sodium ramping in hemodialysis: A study of beneficial and adverse effects. *Am J Kidney Dis* 29:669-677, 1997.
1449. Flanigan MJ, Khairullah QT, Lim VS. Dialysate sodium delivery can alter chronic blood pressure management. *Am J Kidney Dis* 29:383-391, 1997.
1450. Chazot C, Charra B, Laurent G, Didier C, Vo Van C, Terrat JC y cols. Interdialysis blood pressure control by long haemodialysis sessions. *Nephrol Dial Transplant* 10:831-837, 1995
1451. McGregor DO, Buttimore AL, Nicholls MG, Lynn KL. Ambulatory blood pressure monitoring on patients receiving long, slow home haemodialysis. *Nephrol Dial Transplant* 14:2676-2679, 1999.
1452. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, y cols. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. *Lancet* 358:2113-7, 2001.
1453. Katzarski KS, Charra B, Luik AJ, Nisell J, Divino Filho JC, Leypoldt JK y cols. Fluid state and blood pressure control in patients treated with long and short haemodialysis. *Nephrol Dial Transplant* 14:369-375, 1999.
1454. Pierratos A, Ouwendyk M, Francoeur R, Vas S, Raj DS, Ecclestone AM y cols. Nocturnal hemodialysis: Three-year experience. *J Am Soc Nephrol* 1998; 9:859-868, 1998.
1455. Hanly P, Pierratos A. Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. *N Engl J Med* 344:102-107, 2001.
1456. Pierratos A. Nocturnal home haemodialysis. An update on a 5-year experience. *Nephrol Dial Transplant* 14:2835-2840, 1999.
1457. Buoncristiani U, Quintaliani G, Cozzari M, Giombini L, Ragaiolo M. Daily dialysis. Long-term clinical metabolic results. *Kidney Int (suppl 24): 33:S137-S140*, 1998.
1458. Pinciaroli AR. Results of daily haemodialysis in Catanzaro. 12-year experience with 22 patients treated for more than one year. *Home Hemodial Int* 2:12-17, 1998
1459. Luik AJ, Charra B, Katzarski K, Habets J, Cheriex EC, Menheere PP y cols. Blood pressure control and hemodynamic changes in patients on long time dialysis treatment. *Blood Purif* 16:197-209, 1998.
1460. Locatelli F, Covic A, Chazot C, Leunissen K, Luño J, Yaqoob M. Hypertension and cardiovascular risk assessment in dialysis patients. *Nephrol Dial Transplant* 19:1058-1068, 2004.
1461. Zazgornik J, Biesenbach F, Forstenlehner M, Stummvoll K. Profile of antihypertensive drugs in hypertensive patients on renal replacement therapy (RRT). *Clin Nephrol* 48:337-440, 1997.
1462. Fishbane SA, Scribner BH. Blood pressure control in dialysis patients. *Semin Dial* 15:144-145, 2002.
1463. Morse SA, Dang AN, Thakur V, Zhang R, Reisin E. Hypertension in chronic dialysis patients pathophysiology, monitoring, and treatment. *Am J Med Sci* 325: 194-201, 2003.
1464. Griffith TF, Chua BSY, Allen AS, Klassen PS, Donal NR, Szczech LA. Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients. *Am J Kidney Dis* 42:1260-1269, 2003.
1465. Kestenbaum B, Gillen DL, Sherrard DJ, Seliger S, Ball A, Stehman-Breen C. Calcium channel blocker use and mortality among patients with end-stage renal disease. *Kidney Int* 61:2157, 2002.
1466. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med* 342: 145-53, 2000.
1467. Sica DA. Pharmacotherapy in congestive heart failure: angiotensin II and thirst: therapeutic considerations. *Congest Heart Fail* 7(6):325-328, 2001.
1468. Dhondt AW, Vanholder RC, Ringoir SM. Angiotensin-converting enzyme inhibitors and higher erythropoietin requirement in chronic hemodialysis patients. *Nephrol Dial Transplant* 10:2107, 1995.
1469. Toto R, Shultz P, Raij L, Mitchell H, Shaw W, Ramjit D y cols. Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Collaborative Group. *Hypertension* 31: 684-91, 1998.
1470. Saracho R, Martin-Malo A, Martinez I, Aljama P, Montenegro J. Evaluation of the Losartan in Haemodialysis (ELHE) Study. *Kidney Int* 68 (Suppl 1): S125-9, 1998.
1471. Foley RN, Herzog CA, Collins AJ. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. *Kidney Int* 62: 1784-1790, 2002.

BIBLIOGRAFÍA

1472. Ritz E, Dikow R, Adamczak M, Zeier M. Congestive heart failure due to systolic dysfunction: The Cinderella of cardiovascular management in dialysis patients. *Semin Dial* 15:135-140, 2002.
1473. Locatelli F, Monzani C. Treatment modalities in comparison: when do clinical differences emerge? *Nephrol Dial Transplant*. 15 Suppl 1:29-35, 2000.
1474. Saldanha LF, Weiler EW, Gonick HC. Effect of continous ambulatory peritoneal dialysis on blood pressure control. *Am J Kidney Dis* 21:184, 1993.
1475. Gunal AI, Ilkay E, Kirciman E, Karaca I, Dogukan A, Celiker H. Blood pressure control and left ventricular hypertrophy in long-term CAPD hemodialysis patients: a cross-sectional study. *Perit Dial Int* 23:563-567, 2003.
1476. Khandelwal M, Kothari J, Krishnan M, Liakopoulos V, Tziviskou E, Sahu K, y cols. Volume expansion and sodium balance in peritoneal dialysis patients. Part II: newer insights in management. *Adv Perit Dial* 19:44-52, 2003.
1477. Cirit M, Akcicek F, Terzioglu E, Soydas C, Ok E, Ozbasli CF y cols. 'Paradoxical' rise in blood pressure during ultrafiltration in dialysis patients. *Nephrol Dial Transplant* 10:1417-1420, 1995.
1478. Gunal AI, Karaca I, Celiker H, Ilkay E, Duman S. Paradoxical rise in blood pressure during ultrafiltration is caused by increased cardiac output. *J Nephrol* 15:42-47, 2002.
1479. Matas AJ, Humar A, Gilligham KJ, Payne WD, Gruessner RW, Kandaswamy R y cols. Five preventable causes of kidney graft loss in the 1990s: a single-center analysis. *Kidney Int* 62: 704-14, 2002.
1480. Cecka JM. The UNOS scientific renal transplant registry. *Clin Transpl* 1-21, 1999.
1481. Matas AJ, Gilligham KJ and Sutherland DER. Half-life and risk factors for kidney transplant outcome-importance of death with function. *Transplantation* 55: 757-61, 1993.
1482. Bostom AD, Brown RS, Chavers BM, Coffman TM, Cosio FG, Culver K y cols. Prevention of post-transplant cardiovascular disease: report and recommendations of an ad oc group. *Am J Transplant* 2: 491-500, 2002.
1483. Campistol JM. Riesgo cardiovascular en el paciente trasplantado renal. *Nefrología* 22 (Suppl 4): 7-11, 2002.
1484. Hjelmessaeth J, Hartmann A, Mistvedt K, Aakhus S, Stenstrom J, Morkrid L y cols. Metabolic cardiovascular syndrome after renal transplantation. *Nephrol Dial Transplant* 16: 1042-7, 2001.
1485. Guijarro C and Massu ZA. Riesgo cardiovascular y dislipemia postrasplante. *Nefrología* 22 (Suppl 4): 20-6, 2002.
1486. Miller LW. Cardiovascular toxicities of immunosuppressive agents. *Am J Transplant* 2: 807-18, 2002.
1487. Sartori MT, Rigotti P, Marchini F, Spiezia L, Baldan N, Furian L y cols. Plasma fibrinolytic capacity in renal transplant recipients: effect of steroid-free immunosuppression therapy. *Transplantation* 75: 994-8, 2003.
1488. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Medical progress: strategies to improve long-term outcomes after renal transplantation. *N Engl J Med* 346: 580-90, 2002.
1489. Morales JM, González Molina M, Campistol JM del Castillo D, Anaya F, Oppenheimer F y cols. Prevención del riesgo cardiovascular en el trasplante renal. Documento de consenso. *Nefrología* 22 (Suppl 4): 35-56, 2002.
1490. Tamura T, Johnston KE and Bergman SM. Homocysteine and folate concentrations in blood from patients treated with hemodialysis. *J Am Soc Nephrol* 7: 2414-8, 1996.
1491. Duclos D, Motte G, Challier B, Gibey R, Chalopin JM, Serum total homocysteine and cardiovascular disease occurrence in chronic stable renal transplant recipients: a prospective study. *J Am Soc Nephrol* 11: 134-137, 2000.
1492. First MR, Neylan JF, Rocher LL and Tejani A. Hypertension after renal transplantation. *J Am Soc Nephrol* 4 (Suppl 8): 30-6, 1994.
1493. Paul LC. Treatment of posttransplant hypertension: too little, too late? *Transplantation* 76: 1645-6, 2003
1494. Covic A, Segall L and Goldsmith DJ. Ambulatory blood pressure monitoring in renal transplantation: should ABPM be routinely performed in renal transplant patients? *Transplantation* 76 : 1640-2, 2003.
1495. Fernández-Fresnedo G, Escallada R, Rodrigo E, de Francisco AL, Sanz de Castro S, Ruiz JC y cols. Pulse pressure is an independent risk factor of cardiovascular disease in renal transplant recipients. *Transplant Proc* 35: 1730-1, 2003.
1496. Radermacher R, Meiners M, Bramlage C, Kliem V, Behrend M, Schlitt HJ y cols. Pronounced renal vasoconstriction and systemic hypertension in renal transplant patients treated with cyclosporin A versus FK 506. *Transpl Int* 1: 3-10, 1998.
1497. Guckelberger O, Bechstein WO, Neuhaus R, Luesebrink R, Lemmens HP, Kratschmer B y cols. Cardiovascular risk factors in long-term follow-up after orthotopic liver transplantation. *Clin Transplant* 11: 60-5, 1997.
1498. Hollander AA, Hene RJ, Hermans J, van Es LA, van der Woude FJ. Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study. *J Am Soc Nephrol* 8: 294-301, 1997.
1499. Smak-Gregoor PJ, Sévaux RG, Ligtenberg G, Hoitsma AJ, Hene RJ, Weimar W y cols. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomised, prospective, multicenter study. *J Am Soc Nephrol* 13: 1365-73, 2002.
1500. Fernández-Fresnedo G, Rodrigo E, Escallada R, Cotruello JG, Ruiz JC, Zubimendi JA y cols. Factores de riesgo cardiovascular en el trasplante renal: marcadores clínicos. *Nefrología* 22 (Suppl 4): 27-34, 2002.
1501. Fernández-Fresnedo G, Escallada R, de Francisco ALM, Rodrigo E, Zubimendi JA, Ruiz JC y cols. Post-transplant diabetes is a cardiovascular risk factor in renal transplant patients. *Transplant Proc* 35: 700, 2003.
1502. Dijnhoven EM, Christiaans MHL, Boots JM, Nieman FH, Wolffenbuttel BH, van Hooff JP. Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression. *J Am Soc Nephrol* 13: 213-20, 2002.
1503. Jawad F and Rizvi SAH. Posttransplant diabetes mellitus in live-related renal transplantation. *Transplant Proc* 32: 1888, 2000.
1504. Vincenti F. Immunosuppression minimization: current and future trends in transplant immunosuppression. *J Am Soc Nephrol* 14: 1940-8, 2003.
1505. Hricick DE, Bartucci MR, Mayers JT and Schulak JA. The effects of steroid withdrawal on the lipoprotein profiles of cyclosporine-treated kidney and kidney-pancreas transplant recipients. *Transplantation* 64: 868-71, 1992.
1506. Sander M and Victor RG. Hypertension after cardiac transplantation: pathophysiology and management. *Curr Opin Nephrol Hypertens* 4: 443-51, 1995.

1507. Saunders RN, Metcalfe MS and Nicholson ML. Rapamycin in transplantation: a review of the evidence. *Kidney Int* 59: 3-16, 2001.
1508. Legendre C, Campistol JM, Squifflet JP, Burke JT; Sirolimus European Renal Transplant Study Group. Cardiovascular risk factors of sirolimus compared with cyclosporine: early experience from two randomized trials in renal transplantation. *Transplant Proc* 35 (Suppl 3A): S151-S153, 2003.
1509. Oberbauer R, Kreis H, Johnson RWG, Mota A, Claesson K, Ruiz JC y cols. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the rapamune maintenance study. *Transplantation* 76: 364-70, 2003.
1510. Pham SM, Shears LL, Kawaharada N, Li S, Venkataramanan R, Sehgal S. High local production of nitric oxide as a possible mechanism by which rapamycin prevents transplant arteriosclerosis. *Transplant Proc* 30: 953-4, 1998.
1511. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM y cols. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. *Circulation* 103: 192-5, 2001.
1512. Roodnat JJ, Mulder PGH, Rischen-Vos J, Van Riemsdijk IC, van Gelder T, Zietse R y cols. Proteinuria and death risk in renal transplant population. *Transplant Proc* 33: 1170, 2001.
1513. Peddi VR, Dean De, Hariharan S, Cavallo T, Schroeder TJ, First MR. Proteinuria following renal transplantation: correlation with histopathology and outcome. *Transplant Proc* 29: 101, 1997.
1514. Altıparmak MR, Trabulus S, Apaydin S, Basar O, Sariyar M, Serdengeci K y cols. Is losartan as effective as enalapril on posttransplant persistent proteinuria? *Transplant Proc* 33: 3368-9, 2001.
1515. Ersoy A, Dilek K, Usta M, Yavuz M, Gullulu M, Oktay B y cols. Angiotensin-II receptor antagonist losartan reduces microalbuminuria in hypertensive renal transplant recipients. *Clin Transplant* 16: 202-5, 2002.
1516. Suwelack B, Kempkes-Koch M, Kobelt V, Hillebrand U, Matzkies F, Gerhardt U y cols. Impact of ACE polymorphism on renal allograft function, blood pressure and proteinuria under ACE inhibition. *Transplant Proc* 34: 1763-6, 2002.
1517. Fernández-Fresnedo G, Palomar R, Escallada R, Cotorruelo JG, Zubimendi JA, Sanz de Castro S y cols. Hypertension and long-term renal allograft survival: effect of early glomerular filtration rate. *Nephrol Dial Transplant* 16 (Suppl 1): 105-9, 2001.
1518. First MR. Long-term complications after transplantation. *Am J Kidney Dis* 22: 477-86, 1993.
1519. Painter PL; Hector L, Ray K, Lynes L, Paul SM, Dodd M y cols. Effects of exercise training on coronary heart disease risk factors in renal transplant recipients. *Transplantation* 42: 362-9, 2003.
1520. Midtvedt K, Ihlen H, Hartmann A, Bryde P, Bjerkely BL, Foss A y cols. reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: a prospective randomized double-blind study. *Transplantation* 72: 107-11, 2001.
1521. Hernández D, Lacalzada J, Salido E, Linares J, Barragan A, Lorenzo V y cols. Regression of left ventricular hypertrophy by lisinopril after renal transplantation: role of ACE gene polymorphism. *Kidney Int* 58: 889-97, 2000.
1522. Fishel RS, Eisenberg S, Shai S-Y, Redden RA, Bernstein KE, Berk BC. Glucocorticoids induce angiotensin-converting enzyme expression in vascular smooth muscle. *Hypertension* 25: 343-9, 1995.
1523. Zhu J, Shearer GM, Norman JE, Pinto LA, Marincola FM, Prasad A y cols. Host response to cytomegalovirus infection as a determinant of susceptibility to coronary artery disease: sex-based differences in inflammation and type of immune response. *Circulation* 102: 2491-6, 2000.
1524. Potena L, Grigioni F, Ortolani P, Magnani G, Marrozzini C, Falchetti E y cols. Relevance of cytomegalovirus infection and coronary-artery remodelling in the first year after heart transplantation: a prospective three-dimensional intravascular ultrasound study. *Transplantation* 75: 839-43, 2003.
1525. Lemström K, Koskinen P and Häyry P. Molecular mechanisms of chronic allograft rejection. *Kidney Int* 48 (Suppl 52): S2-10, 1995.
1526. Akposso K, Rondeau E, Haymann JP, Peraldi MN, Marlin C and Sraer JD. Long-term prognosis of renal transplantation after preemptive treatment of cytomegalovirus infection. *Transplantation* 63: 974-6, 1997.
1527. Krogerus L, Soots A, Bruggeman C, Loginov R, Ahonen J and Lautenschlager I. CMV increases TNF- α expression in a rat kidney model of chronic rejection. *Transplant Proc* 35: 803, 2003.
1528. Jacobs U, Brensing KA and Klehr HU. Chronic allograft destruction vs chronic allograft rejection. *Transplant Proc* 26: 3119-20, 1994.
1529. Kasiske BL. Immune and nonimmune clinical correlates of chronic renal allograft rejection. *Transplant Proc* 29: 2557, 1997.
1530. Frei U, Schindler R, Wieters D, Grouven U, Brunkhorst and Koch M. Pre-transplant hypertension: a major risk factor for chronic progressive renal allograft dysfunction? *Nephrol Dial Transplant* 10: 1206-11, 1995.
1531. Ritz E, Schwenger V, Wiesel M and Zeier M. Atherosclerotic complications after renal transplantation. *Transpl Int* 13 (suppl 1): S14-S19, 2000.
1532. Rodrigo E, González-Lamuño D, Ruiz JC, Fernández-Fresnedo G, Isla D, Gonzalez-Cotorruelo J y cols. Apolipoprotein C-III and E polymorphisms and cardiovascular syndrome, hyperlipidemia, and insulin resistance in renal transplantation. *Am J Transplant* 2: 343-8, 2002.
1533. Herzog CA. Dismal long-term survival of dialysis patients after acute myocardial infarction: can we alter the outcome? *Nephrol Dial Transplant* 17:7-10, 2002.
1534. Humar A, Kerr SR, Ramcharan T, Gillingham KJ, Matas AJ. Peri-operative cardiac morbidity in kidney transplant recipients: incidence and risk factors. *Clin Transplantation* 15: 154-8, 2001.
1535. Oliveras A, Roquer J, Puig JM, Rodriguez A, Mir M, Orfila MA y cols. Stroke in renal transplant recipients: epidemiology, predictive risk factors and outcome. *Clin Transplant* 17:1-8, 2003.
1536. Moe SM, O'Neill KD, Resterova M, Fineberg N, Persohn S, Meyer CA. Natural history of vascular calcification in dialysis and transplant patients. *Nephrol Dial Transplant* 19:2387-93; 2004
1537. Sung RS, Althoen M, Howell TA, Merion RM. Peripheral vascular occlusive disease in renal transplant recipients: risk factors and impact on kidney allograft survival. *Transplantation* 70:1049-54, 2000.

BIBLIOGRAFÍA

1538. Abbot KC, Hishieh P, Cruess D, Agodoa LY, Welch PG, Taylor AJ y cols. Hospitalized valvular heart disease in patients in renal transplant waiting list: incidence, clinical correlates and outcomes. *Clin Nephrol* 59:79-87, 2003.
1539. Le A, Wilson R, Douek K, Pulliam L, Tolzman D, Norman D y cols. Prospective risk stratification in renal transplant candidates for cardiac death. *Am J Kidney Dis* 24:65-71,1994.
1540. Lewis MS, Wilson RA, Walker KW, Wilson DJ, Norman DJ, Barry JM y cols. Validation of an algorithm for predicting cardiac events in renal transplant candidates. *Am J Cardiol* 89:847-850, 2002.
1541. De Lima JJ, Sabbaga E, Vieira ML, de Paula FJ, Ianhez LE, Krieger EM y cols. Coronary angiography is the best predictor of events in renal transplant candidates compared with non-invasive testing. *Hypertension* 42:263-8, 2003.
1542. Koch MGF, Gradaus F, Schoebel FC, Leschke M, Grabensee B. Relevance of conventional cardiovascular risk factors for the prediction of coronary artery disease in diabetic patients on renal replacement therapy. *Nephrol Dial Transplant* 12:1187-91, 1997.
1543. Fredericks S, Chang R, Gregson H, Bewick M, Collinson PO, Gaze D y cols. Circulating cardiac troponin-T in patients before and after renal transplantation. *Clin Chim Acta* 310:199-203, 2001
1544. Goldsmith DJA and Covic A. Coronary artery disease in uremia: etiology, diagnosis and therapy. *Kidney Int* 60: 2059-78, 2001.
1545. Logar CM, Herzog CA and Beddhu S. Diagnosis and therapy of coronary artery disease in renal failure, end-stage renal disease, and renal transplant populations. *Am J Med Sci* 325: 214-27, 2003.
1546. Roppolo LP, Fitzgerald R, Dillow J, Ziegler T, Rice M, Maisel A. A comparison of troponin T and troponin I as predictors of acardiac events in aptients undergoing chronic dialysis at a Veteran´s Hospital: a pilot study. *J Am Coll Cardiol* 34: 448-54, 1999.
1547. Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ, Schonberger JP y cols. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. *N Engl J Med* 334 (15): 1117-24, 2001.
1548. Haller C. Percutaneous coronary interventions in patients with renal failure: overcoming in-stent restenosis? *Nephrol Dial Transplant* 17: 401-3, 2002.
1549. Herzog CA, Ma JZ and Collins AJ. Long-term outcome of renal transplant recipients in the United States after coronary revascularization procedures. *Circulation* 109: 2866-71, 2004.
1550. Kasiske BL, Chakkerla HA, Louis TA and Ma JZ. A meta-analysis of immunosupresión withdrawal trials in renal transplantation. *J Am Soc Nephrol* 11: 1910-7, 2000.
1551. Australian New Zealand Dialysis, Transplant registry (ANZDATA). ANZATA Report. January 2002.
1552. Mange KC, Cizman B, Joffe M and Feldman HI. Arterial hypertension and renal allograft survival. *JAMA* 283: 633-8, 2000.
1553. Kasiske BL, Anjum S, Shah R, Skogen J, Kandaswamy C, Danielson B y cols. Hypertension after kidney transplantation. *Am J Kidney Dis* 43: 1071-81, 2004.
1554. Opelz G, Wujciak T, Ritz E for the Collaborative Transplant Study: Association of chronic kidney graft failure with recipient blood pressure. *Kidney Int* 53: 217-222, 1998.
1555. K/DOQUI.Guideline1: goals of antihypertensive therapy in CKD. *Am J Kid Dis* 43: S65-S73, 2004.
1556. Zayas CF, Guasch A. Early glomerular dysfunction in human renal allografts. *Kidney Int* 60:1938-1947,2001.
1557. Curtis JJ, Luke RG, Jones P, Diethelm AG. Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent. *Am J Med* 85:134-138,1988.
1558. Branten AJW, Hilbrands LB, Van Hamersvelt HW, Koene RAP and Huysmans FTM. Renal and systemic effects of atenolol and tertatolol in renal transplant recipients on cyclosporine A. *Nephrol Dial Transplant* 13: 423-6, 1998.
1559. Midtvedt K, Hartmann A, Holdaas H and Fauchald P. Efficacy of nifedipine or lisinopril in the treatment of hypertension after renal transplantation: a double-blind randomised comparative trial. *Clin Transplant* 15: 426-31, 2001.
1560. Srinivas TR, Meier-Kriesche HU, Kaplan B, Bennet WM. Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine compared with lisinopril. *Transplantation* 15:1787-92,2001.
1561. Venkat Raman G, Feehally J, Coates RA, Elliott HL, Griffin PJ, Olubodun JO y cols. Renal effects of amlodipine in normotensive renal transplant recipients. *Nephrol Dial Transplant* 14: 384 -8, 1999.
1562. Rump LC, Oberhauser V, Schwertfeger E, Speidel L, Zimmerhackl L, Kirste G, y cols. Dihydropyridine calcium antagonists and renal function in hypertensive kidney transplant recipients. *J Hypertens* 18: 1115-9, 2000.
1563. Chanard J, Toupance O, Lavaud S, Hurault de Ligny B, Bernaud C, Moulin B y cols. Amlodipine reduces cyclosporine-induced hyperuricemia in hypertensive renal transplant recipients. *Nephrol Dial Transplant* 18: 2147-53, 2003.
1564. Iñigo P, Campistol JM, Lario S, Piera C, Campos B, Bescos M, y cols. Effects of losartan and amlodipine on intrarenal hemodynamics and TGF- α 1 plasma levels in a crossover trial in renal transplant recipients. *J Am Soc Nephrol* 12: 822-7, 2001.
1565. Martinez-Castelao A, Hueso M, Sanz V, Rejas J, Alsina J, Grinyo JM. Treatment of hypertension after renal transplantation: long-term efficacy of verapamil, enalapril and doxazosin. *Kidney Int* 54: 130-4, 1998.
1566. Sennesael J, Lamote J, Violet I, Tasse S, Verbeelen D. Comparison of perindopril and amlodipine in cyclosporine-treated renal allograft recipients. *Hypertension* 26: 436-44, 1995.
1567. Asberg A, Midtvedt K, Vassbotn T and Hartmann A. Better microvascular function on long-term treatment with lisinopril than with nifedipine in renal transplant recipients. *Nephrol Dial Transplant* 16: 1465-70, 2001.
1568. Suwelack B, Kobelt V, Erfmann M, Hausberg M, Gerhardt U, Rahn KH y cols. Long-term follow-up of ACE-inhibitor verus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients. *Transpl Int* 16: 313-20, 2003.
1569. Stigart CE, Cohen J, Vivero M, Zoltzman JS. ACE inhibitors and angiotensin II antagonists in renal transplantation : An analysis of safety and efficacy. *Am J Kidney Dis* 35:58-63,2000.
1570. Holgado R, Anaya F and Del Castillo D. Angiotensin II type 1 (AT1) receptor antagonists in the treatment of hypertension after renal transplantation. *Nephrol Dial Transplant* 16 (Suppl 1): 117-20, 2001.

1571. Omoto K, Tanabe K, Tokumoto T, Shimmura H, Ishida H, Toma H. Use of candesartan cilexil decreases proteinuria in renal transplant patients with chronic allograft dysfunction. *Transplantation* 76: 1170-4, 2003.
1572. Rengel M, Gomez Da Silva, Inchaustegui L, Lampreave JL, Robledo R, Echenagusia A y cols. Renal artery stenosis after kidney transplantation: diagnostic and therapeutical approach. *Kidney Int* 68:S99-S106,1998.
1573. Buturovic-Ponikvar J. Renal transplant artery stenosis. *Nephrol Dial Transplant* 18 (Suppl 5): 74-7, 2003.
1574. Fervenza FC, Lafayette RA, Alfrey EJ and Peterson J. Renal artery stenosis in kidney transplant. *Am J Kid Dis* 31: 142-8, 1998.
1575. Wong W, Fynn SP, Higgins RM, Walters H, Evans S, Deane C y cols. Transplant renal artery stenosis in 77 patients-does it have an immunological cause? *Transplantation* 1996; 61: 215-9, 1996.
1576. K/DOQUI. Guideline 4: evaluation for renal artery disease. *Am J Kidney Dis* 43: S101-S106, 2004.
1577. Sacks D, Rundback JH and Martin L. Renal angioplasty/stent placement and hypertension in the year 2000. *J Vasc Interv Radiol* 11 (8): 949-53, 2000.
1578. Montagnino G, Tarantino A, Maccario M, Elli A, Cesana B, Ponticelli C. Long-term results with cyclosporine monotherapy in renal transplant patients: a multivariate analysis of risk factors. *Am J Kid Dis* 35: 1135-43, 2000.
1579. Touchard G, Hauet T, Cogny Van Weydevelt, Hurault de Ligny B, Peyronnet P, Lebranchu Y y cols. Maintenance cyclosporine monotherapy after renal transplantation-clinical predictors of long-term outcome. *Nephrol Dial Transplant* 12: 1956-60, 1997.
1580. Hricik DE, Whalen CC, Lautman J, Bartucci MR, Moir EJ, Mayes JT y cols. Withdrawal of steroids after renal transplantation. Clinical predictors of outcome. *Transplantation* 53: 41-5, 1992.
1581. Gotti E, Perico N, Perna A, Gaspari F, Cattaneo D, Caruso R y cols. Renal transplantation: can we reduce calcineurin inhibitor/stop steroids? Evidence based on protocol biopsy findings. *J Am Soc Nephrol* 14: 755-66, 2003.
1582. Textor SC, Wiesner R, Wilson DJ, Porayko M, Romero JC, Burnett JC Jr y cols. Systemic and renal hemodynamic differences between FK 506 and cyclosporin in liver transplant recipients. *Transplantation* 55: 1332-9, 1993.
1583. Kreis H, Oberbauer R, Campistol JM, Mathew T, Daloz P, Schena FP y cols. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. *J Am Soc Nephrol* 15: 809-17, 2004.